Intel (INTC) 10-K 27 Jan 22 2021 FY Annual report Financial data

Cover Page

Cover Page - USD ($) shares in Millions, $ in Billions	12 Months Ended
	Dec. 25, 2021	Jan. 21, 2022	Jun. 25, 2021
Cover [Abstract]
Document Type	10-K
Document Annual Report	true
Document Period End Date	Dec. 25, 2021
Document Transition Report	false
Entity File Number	000-06217
Entity Registrant Name	INTEL CORPORATION
Entity Central Index Key	0000050863
Company Fiscal Year End Date	--12-25
Document Fiscal Year Focus	2021
Document Fiscal Period Focus	FY
Amendment Flag	false
Entity Incorporation, State or Country Code	DE
Entity Tax Identification Number	94-1672743
Entity Address, Address Line One	2200 Mission College Boulevard,
Entity Address, City or Town	Santa Clara,
Entity Address, State or Province	CA
City Area Code	408
Local Phone Number	765-8080
Title of 12(b) Security	Common stock, $0.001 par value
Trading Symbol	INTC
Security Exchange Name	NASDAQ
Entity Well-known Seasoned Issuer	Yes
Entity Voluntary Filers	No
ICFR Auditor Attestation Flag	true
Entity Filer Category	Large Accelerated Filer
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Emerging Growth Company	false
Entity Small Business	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		4,072
Entity Public Float			$ 226.8
Documents Incorporated by Reference [Text Block]	Portions of the registrant’s proxy statement related to its 2022 Annual Stockholders' Meeting to be filed subsequently are incorporated by reference into Part III of this Form 10-K. Except as expressly incorporated by reference, the registrant's proxy statement shall not be deemed to be part of this report.
Entity Address, Postal Zip Code	95054-1549

Audit Information

Audit Information	12 Months Ended
	Dec. 25, 2021
Audit Information [Abstract]
Auditor Firm ID	42
Auditor Name	Ernst & Young LLP
Auditor Location	San Jose, California

Consolidated Statements of Inco

Consolidated Statements of Income - USD ($) shares in Millions, $ in Millions	12 Months Ended
	Dec. 25, 2021	Dec. 26, 2020	Dec. 28, 2019
Income Statement [Abstract]
Net revenue	$ 79,024	$ 77,867	$ 71,965
Cost of sales	35,209	34,255	29,825
Gross margin	43,815	43,612	42,140
Research and development	15,190	13,556	13,362
Marketing, general and administrative	6,543	6,180	6,350
Restructuring and other charges	2,626	198	393
Operating expenses	24,359	19,934	20,105
Operating income	19,456	23,678	22,035
Gains (losses) on equity investments, net	2,729	1,904	1,539
Interest and other, net	(482)	(504)	484
Income before taxes	21,703	25,078	24,058
Provision for taxes	1,835	4,179	3,010
Net income	$ 19,868	$ 20,899	$ 21,048
Earnings per share—basic	$ 4.89	$ 4.98	$ 4.77
Earnings per share—diluted	$ 4.86	$ 4.94	$ 4.71
Weighted average shares of common stock outstanding:
Basic (shares)	4,059	4,199	4,417
Diluted (shares)	4,090	4,232	4,473

Consolidated Statements of Comp

Consolidated Statements of Comprehensive Income - USD ($) $ in Millions	12 Months Ended
	Dec. 25, 2021	Dec. 26, 2020	Dec. 28, 2019
Statement of Comprehensive Income [Abstract]
Net income	$ 19,868	$ 20,899	$ 21,048
Other comprehensive income, net of tax:
Net unrealized holding gains (losses) on derivatives	(520)	677	177
Actuarial valuation and other pension benefits (expenses), net	451	(183)	(564)
Translation adjustments and other	(60)	35	81
Other comprehensive income (loss)	(129)	529	(306)
Total comprehensive income	$ 19,739	$ 21,428	$ 20,742

Consolidated Balance Sheets

Consolidated Balance Sheets - USD ($) $ in Millions	Dec. 25, 2021	Dec. 26, 2020
Current assets:
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents	$ 4,827	$ 5,865
Short-term investments	2,103	2,292
Trading assets	21,483	15,738
Accounts receivable, net of allowance for doubtful accounts	9,457	6,782
Inventories	10,776	8,427
Assets held for sale	6,942	5,400
Other current assets	2,130	2,745
Total current assets	57,718	47,249
Property, plant and equipment, net	63,245	56,584
Equity investments	6,298	5,152
Other long-term investments	840	2,192
Goodwill	26,963	26,971
Identified intangible assets, net	7,270	9,026
Other long-term assets	6,072	5,917
Total assets	168,406	153,091
Current liabilities:
Short-term debt	4,591	2,504
Accounts payable	5,747	5,581
Accrued compensation and benefits	4,535	3,999
Other accrued liabilities	12,589	12,670
Total current liabilities	27,462	24,754
Debt	33,510	33,897
Contract Liabilities	185	1,367
Income taxes payable, non-current	4,305	4,578
Deferred income taxes	2,667	3,843
Other long-term liabilities	4,886	3,614
Commitments and Contingencies (Note 19)
Stockholders' equity:
Preferred stock, $0.001 par value, 50 shares authorized; none issued	0	0
Common stock, $0.001 par value, 10,000 shares authorized; 4,070 shares issued and outstanding (4,062 issued and outstanding in 2020) and capital in excess of par value	28,006	25,556
Accumulated other comprehensive income (loss)	(880)	(751)
Retained earnings	68,265	56,233
Total stockholders' equity	95,391	81,038
Total liabilities and stockholders' equity	$ 168,406	$ 153,091

Consolidated Balance Sheets (Pa

Consolidated Balance Sheets (Parenthetical) - $ / shares shares in Millions	Dec. 25, 2021	Dec. 26, 2020
Stockholders' equity:
Preferred stock, par value (in dollars per share)	$ 0.001	$ 0.001
Preferred stock, shares authorized	50	50
Preferred stock, shares issued	0	0
Common stock, par value (in dollars per share)	$ 0.001	$ 0.001
Common stock, shares authorized	10,000	10,000
Common stock, shares issued	4,070	4,062
Common stock, shares outstanding	4,070	4,062

Consolidated Statements of Cash

Consolidated Statements of Cash Flows - USD ($) $ in Millions	12 Months Ended
	Dec. 25, 2021	Dec. 26, 2020	Dec. 28, 2019
Statement of Cash Flows [Abstract]
Cash and cash equivalents, beginning of period	$ 5,865	$ 4,194	$ 3,019
Cash flows provided by (used for) operating activities:
Net income	19,868	20,899	21,048
Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation	9,953	10,482	9,204
Share-based compensation	2,036	1,854	1,705
Restructuring and other charges	2,626	198	393
Amortization of intangibles	1,839	1,757	1,622
(Gains) losses on equity investments, net	(1,458)	(1,757)	(892)
Changes in assets and liabilities:
Accounts receivable	(2,674)	883	(935)
Inventories	(2,339)	(687)	(1,481)
Accounts payable	1,190	405	696
Accrued compensation and benefits	515	348	(260)
Customer deposits and prepaid supply agreements	(1,583)	(181)	(782)
Income taxes	(441)	1,620	885
Other assets and liabilities	459	(437)	1,942
Total adjustments	10,123	14,485	12,097
Net cash provided by operating activities	29,991	35,384	33,145
Cash flows provided by (used for) investing activities:
Additions to property, plant and equipment	(18,733)	(14,259)	(16,213)
Additions to held for sale NAND property, plant, and equipment	1,596	194	0
Acquisitions, net of cash acquired	(209)	(837)	(1,958)
Purchases of available-for-sale debt investments	(5,051)	(6,862)	(2,268)
Maturities and sales of available-for-sale debt investments	6,467	6,781	4,226
Purchases of trading assets	(35,503)	(22,377)	(9,162)
Maturities and sales of trading assets	28,832	15,377	7,178
Purchases of equity investments	(613)	(720)	(522)
Proceeds from Equity Method Investment, Distribution, Return of Capital	581	910	2,688
Other investing	658	1,385	1,626
Net cash used for investing activities	(25,167)	(20,796)	(14,405)
Cash flows provided by (used for) financing activities:
Issuance of term debt, net of issuance costs	4,974	10,247	3,392
Repayments of Long-term Debt	(2,500)	(4,525)	(2,627)
Proceeds from sales of common stock through employee equity incentive plans	1,020	897	750
Repurchase of common stock	(2,415)	(14,229)	(13,576)
Payment of dividends to stockholders	(5,644)	(5,568)	(5,576)
Other financing	(1,297)	261	72
Net cash provided by (used for) financing activities	(5,862)	(12,917)	(17,565)
Net increase (decrease) in cash and cash equivalents	(1,038)	1,671	1,175
Cash and cash equivalents, end of period	4,827	5,865	4,194
Supplemental disclosures:
Acquisition of property, plant and equipment included in accounts payable and accrued liabilities	1,619	2,973	1,761
Interest, net of capitalized interest	545	594	469
Income taxes, net of refunds	$ 2,263	$ 2,436	$ 2,110

Consolidated Statements of Stoc

Consolidated Statements of Stockholders' Equity - USD ($) shares in Millions, $ in Millions	Total	Cumulative Effect, Period of Adoption, Adjustment	Cumulative Effect, Period of Adoption, Adjusted Balance	Common Stock and Capital in Excess of Par Value [Member]	Common Stock and Capital in Excess of Par Value [Member]Cumulative Effect, Period of Adoption, Adjusted Balance	Accumulated Other Comprehensive Income (Loss) [Member]	Accumulated Other Comprehensive Income (Loss) [Member]Cumulative Effect, Period of Adoption, Adjusted Balance	Retained Earnings [Member]	Retained Earnings [Member]Cumulative Effect, Period of Adoption, Adjustment	Retained Earnings [Member]Cumulative Effect, Period of Adoption, Adjusted Balance
Beginning Balance, shares at Dec. 29, 2018				4,516
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Stock Issued During Period, Shares, Employee Stock Purchase Plans				55
Repurchase of common stock, shares				(272)
Restricted stock unit withholdings, shares				(9)
Ending Balance, shares at Dec. 28, 2019				4,290
Beginning Balance at Dec. 29, 2018	$ 74,563			$ 25,365		$ (974)		$ 50,172
Components of comprehensive income, net of tax:
Net income	21,048							21,048
Other comprehensive income (loss)	(306)					(306)
Total comprehensive income	20,742
APIC, Share-based Payment Arrangement, ESPP, Increase for Cost Recognition	892			892				0
Share-based compensation	1,705			1,705
Reclassifications of Temporary to Permanent Equity	265			265
Temporary Equity, Carrying Amount, Period Increase (Decrease)	(1,032)			(1,032)
Repurchase of common stock	(13,565)			(1,592)				(11,973)
Restricted stock unit withholdings	(488)			(342)				(146)
Cash dividends declared	(5,578)							(5,578)
Ending Balance at Dec. 28, 2019	$ 77,504			$ 25,261		(1,280)		53,523
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Stock Issued During Period, Shares, Employee Stock Purchase Plans				55
Repurchase of common stock, shares				(275)
Restricted stock unit withholdings, shares				(8)
Ending Balance, shares at Dec. 26, 2020	4,062			4,062	4,062
Components of comprehensive income, net of tax:
Net income	$ 20,899							20,899
Other comprehensive income (loss)	529					529
Total comprehensive income	21,428
APIC, Share-based Payment Arrangement, ESPP, Increase for Cost Recognition	1,018			$ 1,018
Share-based compensation	1,854			1,854
Reclassifications of Temporary to Permanent Equity	155			155
Temporary Equity, Carrying Amount, Period Increase (Decrease)	(750)			(750)
Repurchase of common stock	(14,109)			(1,628)				(12,481)
Restricted stock unit withholdings	(494)			(354)				(140)
Cash dividends declared	(5,568)							(5,568)
Ending Balance at Dec. 26, 2020	$ 81,038	$ 35	$ 81,073	$ 25,556	$ 25,556	(751)	$ (751)	56,233	$ 35	$ 56,268
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Stock Issued During Period, Shares, Employee Stock Purchase Plans				54
Repurchase of common stock, shares				(40)
Restricted stock unit withholdings, shares				(6)
Ending Balance, shares at Dec. 25, 2021	4,070			4,070
Components of comprehensive income, net of tax:
Net income	$ 19,868							19,868
Other comprehensive income (loss)	(129)					(129)
Total comprehensive income	19,739
APIC, Share-based Payment Arrangement, ESPP, Increase for Cost Recognition	1,022			$ 1,022
Share-based compensation	2,036			2,036
Reclassifications of Temporary to Permanent Equity	0			0
Temporary Equity, Carrying Amount, Period Increase (Decrease)	0			0
Repurchase of common stock	(2,415)			(249)				(2,166)
Restricted stock unit withholdings	(420)			(359)				(61)
Cash dividends declared	(5,644)							(5,644)
Ending Balance at Dec. 25, 2021	$ 95,391			$ 28,006		$ (880)		$ 68,265

Consolidated Statements of St_2

Consolidated Statements of Stockholders' Equity (Parenthetical) - $ / shares	12 Months Ended
	Dec. 25, 2021	Dec. 26, 2020	Dec. 28, 2019
Retained Earnings [Member]
Cash dividends declared per common share (in dollars per share)	$ 1.3900	$ 1.32	$ 1.26

Basis of Presentation

Basis of Presentation	12 Months Ended
	Dec. 25, 2021
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Basis of Presentation [Text Block]	Note 1 : Basis of Presentation We have a 52- or 53-week fiscal year that ends on the last Saturday in December. Fiscal years 2021, 2020, and 2019 were 52-week fiscal years; 2022 is a 53-week fiscal year. Our Consolidated Financial Statements include the accounts of Intel and our subsidiaries. We have eliminated intercompany accounts and transactions. We have reclassified certain prior period amounts to conform to current period presentation. Use of Estimates The preparation of Consolidated Financial Statements in conformity with US GAAP requires us to make estimates and judgments that affect the amounts reported in our Consolidated Financial Statements and the accompanying notes. The actual results that we experience may differ materially from our estimates.

Accounting Policies

Accounting Policies	12 Months Ended
	Dec. 25, 2021
Accounting Policies [Abstract]
Accounting Policies [Text Block]	Note 2 : Accounting Policies Revenue Recognition We recognize net product revenue when we satisfy performance obligations as evidenced by the transfer of control of our products or services to customers. Substantially all of our revenue is derived from product sales. In accordance with contract terms, revenue for product sales is recognized at the time of product shipment from our facilities or delivery to the customer location, as determined by the agreed upon shipping terms. We measure revenue based on the amount of consideration we expect to be entitled to in exchange for products or services. Variable consideration is estimated and reflected as an adjustment to the transaction price. We determine variable consideration, which consists primarily of various sales price concessions, by estimating the most likely amount of consideration we expect to receive from the customer based on historical analysis of customer purchase volumes. Sales rebates earned by customers are offset against their receivable balances. Rebates earned by customers when they do not have outstanding receivable balances are recorded within other accrued liabilities. We make payments to our customers through cooperative advertising programs for marketing activities for some of our products. We generally record the payment as a reduction in revenue in the period that the revenue is earned, unless the payment is for a distinct service, which we record as expense when the marketing activities occur. Inventories We compute inventory cost on a first-in, first-out basis. Our process and product development life cycle corresponds with substantive engineering milestones. These engineering milestones are regularly and consistently applied in assessing the point at which our activities and associated costs change in nature from R&D to cost of sales, and when cost of sales can be capitalized as inventory. For a product to be manufactured in high volumes and sold to our customers under our standard warranty, it must meet our rigorous technical quality specifications. This milestone is known as PRQ. We have identified PRQ as the point at which the costs incurred to manufacture our products are included in the valuation of inventory. A single PRQ has previously valued inventory up to $870 million in the quarter the PRQ milestone was achieved. Prior to PRQ, costs that do not meet the criteria for R&D are included in cost of sales in the period incurred. The valuation of inventory includes determining which fixed production overhead costs can be included in inventory based on the normal capacity of our manufacturing and assembly and test facilities. We apply our historical loadings compared to our total available capacity in a statistical model to determine our normal capacity level. If the factory loadings are below the established normal capacity level, a portion of our fixed production overhead costs would not be included in the cost of inventory; instead, it would be recognized as cost of sales in that period. We refer to these costs as excess capacity charges. Excess capacity charges are insignificant in the years presented. Charges in years prior to those presented have ranged up to $1.1 billion taken in connection with the 2009 economic recession. Inventory is valued at the lower of cost or net realizable value, based upon assumptions about future demand and market conditions. Product-specific facts and circumstances reviewed in the inventory valuation process include a review of our customer base, the stage of the product life cycle, variations in market pricing, and an assessment of selling price in relation to product cost. Lower of cost or net realizable value inventory reserves fluctuate as we ramp new process technologies, with costs improving over time due to scale and improved yields. Additionally, inventory valuation is impacted by cyclical changes in market conditions and the associated pricing environment. Property, Plant and Equipment We compute depreciation using the straight-line method over the estimated useful life of assets. We also capitalize interest on borrowings related to eligible capital expenditures. Capitalized interest is added to the cost of qualified assets and depreciated together with that asset cost. We record capital-related government grants earned as a reduction to property, plant and equipment. We evaluate the period over which we expect to recover the economic value of our property, plant and equipment, considering factors such as the process technology cadence between node transitions, changes in machinery and equipment technology, and re-use of machinery and tools across each generation of process technology. As we make manufacturing process conversions and other factory planning decisions, we use assumptions involving the use of management judgments regarding the remaining useful lives of assets, primarily process-specific semiconductor manufacturing tools and building improvements. When we determine that the useful lives of assets are shorter or longer than we had originally estimated, we adjust the rate of depreciation to reflect the assets' revised useful lives. Assets are categorized and evaluated for impairment at the lowest level of identifiable cash flows. Factors that we consider in deciding when to perform an impairment review include significant under-performance of a business or product line in relation to expectations, significant negative industry or economic trends, and significant changes or planned changes in our use and fungibility of the assets. If an asset grouping carrying value is not recoverable through the related undiscounted cash flows, the asset grouping is considered to be impaired. Fair Value When determining fair value, we consider the principal or most advantageous market in which we would transact, as well as assumptions that market participants would use when pricing the asset or liability. Our financial assets are measured and recorded at fair value on a recurring basis, except for equity securities measured using the measurement alternative, equity method investments, and grants receivable. We assess fair value hierarchy levels for our issued debt and fixed-income investment portfolio based on the underlying instrument type. The three levels of inputs that may be used to measure fair value are: ▪ Level 1 . Quoted prices in active markets for identical assets or liabilities. We evaluate security-specific market data when determining whether a market is active. ▪ Level 2. Observable inputs other than Level 1 prices, such as quoted prices for similar assets or liabilities, quoted prices in less active markets, or model-derived valuations. All significant inputs used in our valuations, such as discounted cash flows, are observable or can be derived principally from or corroborated with observable market data for substantially the full term of the assets or liabilities. We use LIBOR-based yield curves, overnight indexed swap curves, currency spot and forward rates, and credit ratings as significant inputs in our valuations. Level 2 inputs also include non-binding market consensus prices, as well as quoted prices that were adjusted for security-specific restrictions. When we use non-binding market consensus prices, we corroborate them with quoted market prices for similar instruments or compare them to output from internally developed pricing models such as discounted cash flow models. ▪ Level 3. Unobservable inputs to the valuation methodology that are significant to the measurement of the fair value of assets or liabilities. We monitor and review the inputs and results of these valuation models to help ensure the fair value measurements are reasonable and consistent with market experience in similar asset classes. Level 3 inputs also include non-binding market consensus prices or non-binding broker quotes that we were unable to corroborate with observable market data. Debt Investments We consider all highly liquid debt investments with original maturities from the date of purchase of three months or less as cash equivalents. Cash equivalents can include investments such as corporate debt, financial institution instruments, government debt, and reverse repurchase agreements. Marketable debt investments are generally designated as trading assets when a market risk is economically hedged at inception with a related derivative instrument, or when the marketable debt investment itself is used to economically hedge currency exchange rate risk from remeasurement. Investments designated as trading assets are reported at fair value. Gains or losses on these investments arising from changes in fair value due to interest rate and currency market fluctuations and credit market volatility, largely offset by losses or gains on the related derivative instruments and balance sheet remeasurement, are recorded in interest and other, net. Marketable debt investments are considered available-for-sale investments when the interest rate and foreign currency risks are not hedged at the inception of the investment or when our criteria for designation as trading assets are not met. Available-for-sale debt investments with original maturities of approximately three months or less from the date of purchase are classified within cash and cash equivalents. Available-for-sale debt investments with original maturities at the date of purchase greater than approximately three months and remaining maturities of less than one year are classified as short-term investments. Available-for-sale debt investments with remaining maturities beyond one year are classified as other long-term investments. Available-for-sale debt investments are reported at fair value, with unrealized gains or losses, net of tax, recorded in accumulated other comprehensive income (loss). We determine the cost of the investment sold based on an average cost basis at the individual security level, and record the interest income and realized gains or losses on the sale of these investments in interest and other, net. Our available-for-sale debt investments are subject to periodic impairment reviews. For investments in an unrealized loss position, we determine whether a credit loss exists by considering information about the collectability of the instrument, current market conditions, and reasonable and supportable forecasts of economic conditions. We recognize an allowance for credit losses, up to the amount of the unrealized loss when appropriate, and write down the amortized cost basis of the investment if it is more likely than not we will be required or we intend to sell the investment before recovery of its amortized cost basis. Allowances for credit losses and write-downs are recognized in interest and other, net, and unrealized losses not related to credit losses are recognized in other comprehensive income (loss). Equity Investments We regularly invest in equity securities of public and private companies to promote business and strategic objectives. Equity investments are measured and recorded as follows: ▪ Marketable equity securities are equity securities with RDFV that are measured and recorded at fair value on a recurring basis with changes in fair value, whether realized or unrealized, recorded through the income statement. ▪ Non-marketable equity securities are equity securities without RDFV that are measured and recorded using a measurement alternative that measures the securities at cost minus impairment, if any, plus or minus changes resulting from qualifying observable price changes. ▪ Equity method investments are equity securities in investees we do not control but over which we have the ability to exercise significant influence. Equity method investments are measured at cost minus impairment, if any, plus or minus our share of equity method investee income or loss. Our proportionate share of the income or loss from equity method investments is recognized on a one-quarter lag. Realized and unrealized gains and losses resulting from changes in fair value or the sale of our equity investments are recorded in gains (losses) on equity investments, net. The carrying value of our non-marketable equity securities is adjusted for qualifying observable price changes resulting from the issuance of similar or identical securities in an orderly transaction by the same issuer. Determining whether an observed transaction is similar to a security within our portfolio requires judgment based on the rights and preferences of the securities. Recording upward and downward adjustments to the carrying value of our equity securities as a result of observable price changes requires quantitative assessments of the fair value of our securities using various valuation methodologies and involves the use of estimates. Non-marketable equity securities and equity method investments (collectively referred to as non-marketable equity investments) are also subject to periodic impairment reviews. Our quarterly impairment analysis considers both qualitative and quantitative factors that may have a significant impact on the investee's fair value. Qualitative factors considered include the investee's financial condition and business outlook, industry and sector performance, market for technology, operational and financing cash flow activities, and other relevant events and factors affecting the investee. When indicators of impairment exist, we prepare quantitative assessments of the fair value of our non-marketable equity investments using both the market and income approaches, which require judgment and the use of estimates, including discount rates, investee revenue and costs, and comparable market data of private and public companies, among others. ▪ Non-marketable equity securities are tested for impairment using a qualitative model similar to the model used for goodwill and long-lived assets. Upon determining that an impairment may exist, the security's fair value is calculated and compared to its carrying value and an impairment is recognized immediately if the carrying value exceeds the fair value. ▪ Equity method investments are subject to periodic impairment reviews using the other-than-temporary impairment model, which considers the severity and duration of a decline in fair value below cost and our ability and intent to hold the investment for a sufficient period of time to allow for recovery. Impairments of equity investments are recorded in gains (losses) on equity investments, net. Derivative Financial Instruments Our primary objective for holding derivative financial instruments is to manage currency exchange rate risk and interest rate risk, and, to a lesser extent, equity market risk, commodity price risk, and credit risk. We enter into master netting arrangements to mitigate credit risk in derivative transactions by permitting net settlement of transactions with the same counterparty. We also enter into collateral security arrangements with certain of our counterparties to exchange cash collateral when the net fair value of certain derivative instruments fluctuates from contractually established thresholds. For presentation on our Consolidated Balance Sheets, we do not offset fair value amounts recognized for derivative instruments under master netting arrangements. Our derivative financial instruments, including related collateral amounts, are presented at fair value on a gross basis and are included in other current assets, other long-term assets, other accrued liabilities, or other long-term liabilities. Cash flow hedges use foreign currency contracts, such as currency forwards and currency interest rate swaps, to hedge exposures for variability in the US-dollar equivalent of non-US-dollar-denominated cash flows associated with our forecasted operating and capital purchases spending. The after-tax gains or losses from the effective portion of a cash flow hedge is reported as a component of accumulated other comprehensive income (loss) and reclassified into earnings in the same period or periods in which the hedged transaction affects earnings, and in the same line item on the Consolidated Statements of Income as the impact of the hedge transaction. For foreign currency contracts hedging our capital purchases, forward points are excluded from the hedge effectiveness assessment, and are recognized in earnings in the same income statement line item used to present the earnings effect of the hedged item. If the cash flow hedge transactions become improbable, the corresponding amounts deferred in accumulated other comprehensive income (loss) would be immediately reclassified to interest and other, net. These derivatives are classified in the Consolidated Statements of Cash Flows in the same section as the underlying item. Fair value hedges use interest rate contracts, such as interest rate swaps, to hedge against changes in the fair value on certain of our fixed-rate indebtedness attributable to changes in the benchmark interest rate. The gains or losses on these hedges, as well as the offsetting losses or gains related to the changes in the fair value of the underlying hedged item attributable to the hedged risk, are recognized in earnings in the current period, primarily in interest and other, net. These derivatives are classified in the Consolidated Statements of Cash Flows in the same section as the underlying item, primarily within cash flows from financing activities. Credit Risk Financial instruments that potentially subject us to concentrations of credit risk consist principally of investments in debt instruments, derivative financial instruments, loans receivable, reverse repurchase agreements, and trade receivables. We generally place investments with high-credit-quality counterparties and, by policy, we limit the amount of credit exposure to any one counterparty based on our analysis of that counterparty's relative credit standing. As required per our investment policy, substantially all of our investments in debt instruments are in investment-grade instruments. Credit-rating criteria for derivative instruments are similar to those for other investments. We enter into master netting arrangements to mitigate credit risk in derivative transactions by permitting net settlement of transactions with the same counterparty. Due to master netting arrangements, the amounts subject to credit risk related to derivative instruments are generally limited to the amounts, if any, by which the counterparty's obligations exceed our obligations with that counterparty. As of December 25, 2021, our total credit exposure to any single counterparty, excluding money market funds invested in US treasury and US agency securities and reverse repurchase agreements collateralized by treasury and agency securities, did not exceed $2.6 billion. To further reduce credit risk, we enter into collateral security arrangements with certain of our derivative counterparties and obtain and secure collateral from counterparties against obligations, including securities lending transactions when we deem it appropriate. Cash collateral exchanged under our collateral security arrangements are included in other current assets, other long-term assets, other accrued liabilities, or other long-term liabilities. For reverse repurchase agreements collateralized by other securities, we do not record the collateral as an asset or a liability unless the collateral is repledged. A substantial majority of our trade receivables are derived from sales to OEMs and ODMs. We also have accounts receivable derived from sales to industrial and communications equipment manufacturers in the computing and communications industries. We believe the net accounts receivable balances from our three largest customers (42% as of December 25, 2021) do not represent a significant credit risk, based on cash flow forecasts, balance sheet analysis, and past collection experience. We have adopted credit policies and standards intended to accommodate industry growth and inherent risk. We believe credit risks are moderated by the financial stability of our major customers. We assess credit risk through quantitative and qualitative analysis. From this analysis, we establish shipping and credit limits, and determine whether we will seek to use one or more credit support protection devices, such as obtaining a parent guarantee, standby letter of credit, or credit insurance. Business Combinations We allocate the purchase price paid for assets acquired and liabilities assumed in connection with our acquisitions based on their estimated fair values at the time of acquisition. This allocation involves a number of assumptions, estimates, and judgments in determining the fair value of the following: ▪ inventory; property, plant and equipment; pre-existing liabilities or legal claims; and contingent consideration, each as may be applicable; ▪ intangible assets, including the valuation methodology, estimations of future cash flows, discount rates, market segment growth rates, and our assumed market segment share, as well as the estimated useful life of intangible assets; ▪ deferred tax assets and liabilities, uncertain tax positions, and tax-related valuation allowances, which are initially estimated as of the acquisition date; and ▪ goodwill as measured as the excess of consideration transferred over the net of the acquisition date fair values of the assets acquired and the liabilities assumed. Our assumptions and estimates are based upon comparable market data and information obtained from our management and the management of the acquired companies. We allocate goodwill to the reporting units of the business that are expected to benefit from the business combination. Goodwill We perform an annual impairment assessment of goodwill at the reporting unit level in the fourth quarter of each year, or more frequently if indicators of potential impairment exist. The analysis may include both qualitative and quantitative factors to assess the likelihood of an impairment. The reporting unit's carrying value used in an impairment test represents the assignment of various assets and liabilities, excluding certain corporate assets and liabilities, such as cash, investments, and debt. Qualitative factors include industry and market considerations, overall financial performance, and other relevant events and factors affecting the reporting unit. Additionally, as part of this assessment, we may perform a quantitative analysis to support the qualitative factors above by applying sensitivities to assumptions and inputs used in measuring a reporting unit's fair value. Our quantitative impairment test considers both the income approach and the market approach to estimate a reporting unit's fair value. Significant estimates include market segment growth rates, our assumed market segment share, estimated gross margins, operating expenses, and discount rates based on a reporting unit's weighted average cost of capital. Identified Intangible Assets We amortize acquisition-related intangible assets that are subject to amortization over their estimated useful life. Acquisition-related in-process R&D assets represent the fair value of incomplete R&D projects that had not reached technological feasibility as of the date of acquisition; initially, these are classified as in-process R&D and are not subject to amortization. Once these R&D projects are completed, the asset balances are transferred from in-process R&D to acquisition-related developed technology and are subject to amortization from that point forward. The asset balances relating to projects that are abandoned after acquisition are impaired and expensed to R&D. Employee Equity Incentive Plans We use the straight-line amortization method to recognize share-based compensation expense over the service period of the award, net of estimated forfeitures. Upon exercise, cancellation, forfeiture, or expiration of stock options, or upon vesting or forfeiture of RSUs, we eliminate deferred tax assets for options and RSUs with multiple vesting dates for each vesting period on a first-in, first-out basis as if each vesting period were a separate award. Income Taxes We compute the provision for income taxes using the asset and liability method, under which deferred tax assets and liabilities are recognized for the expected future tax consequences of temporary differences between the financial reporting and tax bases of assets and liabilities, and for operating losses and tax credit carryforwards. We measure deferred tax assets and liabilities using the currently enacted tax rates that apply to taxable income in effect for the years in which those tax assets are expected to be realized or settled. We assess the likelihood that we will be able to recover our deferred tax assets. If recovery is not likely, we must increase our provision for taxes by recording a valuation allowance against the deferred tax assets that we estimate will not ultimately be recoverable. We believe that we will ultimately recover the deferred tax assets recorded on our Consolidated Balance Sheets. Recovery of a portion of our deferred tax assets is affected by management's plans with respect to holding or disposing of certain investments; therefore, such changes could also affect our future provision for taxes. We recognize tax benefits from uncertain tax positions only if (based on the technical merits of the position) it is more likely than not that the tax positions will be sustained on examination by the tax authority. The tax benefits recognized in the financial statements from such positions are measured based on the largest amount that is more than 50% likely to be realized upon ultimate settlement. We recognize interest and penalties related to unrecognized tax benefits within the provision for taxes on the Consolidated Statements of Income. Leases Leases consist of real property and machinery and equipment. Our lease terms may include options to extend when it is reasonably certain that we will exercise that option. We have lease agreements with lease and non-lease components, and the non-lease components are accounted for separately and not included in our leased assets and corresponding liabilities. Payments on leases may be fixed or variable, and variable lease payments are based on output of the underlying leased assets. Loss Contingencies We are subject to loss contingencies, including various legal and regulatory proceedings, asserted and potential claims, liabilities related to repair or replacement of parts in connection with product defects, as well as product warranties and potential asset impairments that arise in the ordinary course of business. An estimated loss from such contingencies is recognized as a charge to income if it is probable that a liability has been incurred and the amount of the loss can be reasonably estimated. We evaluate developments that could affect the amount of liability that has been previously accrued and reasonably possible losses disclosed, and make adjustments as appropriate. Significant judgment is required to determine both likelihood of there being, and the estimated amount of, a loss related to such matters.

Operating Segments

Operating Segments	12 Months Ended
	Dec. 25, 2021
Segment Reporting [Abstract]
Operating Segments	Note 3 : Operating Segments We manage our business through the following operating segments: ▪ CCG ▪ DCG ▪ IOTG ▪ Mobileye ▪ NSG ▪ PSG We derive a substantial majority of our revenue from platform products, which are our principal products and considered as one class of product. We offer platform products that incorporate various components and technologies, including a microprocessor and chipset, a stand-alone SoC, or a multichip package, based on Intel architecture. Platform products are used in various form factors across our CCG, DCG, and IOTG operating segments. Our non-platform, or adjacent, products can be combined with platform products to form comprehensive platform solutions to meet customer needs. CCG and DCG are our reportable operating segments. IOTG, Mobileye, NSG, and PSG do not meet the quantitative thresholds to qualify as reportable operating segments; however, we have elected to disclose the results of these non-reportable operating segments. Our Internet of Things portfolio, presented as Internet of Things, is comprised of the IOTG and Mobileye operating segments. For 2021, the results of our Intel Optane memory business are included in our DCG operating segment, and our NSG segment is comprised of our NAND memory business to align to the pending divestiture of our NAND memory business. Refer to "Note 10 : Acquisitions and Divestitures" within Notes to Consolidated Financial Statements for further information on the divestiture. We have sales and marketing, manufacturing, engineering, finance, and administration groups. Expenses for these groups are generally allocated to the operating segments. We have an "all other" category that includes revenue, expenses, and charges such as: ▪ results of operations from non-reportable segments not otherwise presented; ▪ historical results of operations from divested businesses; ▪ results of operations of start-up businesses that support our initiatives, including our foundry business; ▪ amounts included within restructuring and other charges; ▪ a portion of employee benefits, compensation, and other expenses not allocated to the operating segments; and ▪ acquisition-related costs, including amortization and any impairment of acquisition-related intangibles and goodwill. The CODM, who is our CEO, allocates resources to and assesses the performance of each operating segment using information about the operating segment's revenue and operating income (loss). The CODM does not evaluate operating segments using discrete asset information and we do not identify or allocate assets by operating segments. Based on the interchangeable nature of our manufacturing and assembly and test assets, most of the related depreciation expense is not directly identifiable within our operating segments, as it is included in overhead cost pools and subsequently absorbed into inventory as each product passes through our manufacturing process. Because our products are then sold across multiple operating segments, it is impracticable to determine the total depreciation expense included as a component of each operating segment's operating income (loss) results. Operating segments do not record inter-segment revenue. We do not allocate gains and losses from equity investments, interest and other income, or taxes to operating segments. Although the CODM uses operating income to evaluate the segments, operating costs included in one segment may benefit other segments. The accounting policies for segment reporting are the same as for Intel as a whole. Net revenue and operating income (loss) for each period were as follows: Years Ended (In Millions) Dec 25, 2021 Dec 26, 2020 Dec 28, 2019 Net revenue: Client Computing Group Platform $ 37,376 $ 35,642 $ 32,681 Adjacent 3,135 4,415 4,465 40,511 40,057 37,146 Data Center Group Platform 22,703 23,056 21,441 Adjacent 3,118 3,047 2,040 25,821 26,103 23,481 Internet of Things IOTG 3,998 3,007 3,821 Mobileye 1,386 967 879 5,384 3,974 4,700 Non-Volatile Memory Solutions Group 4,306 5,358 4,362 Programmable Solutions Group 1,934 1,853 1,987 All other 1,068 522 289 Total net revenue $ 79,024 $ 77,867 $ 71,965 Operating income (loss): Client Computing Group $ 14,672 $ 15,129 $ 15,202 Data Center Group 6,997 10,571 10,227 Internet of Things IOTG 1,045 497 1,097 Mobileye 460 241 245 1,505 738 1,342 Non-Volatile Memory Solutions Group 1,369 361 (1,176) Programmable Solutions Group 297 260 318 All other (5,384) (3,381) (3,878) Total operating income $ 19,456 $ 23,678 $ 22,035 Disaggregated net revenue for each period was as follows: Years Ended (In Millions) Dec 25, 2021 Dec 26, 2020 Dec 28, 2019 Platform revenue CCG notebook platform $ 25,475 $ 24,903 $ 20,779 CCG desktop platform 11,835 10,692 11,822 CCG other platform 1 66 47 80 DCG platform 22,703 23,056 21,441 IOTG platform 3,658 2,705 3,440 63,737 61,403 57,562 Adjacent revenue 2 15,287 16,464 14,403 Total revenue $ 79,024 $ 77,867 $ 71,965 1 Includes our tablet and service provider revenue. Net revenue by region, based on the billing location of the customer, was as follows: Years Ended (In Millions) Dec 25, 2021 Dec 26, 2020 Dec 28, 2019 China $ 21,141 $ 20,257 $ 20,026 Singapore 14,254 17,845 15,650 United States 14,107 16,573 15,617 Taiwan 13,461 11,605 10,058 Other regions 16,061 11,587 10,614 Total net revenue $ 79,024 $ 77,867 $ 71,965

Earnings Per Share

Earnings Per Share	12 Months Ended
	Dec. 25, 2021
Earnings Per Share [Abstract]
Earnings Per Share [Text Block]	Note 4 : Earnings Per Share Years Ended (In Millions, Except Per Share Amounts) Dec 25, 2021 Dec 26, 2020 Dec 28, 2019 Net income available to common stockholders $ 19,868 $ 20,899 $ 21,048 Weighted average shares of common stock outstanding—basic 4,059 4,199 4,417 Dilutive effect of employee incentive plans 31 33 41 Dilutive effect of convertible debt — — 15 Weighted average shares of common stock outstanding—diluted 4,090 4,232 4,473 Earnings per share—basic $ 4.89 $ 4.98 $ 4.77 Earnings per share—diluted $ 4.86 $ 4.94 $ 4.71 We computed diluted earnings per share of common stock based on the weighted average number of shares of common stock outstanding plus potentially dilutive shares of common stock outstanding during the period. Potentially dilutive shares of common stock from employee incentive plans are determined by applying the treasury stock method to the assumed exercise of outstanding stock options, the assumed vesting of outstanding RSUs, and the assumed issuance of common stock under the 2006 ESPP. In January 2020, we fully redeemed the remaining principal of our 2009 Debentures. We included our 2009 Debentures in the calculation of diluted earnings per share of common stock in 2019 by applying the treasury stock method because the average market price was above the conversion price. Securities that would have been anti-dilutive are insignificant and are excluded from the computation of diluted earnings per share in all periods presented.

Contract Liabilities

Contract Liabilities	12 Months Ended
	Dec. 25, 2021
Revenue from Contract with Customer [Abstract]
Contract Liabilities	Note 5 : Contract Liabilities Contract liabilities consist of prepayments received on long-term prepaid customer supply agreements toward future product delivery and other revenue deferrals from regular ongoing business activity. Contract liabilities were $498 million as of December 25, 2021 ($1.9 billion as of December 26, 2020). The following table shows the changes in contract liability balances relating to long-term prepaid customer supply agreements during 2021: (In Millions) Prepaid customer supply agreements balance as of December 26, 2020 $ 1,625 Concession payment (950) Prepaids utilized (633) Prepaid customer supply agreements balance as of December 25, 2021 $ 42

Other Financial Statement Detai

Other Financial Statement Details	12 Months Ended
	Dec. 25, 2021
Other Financial Statement Details [Abstract]
Other Financial Statement Details [Text Block]	Note 6 : Other Financial Statement Details Inventories (In Millions) Dec 25, 2021 Dec 26, 2020 Raw materials $ 1,441 $ 908 Work in process 6,656 5,693 Finished goods 2,679 1,826 Total inventories $ 10,776 $ 8,427 Property, Plant and Equipment (In Millions) Dec 25, 2021 Dec 26, 2020 Land and buildings $ 40,039 $ 37,536 Machinery and equipment 86,955 79,384 Construction in progress 21,545 17,309 Total property, plant and equipment, gross 148,539 134,229 Less: accumulated depreciation (85,294) (77,645) Total property, plant and equipment, net $ 63,245 $ 56,584 Our depreciable property, plant and equipment assets are depreciated over the following estimated useful lives: machinery and equipment, 2 to 5 years; and buildings, 10 to 25 years. Net property, plant and equipment by country at the end of each period was as follows: (In Millions) Dec 25, 2021 Dec 26, 2020 United States $ 43,428 $ 38,829 Israel 7,754 7,837 Ireland 7,503 5,828 Other countries 4,560 4,090 Total property, plant and equipment, net $ 63,245 $ 56,584 Other Accrued Liabilities Other accrued liabilities include deferred compensation of $2.8 billion as of December 25, 2021 ($2.5 billion as of December 26, 2020) and collateral received for derivatives under credit support annex agreements of $1.0 billion as of December 25, 2021 ($2.0 billion as of December 26, 2020). Interest and Other, Net Years Ended (In Millions) Dec 25, 2021 Dec 26, 2020 Dec 28, 2019 Interest income $ 144 $ 272 $ 483 Interest expense (597) (629) (489) Other, net (29) (147) 490 Total interest and other, net $ (482) $ (504) $ 484 Interest expense in the preceding table is net of

Restructuring and Other Charges

Restructuring and Other Charges	12 Months Ended
	Dec. 25, 2021
Restructuring Costs and Asset Impairment Charges [Abstract]
Restructuring and Other Charges [Text Block]	Note 7 : Restructuring and Other Charges Restructuring and other charges (benefits) by type are as follows: Years Ended (In Millions) Dec 25, 2021 Dec 26, 2020 Employee severance and benefit arrangements $ 48 $ 124 Litigation charges and other 2,291 67 Asset impairment charges 287 7 Total restructuring and other charges $ 2,626 $ 198 A restructuring program was approved in the first quarter of 2020 to further align our workforce with our continuing investments in the business and to execute the planned divestiture of Home Gateway Platform, a division of CCG. These actions were substantially complete as of September 25, 2021. Litigation charges and other includes a charge of $2.2 billion in the first quarter of 2021 related to the VLSI Technology LLC (VLSI) litigation, which is recorded as a Corporate charge in the "all other" category presented in "Note 3: Operating Segments" within Notes to Consolidated Financial Statements. Refer to "Note 19: Commitments and Contingencies" within Notes to Consolidated Financial Statements for further information on legal proceedings related to the VLSI litigation. Asset impairment charges includes impairments related to the shutdown in the second quarter of 2021 of two of our non-strategic businesses, the results of which are included in the "all other" category presented in "Note 3: Operating Segments" within Notes to Consolidated Financial Statements. The goodwill related to these businesses was impaired, resulting in a charge of $238 million recognized in the second quarter of 2021 in the "all other" category along with other impairment charges related to these businesses.

Income Taxes

Income Taxes	12 Months Ended
	Dec. 25, 2021
Income Tax Disclosure [Abstract]
Income Taxes [Text Block]	Note 8 : Income Taxes Income Tax Provision Years Ended (In Millions) Dec 25, 2021 Dec 26, 2020 Dec 28, 2019 Income before taxes: US $ 9,361 $ 15,452 $ 13,729 Non-US 12,342 9,626 10,329 Total income before taxes 21,703 25,078 24,058 Provision for taxes: Current: Federal 1,304 1,120 1,391 State 75 46 37 Non-US 1,198 1,244 1,060 Total current provision for taxes 2,577 2,410 2,488 Deferred: Federal (863) 1,369 597 State (25) 25 1 Non-US 146 375 (76) Total deferred provision for taxes (742) 1,769 522 Total provision for taxes $ 1,835 $ 4,179 $ 3,010 Effective tax rate 8.5 % 16.7 % 12.5 % The difference between the tax provision at the statutory federal income tax rate and the tax provision as a percentage of income before income taxes (effective tax rate) for each period was as follows: Years Ended Dec 25, 2021 Dec 26, 2020 Dec 28, 2019 Statutory federal income tax rate 21.0 % 21.0 % 21.0 % Increase (reduction) in rate resulting from: Non-US income taxed at different rates (5.9) (3.7) (3.7) Research and development tax credits (2.4) (2.1) (2.3) Restructuring of certain non-U.S. subsidiaries (3.4) — — Foreign derived intangible income benefit (2.2) (1.9) (3.2) Change in permanent reinvestment assertion — 1.6 — Other 1.4 1.8 0.7 Effective tax rate 8.5 % 16.7 % 12.5 % Our effective tax rate decreased in 2021 compared to 2020, primarily driven by one-time tax benefits due to the restructuring of certain non-US subsidiaries as well as a higher proportion of our income in non-US jurisdictions. As a result of the restructuring, we established deferred tax assets and released the valuation allowances of certain foreign deferred tax assets. The majority of these deferred tax assets established in 2021 fully offset the deferred tax liabilities recognized in 2020 driven by a change in our permanent reinvestment assertion with respect to undistributed earnings in China, as a result of the planned divestiture of our NAND memory business. Our effective tax rate increased in 2020 compared to 2019, primarily driven by a change in our permanent reinvestment assertion with respect to undistributed earnings in China, as a result of the planned divestiture of our NAND memory business. It also increased due to the reduction in our foreign derived intangible income benefit in 2020. We derive the effective tax rate benefit attributed to non-US income taxed at different rates primarily from our operations in Hong Kong, Ireland, Israel, and Malaysia. The statutory tax rates in these jurisdictions range from 12.5% to 24.0%. We are subject to reduced tax rates in Israel and Malaysia as long as we conduct certain eligible activities and make certain capital investments. We have conditional reduced tax rates that expire at various dates through 2056 and we expect to apply for renewals upon expiration. Deferred and Current Income Taxes Deferred income taxes reflect the net tax effects of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts for income tax purposes. Significant components of our deferred tax assets and liabilities at the end of each period were as follows: (In Millions) Dec 25, 2021 Dec 26, 2020 Deferred tax assets: Accrued compensation and other benefits $ 1,019 $ 865 Share-based compensation 477 324 Litigation charge 467 — Inventory 914 835 R&D expenditures capitalization 519 — State credits and net operating losses 2,010 1,829 Other, net 819 617 Gross deferred tax assets 6,225 4,470 Valuation allowance (2,259) (1,963) Total deferred tax assets 3,966 2,507 Deferred tax liabilities: Property, plant and equipment (4,213) (3,109) Licenses and intangibles (486) (725) Unrealized gains on investments and derivatives (819) (735) Unremitted earnings of non-US subsidiaries — (403) Other, net (241) (146) Total deferred tax liabilities (5,759) (5,118) Net deferred tax assets (liabilities) $ (1,793) $ (2,611) Reported as: Deferred tax assets 874 1,232 Deferred tax liabilities (2,667) (3,843) Net deferred tax assets (liabilities) $ (1,793) $ (2,611) Change in valuation allowance for deferred tax assets were as follows: Years Ended (In Millions) Balance at Beginning of Year Additions Charged to Expenses/ Net Balance at Valuation allowance for deferred tax assets December 25, 2021 $ 1,963 $ 442 $ (146) $ 2,259 December 26, 2020 $ 1,534 $ 378 $ 51 $ 1,963 December 28, 2019 $ 1,302 $ 239 $ (7) $ 1,534 Deferred tax assets are included within other long-term assets on the Consolidated Balance Sheets. The valuation allowance as of December 25, 2021 included allowances primarily related to unrealized state credit carryforwards of $2.0 billion. As of December 25, 2021, our federal and non-US net operating loss carryforwards for income tax purposes were $644 million and $1.1 billion, respectively. Most of the non-US net operating loss carryforwards have no expiration date. The remaining non-US and US federal net operating loss carryforwards expire at various dates through 2040. A significant amount of the net operating loss carryforwards in the US relates to acquisitions and, as a result, is limited in the amount that can be recognized in any one year. The federal and non-US net operating loss carryforwards include $357 million and $860 million, respectively, that is not likely to be recovered and has been reduced by a valuation allowance. At December 25, 2021, we have undistributed earnings of certain foreign subsidiaries of approximately $18.9 billion that we have indefinitely invested, and on which we have not recognized deferred taxes. Estimating the amount of potential tax is not practicable because of the complexity and variety of assumptions necessary to compute the tax. Current income taxes receivable of $23 million as of December 25, 2021 ($131 million as of December 26, 2020) are included in other current assets. Current income taxes payable of $1.1 billion as of December 25, 2021 ($756 million as of December 26, 2020) are included in other accrued liabilities. Long-term income taxes payable of $4.3 billion as of December 25, 2021 ($4.6 billion as of December 26, 2020) is primarily comprised of the transition tax from Tax Reform, which is payable over eight years beginning in 2018, as well as amounts for uncertain tax positions, reduced by the associated deduction for state taxes and non-US tax credits. Uncertain Tax Positions (In Millions) Dec 25, 2021 Dec 26, 2020 Dec 28, 2019 Beginning gross unrecognized tax benefits $ 828 $ 548 $ 283 Settlements and effective settlements with tax authorities (25) (142) (4) Changes in balances related to tax position taken during prior periods (26) 165 122 Changes in balances related to tax position taken during current period 243 257 147 Ending gross unrecognized tax benefits $ 1,020 $ 828 $ 548 If the remaining balance of unrecognized tax benefits were recognized in a future period, it would result in a tax benefit of $721 million as of December 25, 2021 ($550 million as of December 26, 2020) and a reduction in the effective tax rate. Interest, penalties, and accrued interest related to unrecognized tax benefits were insignificant in the periods presented. We regularly engage in discussions and negotiations with tax authorities regarding tax matters in the various jurisdictions in which we conduct business. Although the timing of the resolutions and/or closures of audits is highly uncertain, it is reasonably possible that certain US federal and non-US tax audits may be concluded within the next 12 months, which could increase or decrease the balance of our gross unrecognized tax benefits. We estimate that the unrecognized tax benefits as of December 25, 2021 could decrease by as much as $327 million in the next 12 months. We file federal, state, and non-US tax returns. Excluding pre-acquisition Altera tax years, we are no longer subject to US federal and non-US tax examinations for years prior to 2013. For US state tax returns, we are no longer subject to tax examination for years prior to 2014.

Investments

Investments	12 Months Ended
	Dec. 25, 2021
Investments [Abstract]
Investments [Text Block]	Note 9 : Investments Debt Investments Trading Assets For trading assets still held at the reporting date, we recorded net losses of $606 million in 2021 (net gains of $694 million in 2020 and net gains of $26 million in 2019). Net gains on the related derivatives were $609 million in 2021 (net losses of $667 million in 2020 and net gains of $22 million in 2019). Available-for-Sale Debt Investments Available-for-sale investments include corporate debt, government debt, and financial institution instruments. Government debt includes instruments such as non-US government bonds and US agency securities. Financial institution instruments include instruments issued or managed by financial institutions in various forms, such as commercial paper, fixed- and floating-rate bonds, money market fund deposits, and time deposits. As of December 25, 2021 and December 26, 2020, substantially all time deposits were issued by institutions outside the US. The adjusted cost of our available-for-sale investments was $5.0 billion as of December 25, 2021 ($7.8 billion as of December 26, 2020). The adjusted cost of our available-for-sale investments approximated the fair value for these periods. The fair values of available-for-sale debt investments by contractual maturity as of December 25, 2021 were as follows: (In Millions) Fair Value Due in 1 year or less $ 2,931 Due in 1–2 years 559 Due in 2–5 years 281 Due after 5 years — Instruments not due at a single maturity date 1,216 Total $ 4,987 Equity Investments (In Millions) Dec 25, 2021 Dec 26, 2020 Marketable equity securities $ 2,171 $ 1,830 Non-marketable equity securities 4,111 3,304 Equity method investments 16 18 Total $ 6,298 $ 5,152 The components of gains (losses) on equity investments, net for each period were as follows: Years Ended (In Millions) Dec 25, 2021 Dec 26, 2020 Dec 28, 2019 Ongoing mark-to-market adjustments on marketable equity securities $ (130) $ (133) $ 277 Observable price adjustments on non-marketable equity securities 750 176 293 Impairment charges (154) (303) (122) Sale of equity investments and other 1 2,263 2,164 1,091 Total gains (losses) on equity investments, net $ 2,729 $ 1,904 $ 1,539 1 Sale of equity investments and other includes initial fair value adjustments recorded upon a security becoming marketable, realized gains (losses) on sales of non-marketable equity investments, and our share of equity method investee gains (losses) and distributions. In 2021, we recognized impairments of $154 million on non-marketable equity securities ($290 million in 2020 and $122 million in 2019). As of December 25, 2021 the cumulative amount of impairments for equity securities without readily determinable fair value is $916 million and upward observable price adjustments were $1.1 billion. Net unrealized gains and losses for our marketable and non-marketable equity securities during each period were as follows: (In Millions) Dec 25, 2021 Dec 26, 2020 Dec 28, 2019 Net gains (losses) recognized during the period on equity securities $ 1,210 $ 1,679 $ 734 Less: Net (gains) losses recognized during the period on equity securities sold during the period (259) (254) (424) Net unrealized gains (losses) recognized during the period on equity securities still held at the reporting date $ 951 $ 1,425 $ 310 McAfee Corp. McAfee completed its initial public offering in October 2020. Due to our 41% ownership and significant influence as of December 25, 2021, we account for it as an equity method investment. We had no accounting carrying value as of December 25, 2021 and as of December 26, 2020. During 2021, we recognized McAfee dividends of $1.3 billion, which includes a special dividend of $1.1 billion paid in connection with the sale of McAfee's Enterprise Business to Symphony Technology Group and $228 million related to the partial sale of our investment in McAfee. We recognized McAfee dividends of $126 million in 2020 and $632 million in 2019. In November 2021, McAfee announced an agreement to be acquired by an investor group, which is subject to closing conditions. Beijing Unisoc Technology Ltd. We account for our interest in Beijing Unisoc Technology Ltd. (Unisoc) as a non-marketable equity security. In the first quarter of 2021, we recognized $471 million in observable price adjustments in our investment in Unisoc and as of December 25, 2021, the net book value of the investment was $1.1 billion ($658 million as of December 26, 2020).

Acquisitions & Divestitures

Acquisitions & Divestitures	12 Months Ended
	Dec. 25, 2021
Business Combinations [Abstract]
Acquisitions and Divestitures [Text Block]	Note 10 : Acquisitions and Divestitures Acquisitions We completed four acquisitions in 2021 and six acquisitions in 2020, all of which qualified as business combinations. The consideration for the acquisitions in 2021 and 2020 primarily consisted of cash and was allocated to goodwill and identified intangible assets. For information on the assignment of goodwill to our operating segments, see "Note 11: Goodwill," and for information on the classification of intangible assets, see "Note 12: Identified Intangible Assets." Moovit On May 4, 2020, we acquired Moovit, a MaaS solutions company, for total consideration of $915 million. The fair values of the assets acquired relate to goodwill of $638 million and intangible assets of $331 million. The goodwill arising from the acquisition is attributed to the expected synergies and other benefits that will be generated from the combination of Intel and Moovit. Substantially all of the goodwill will not be deductible for local tax purposes. The acquisition-related intangible assets are primarily related to Moovit's monthly active user base and application platform. The goodwill and operating results of Moovit are included in our Mobileye operating segment. Divestitures NAND Memory Business In October 2020, we signed an agreement with SK hynix Inc. (SK hynix) to divest our NAND memory business for $9.0 billion in cash. The NAND memory business includes our NAND memory fabrication facility in Dalian, China and certain related equipment and tangible assets (the Fab Assets), our NAND SSD business (the NAND SSD Business), and our NAND memory technology and manufacturing business (the NAND OpCo Business). The transaction will be completed in two closings. The first closing was completed on December 29, 2021, subsequent to our fiscal 2021 year-end. At first closing, SK hynix paid $7.0 billion of consideration, with the remaining $2.0 billion to be received at the second closing of the transaction, expected to be no earlier than March 2025. In connection with the first closing, we expect to recognize a pre-tax gain of approximately $1.0 billion within interest and other, net, and tax expense of approximately $450 million. Based on our ongoing obligation under the NAND wafer manufacturing and sale agreement, approximately $600 million of the initial closing consideration will be deferred and recognized between first and second closing within interest and other, net. At the first closing, we sold to SK hynix the Fab Assets and the NAND SSD Business and transferred certain employees, IP, and other assets related to the NAND OpCo Business to separately created wholly owned subsidiaries of Intel. The equity interest of the NAND OpCo Business will transfer to SK hynix at the second closing. In connection with the first closing, we and certain affiliates of SK hynix also entered into a NAND wafer manufacturing and sale agreement, pursuant to which we will manufacture and sell to SK hynix NAND memory wafers to be manufactured using the Fab Assets in Dalian, China until the second closing. We have concluded based on the terms of the transaction agreements that the subsidiaries will be variable interest entities for which we are not the primary beneficiary, because the governance structure of these entities does not allow us to direct the activities that would most significantly impact their economic performance. In line with this conclusion, we will fully deconsolidate our ongoing interests in the NAND OpCo Business in the first quarter of 2022, and will record a receivable for the second closing proceeds of $1.9 billion. The carrying amounts of the major classes of NAND assets held for sale included the following: (In Millions) Dec 25, 2021 Dec 26, 2020 Inventories $ 953 $ 962 Property, plant and equipment, net 5,989 4,363 Total assets $ 6,942 $ 5,325 We ceased recording depreciation on property, plant and equipment as of the date the assets triggered held for sale accounting. The agreement provided for continued capital purchases through first closing and we invested $1.6 billion in 2021, which is classified as assets held for sale at period end and sold at first closing. Home Gateway Platform Division On July 31, 2020, we completed the divestiture of the majority of Home Gateway Platform, a division of CCG, for proceeds of $150 million. The divestiture included the transfer of certain employees, equipment, and an ongoing supply agreement for future units. Smartphone Modem Business

Goodwill

Goodwill	12 Months Ended
	Dec. 25, 2021
Business Combination, Goodwill [Abstract]
Goodwill [Text Block]	Note 11 : Goodwill Dec 26, 2020 Acquisitions Other Dec 25, 2021 Client Computing Group $ 4,360 $ 73 $ — $ 4,433 Data Center Group 7,232 123 — 7,355 Internet of Things Group 1,591 — — 1,591 Mobileye 10,928 — — 10,928 Programmable Solutions Group 2,622 — 34 2,656 All other 238 — (238) — Total $ 26,971 $ 196 $ (204) $ 26,963 (In Millions) Dec 28, 2019 Acquisitions Other Dec 26, 2020 Client Computing Group $ 4,333 $ 27 $ — $ 4,360 Data Center Group 7,182 50 — 7,232 Internet of Things Group 1,579 12 — 1,591 Mobileye 10,290 638 — 10,928 Programmable Solutions Group 2,654 2 (34) 2,622 All other 238 — — 238 Total $ 26,276 $ 729 $ (34) $ 26,971

Identified Intangible Assets

Identified Intangible Assets	12 Months Ended
	Dec. 25, 2021
Intangible Assets, Net (Excluding Goodwill) [Abstract]
Identified Intangible Assets [Text Block]	Note 12 : Identified Intangible Assets December 25, 2021 December 26, 2020 (In Millions) Gross Assets Accumulated Amortization Net Gross Assets Accumulated Amortization Net Developed technology $ 11,102 $ (6,026) $ 5,076 $ 10,188 $ (4,880) $ 5,308 Customer relationships and brands 2,110 (1,063) 1,047 2,110 (854) 1,256 Licensed technology and patents 2,893 (1,746) 1,147 2,836 (1,629) 1,207 In-process R&D — — — 954 — 954 Other non-amortizing intangibles — — — 301 — 301 Total identified intangible assets $ 16,105 $ (8,835) $ 7,270 $ 16,389 $ (7,363) $ 9,026 Amortization expenses recorded for identified intangible assets in the Consolidated Statements of Income for each period and the weighted average useful life were as follows: Years Ended (In Millions) Location Dec 25, 2021 Dec 26, 2020 Dec 28, 2019 Weighted Average Useful Life 1 Developed technology Cost of sales $ 1,283 $ 1,211 $ 1,124 9 years Customer relationships and brands Marketing, general and administrative 209 205 200 11 years Licensed technology and patents Cost of sales 347 341 298 13 years Total amortization expenses $ 1,839 $ 1,757 $ 1,622 1 Represents weighted average useful life in years of intangible assets during 2021. We expect future amortization expense for the next five years and thereafter to be as follows: (In Millions) 2022 2023 2024 2025 2026 Thereafter Total Future amortization expenses $ 1,854 $ 1,622 $ 1,188 $ 779 $ 598 $ 1,229 $ 7,270

Borrowings

Borrowings	12 Months Ended
	Dec. 26, 2020
Debt Disclosure [Abstract]
Borrowings [Text Block]	Note 13 : Borrowings Short-Term Debt Short-term debt, which primarily includes the current portion of long-term debt, was $4.6 billion as of December 25, 2021 and $2.5 billion as of December 26, 2020. The current portion of long-term debt includes debt classified as short term based on time remaining until maturity. We have an ongoing authorization from our Board of Directors to borrow up to $10.0 billion under our commercial paper program. Long-Term Debt Dec 25, 2021 Dec 26, 2020 (In Millions) Effective Interest Rate Amount Amount Floating-rate senior note: Three-month LIBOR plus 0.35%, due May 2022 0.55% $ 800 $ 800 Fixed-rate senior notes: 1.70%, due May 2021 —% — 500 3.30%, due October 2021 —% — 2,000 2.35%, due May 2022 1.96% 750 750 3.10%, due July 2022 2.70% 1,000 1,000 4.00%, due December 2022 1 2.96% 398 417 2.70%, due December 2022 2.28% 1,500 1,500 4.10%, due November 2023 3.22% 400 400 2.88%, due May 2024 2.31% 1,250 1,250 2.70%, due June 2024 2.14% 600 600 3.40%, due March 2025 3.45% 1,500 1,500 3.70%, due July 2025 2.16% 2,250 2,250 2.60%, due May 2026 0.63% 1,000 1,000 3.75%, due March 2027 3.79% 1,000 1,000 3.15%, due May 2027 1.21% 1,000 1,000 1.60%, due August 2028 1.68% 1,000 — 2.45%, due November 2029 2.39% 2,000 2,000 3.90%, due March 2030 3.93% 1,500 1,500 2.00%, due August 2031 2.04% 1,250 — 4.00%, due December 2032 1.24% 750 750 4.60%, due March 2040 4.61% 750 750 2.80%, due August 2041 2.82% 750 — 4.80%, due October 2041 2.01% 802 802 4.25%, due December 2042 1.42% 567 567 4.90%, due July 2045 2.13% 772 772 4.10%, due May 2046 1.40% 1,250 1,250 4.10%, due May 2047 1.37% 1,000 1,000 4.10%, due August 2047 0.92% 640 640 3.73%, due December 2047 1.77% 1,967 1,967 3.25%, due November 2049 3.20% 2,000 2,000 4.75%, due March 2050 4.74% 2,250 2,250 3.05%, due August 2051 3.07% 1,250 — 3.10%, due February 2060 3.11% 1,000 1,000 4.95%, due March 2060 4.99% 1,000 1,000 3.20%, due August 2061 3.22% 750 — Oregon and Arizona bonds: 2.40% - 2.70%, due December 2035 - 2040 2.49% 423 423 5.00%, due March 2049 2.13% 138 138 5.00%, due June 2049 2.15% 438 438 Total senior notes and other borrowings 37,695 35,214 Unamortized premium/discount and issuance costs (405) (378) Hedge accounting fair value adjustments 811 1,565 Long-term debt 38,101 36,401 Current portion of long-term debt (4,591) (2,504) Total long-term debt $ 33,510 $ 33,897 1 To manage foreign currency risk associated with the Australian-dollar-denominated notes issued in 2015, we entered into currency interest rate swaps with an aggregate notional amount of $396 million at December 25, 2021, which effectively converted these notes to US-dollar-denominated notes. For further discussion on derivatives in cash flow hedging relationships, see "Note 16: Derivative Financial Instruments." Principal and unamortized discount/issuance costs for the Australian-dollar-denominated notes in the table above were calculated using foreign currency exchange rates as of December 25, 2021 and December 26, 2020. Senior Notes In 2021, we issued a total of $5.0 billion aggregate principal amount of senior notes. Net proceeds from the offerings are being used for general corporate purposes, which may include refinancing outstanding debt, funding for working capital, and capital expenditures. During 2021, we repaid $500 million of our 1.70% senior notes that matured in May 2021 and $2.0 billion of our 3.30% senior notes that matured in October 2021. In 2020, we issued a total of $10.3 billion aggregate principal amount of senior notes and repaid $1.0 billion of our 1.85% senior notes that matured in May 2020 and $1.8 billion of our 2.45% senior notes that matured in July 2020. We also repaid $700 million in floating-rate senior notes that matured in May 2020. Our floating-rate senior note pays interest quarterly and our fixed-rate senior notes pay interest semiannually. We may redeem the fixed-rate notes prior to their maturity at our option at specified redemption prices and subject to certain restrictions. The obligations under the notes rank equally in right of payment with all of our other existing and future senior unsecured indebtedness and will effectively rank junior to all liabilities of our subsidiaries. Revolving Credit Facility In 2021, we entered into a $5.0 billion variable-rate revolving credit facility that, if drawn, is expected to be used for general corporate purposes. The revolving credit facility matures in March 2026 and had no borrowings outstanding as of December 25, 2021. Convertible Debentures In 2009, we issued the 2009 Debentures, which were convertible, subject to certain conditions, into shares of our common stock and paid a fixed rate of interest semiannually. In 2020, we paid $1.1 billion in cash to settle our remaining $372 million in principal, resulting in a loss of $109 million in interest and other, net and $750 million as a reduction in stockholders' equity related to the conversion feature. Debt Maturities Our aggregate debt maturities, excluding commercial paper and drafts payable, based on outstanding principal as of December 25, 2021, by year payable, are as follows: (In Millions) 2022 2023 2024 2025 2026 2027 and thereafter Total $ 4,586 $ 400 $ 1,850 $ 3,750 $ 1,000 $ 26,109 $ 37,695

Fair Value

Fair Value	12 Months Ended
	Dec. 25, 2021
Fair Value Disclosures [Abstract]
Fair Value [Text Block]	Note 14 : Fair Value Assets and Liabilities Measured and Recorded at Fair Value on a Recurring Basis December 25, 2021 December 26, 2020 Fair Value Measured and Recorded at Reporting Date Using Total Fair Value Measured and Total (In Millions) Level 1 Level 2 Level 3 Level 1 Level 2 Level 3 Assets Cash equivalents: Corporate debt $ — $ 65 $ — $ 65 $ — $ 50 $ — $ 50 Financial institution instruments 1 1,216 763 — 1,979 2,781 636 — 3,417 Reverse repurchase — 1,595 — 1,595 — 1,900 — 1,900 Short-term investments: Corporate debt — 648 — 648 — 428 — 428 Financial institution instruments 1 — 1,243 — 1,243 — 1,179 — 1,179 Government debt 2 — 212 — 212 — 685 — 685 Trading assets: Corporate debt — 5,143 — 5,143 — 3,815 — 3,815 Financial institution instruments 1 154 3,729 — 3,883 131 2,847 — 2,978 Government debt 2 — 12,457 — 12,457 — 8,945 — 8,945 Other current assets: Derivative assets 80 576 — 656 48 644 — 692 Loans receivable 3 — 152 — 152 — 439 — 439 Marketable equity securities 1,854 317 — 2,171 136 1,694 — 1,830 Other long-term investments: Corporate debt — 576 — 576 — 1,520 — 1,520 Financial institution instruments 1 — 190 — 190 — 257 — 257 Government debt 2 50 24 — 74 — 415 — 415 Other long-term assets: Derivative assets — 772 7 779 — 1,520 30 1,550 Loans receivable 3 — 57 — 57 — 157 — 157 Total assets measured and recorded at fair value $ 3,354 $ 28,519 $ 7 $ 31,880 $ 3,096 $ 27,131 $ 30 $ 30,257 Liabilities Other accrued liabilities: Derivative liabilities $ 4 $ 516 $ — $ 520 $ — $ 810 $ — $ 810 Other long-term liabilities: Derivative liabilities — 9 — 9 — 5 — 5 Total liabilities measured and recorded at fair value $ 4 $ 525 $ — $ 529 $ — $ 815 $ — $ 815 1 Level 1 investments in financial institution instruments consist of money market funds. Level 2 investments consist primarily of commercial paper, certificates of deposit, time deposits, and notes and bonds issued by financial institutions. 2 Level 1 investments consist primarily of US Treasury securities. Level 2 investments in government debt consist primarily of non-US government debt, as well as marketable equity securities subject to security-specific restrictions. 3 The fair value of our loans receivable for which we elected the fair value option did not significantly differ from the contractual principal balance based on the contractual currency. Assets Measured and Recorded at Fair Value on a Non-Recurring Basis Our non-marketable equity securities, equity method investments, and certain non-financial assets, such as intangible assets and property, plant and equipment, are recorded at fair value only if an impairment or observable price adjustment is recognized in the current period. If an impairment or observable price adjustment is recognized on our non-marketable equity securities during the period, we classify these assets as Level 3. We classify non-marketable equity securities and non-marketable equity method investments as Level 3. Impairments recognized on these investments held as of December 25, 2021 were $138 million ($266 million on investments held as of December 26, 2020 and $113 million on investments held as of December 28, 2019). Financial Instruments Not Recorded at Fair Value on a Recurring Basis Financial instruments not recorded at fair value on a recurring basis include non-marketable equity securities and equity method investments that have not been remeasured or impaired in the current period, grants receivable, and issued debt. We classify the fair value of grants receivable as Level 2. The estimated fair value of these financial instruments approximates their carrying value. The aggregate carrying value of grants receivable as of December 25, 2021 was $317 million (the aggregate carrying value of grants receivable as of December 26, 2020 was $139 million).

Other Comprehensive Income (Los

Other Comprehensive Income (Loss)	12 Months Ended
	Dec. 25, 2021
Equity [Abstract]
Other Comprehensive Income (Loss) [Text Block]	Note 15 : Other Comprehensive Income (Loss) The changes in accumulated other comprehensive income (loss) by component and related tax effects for each period were as follows: (In Millions) Unrealized Holding Gains (Losses) on Derivatives Actuarial Valuation and Other Pension Expenses Translation Adjustments and Other Total December 29, 2018 $ (123) $ (818) $ (33) $ (974) Other comprehensive income (loss) before reclassifications (11) (753) 109 (655) Amounts reclassified out of accumulated other comprehensive income (loss) 195 67 (6) 256 Tax effects (7) 122 (22) 93 Other comprehensive income (loss) 177 (564) 81 (306) December 28, 2019 54 (1,382) 48 (1,280) Other comprehensive income (loss) before reclassifications 806 (323) 55 538 Amounts reclassified out of accumulated other comprehensive income (loss) (8) 89 (11) 70 Tax effects (121) 51 (9) (79) Other comprehensive income (loss) 677 (183) 35 529 December 26, 2020 731 (1,565) 83 (751) Other comprehensive income (loss) before reclassifications (434) 476 (58) (16) Amounts reclassified out of accumulated other comprehensive income (loss) (226) 101 (19) (144) Tax effects 140 (126) 17 31 Other comprehensive income (loss) (520) 451 (60) (129) December 25, 2021 $ 211 $ (1,114) $ 23 $ (880)

Derivative Financial Instrument

Derivative Financial Instruments	12 Months Ended
	Dec. 25, 2021
Derivative Instruments and Hedging Activities Disclosure [Abstract]
Derivative Financial Instruments [Text Block]	Note 16 : Derivative Financial Instruments Volume of Derivative Activity Total gross notional amounts for outstanding derivatives (recorded at fair value) at the end of each period were as follows: (In Millions) Dec 25, 2021 Dec 26, 2020 Dec 28, 2019 Foreign currency contracts $ 38,024 $ 31,209 $ 23,981 Interest rate contracts 15,209 14,461 14,302 Other 2,517 2,026 1,753 Total $ 55,750 $ 47,696 $ 40,036 During 2021 and 2020, we did not enter into any new pay-variable, receive-fixed interest rate swaps to hedge against changes in the fair value attributable to benchmark interest rates related to our outstanding senior notes. The total notional amount of outstanding pay-variable, receive-fixed interest rate swaps was $12.0 billion as of December 25, 2021 and $12.0 billion as of December 26, 2020. In 2019, we unwound $7.1 billion of these swaps, resulting in a $111 million gain to be amortized over the remaining life of the debt. Fair Value of Derivative Instruments in the Consolidated Balance Sheets December 25, 2021 December 26, 2020 (In Millions) Assets 1 Liabilities 2 Assets 1 Liabilities 2 Derivatives designated as hedging instruments: Foreign currency contracts 3 $ 80 $ 163 $ 551 $ 2 Interest rate contracts 774 — 1,498 — Total derivatives designated as hedging instruments 854 163 2,049 2 Derivatives not designated as hedging instruments: Foreign currency contracts 3 475 297 142 685 Interest rate contracts 26 65 3 128 Equity contracts 80 4 48 — Total derivatives not designated as hedging instruments 581 366 193 813 Total derivatives $ 1,435 $ 529 $ 2,242 $ 815 1 Derivative assets are recorded as other assets, current and long-term. 2 Derivative liabilities are recorded as other liabilities, current and long-term. 3 The majority of these instruments mature within 12 months. Amounts Offset in the Consolidated Balance Sheets Agreements subject to master netting arrangements with various counterparties, and cash and non-cash collateral posted under such agreements at the end of each period were as follows: December 25, 2021 Gross Amounts Not Offset in the Balance Sheet (In Millions) Gross Amounts Recognized Gross Amounts Offset in the Balance Sheet Net Amounts Presented in the Balance Sheet Financial Instruments Cash and Non-Cash Collateral Received or Pledged Net Amount Assets: Derivative assets subject to master netting arrangements $ 1,427 $ — $ 1,427 $ (332) $ (986) $ 109 Reverse repurchase agreements 1,595 — 1,595 — (1,595) — Total assets 3,022 — 3,022 (332) (2,581) 109 Liabilities: Derivative liabilities subject to master netting arrangements 392 — 392 (332) (60) — Total liabilities $ 392 $ — $ 392 $ (332) $ (60) $ — December 26, 2020 Gross Amounts Not Offset in the Balance Sheet (In Millions) Gross Amounts Recognized Gross Amounts Offset in the Balance Sheet Net Amounts Presented in the Balance Sheet Financial Instruments Cash and Non-Cash Collateral Received or Pledged Net Amount Assets: Derivative assets subject to master netting arrangements $ 2,235 $ — $ 2,235 $ (264) $ (1,904) $ 67 Reverse repurchase agreements 1,900 — 1,900 — (1,900) — Total assets 4,135 — 4,135 (264) (3,804) 67 Liabilities: Derivative liabilities subject to master netting arrangements 711 — 711 (264) (447) — Total liabilities $ 711 $ — $ 711 $ (264) $ (447) $ — We obtain and secure available collateral from counterparties against obligations, including securities lending transactions and reverse repurchase agreements, when we deem it appropriate. Derivatives in Cash Flow Hedging Relationships The before-tax net gains or losses attributed to the effective portion of cash flow hedges recognized in other comprehensive income (loss) were $434 million net losses in 2021 ($806 million net gains in 2020 and $11 million net losses in 2019). Substantially all of our cash flow hedges are foreign currency contracts for all periods presented. Amounts excluded from effectiveness testing were insignificant during all periods presented. For information on the unrealized holding gains (losses) on derivatives reclassified out of accumulated other comprehensive income into the Consolidated Statements of Income, see "Note 15: Other Comprehensive Income (Loss)." Derivatives in Fair Value Hedging Relationships The effects of derivative instruments designated as fair value hedges, recognized in interest and other, net for each period were as follows: Gains (Losses) Recognized in Statement of Income on Derivatives Years Ended (In Millions) Dec 25, 2021 Dec 26, 2020 Dec 28, 2019 Interest rate contracts $ (723) $ 817 $ 1,071 Hedged items 723 (817) (1,071) Total $ — $ — $ — The amounts recorded on the Consolidated Balance Sheet related to cumulative basis adjustments for fair value hedges for each period were as follows: Line Item in the Consolidated Balance Sheet in Which the Hedged Item Is Included Carrying Amount of the Hedged Item Assets/(Liabilities) Cumulative Amount of Fair Value Hedging Adjustment Included in the Carrying Amount Assets/(Liabilities) Years Ended (In Millions) Dec 25, 2021 Dec 26, 2020 Dec 25, 2021 Dec 26, 2020 Long-term debt $ (12,772) $ (13,495) $ (775) $ (1,498) Derivatives Not Designated as Hedging Instruments The effects of derivative instruments not designated as hedging instruments on the Consolidated Statements of Income for each period were as follows: Years Ended (In Millions) Location of Gains (Losses) Dec 25, 2021 Dec 26, 2020 Dec 28, 2019 Foreign currency contracts Interest and other, net $ 677 $ (572) $ 204 Interest rate contracts Interest and other, net 31 (90) (32) Other Various 360 284 297 Total $ 1,068 $ (378) $ 469

Retirement Benefit Plans

Retirement Benefit Plans	12 Months Ended
	Dec. 25, 2021
Retirement Benefits [Abstract]
Retirement Benefit Plans [Text Block]	Note 17 : Retirement Benefit Plans Defined Contribution Plans We provide tax-qualified defined contribution plans for the benefit of eligible employees, former employees, and retirees in the US and certain other countries. The plans are designed to provide employees with an accumulation of funds for retirement on a tax-deferred basis. For the benefit of eligible US employees, we also provide an unfunded non-tax-qualified supplemental deferred compensation plan for certain highly compensated employees. We expensed $444 million in 2021 and $398 million in 2020 for matching contributions based on the amount of employee contributions under the US qualified defined contribution and non-qualified deferred compensation plans. Prior to 2020, the contributions were discretionary and we expensed $379 million in 2019. US Retiree Medical Plan Upon retirement, we provide certain benefits to eligible US employees who were hired prior to 2014 under the US Retiree Medical Plan. The benefits can be used to pay all or a portion of the cost to purchase eligible coverage in a medical plan. As of December 25, 2021 and December 26, 2020, the projected benefit obligation was $682 million and $741 million, which used the discount rate of 2.8% and 2.4%. The December 25, 2021 and December 26, 2020 corresponding fair value of plan assets was $669 million and $600 million. The investment strategy for US Retiree Medical Plan assets is to invest primarily in liquid assets, due to the level of expected future benefit payments. The assets are invested in tax-aware global equity and fixed-income long credit portfolios. Both portfolios are actively managed by external managers. The tax-aware global equity portfolio is composed of a diversified mix of equities in developed countries. The tax-aware fixed-income long credit portfolio is composed of domestic securities. The allocation to each asset class will fluctuate with market conditions, such as volatility and liquidity concerns, and will typically be rebalanced when outside the target ranges, which are 65% equity and 35% fixed income investments. As of December 25, 2021, the majority of the US Retiree Medical Plan assets were invested in exchange-traded equity securities and were measured at fair value using Level 1 inputs. The remaining US Retiree Medical Plan assets were invested in fixed income investments and were measured at fair value using Level 2 inputs. The estimated benefit payments for this plan over the next 10 years are as follows: (In Millions) 2022 2023 2024 2025 2026 2027-2031 Postretirement Medical Benefits $ 37 $ 38 $ 39 $ 41 $ 42 $ 219 Pension Benefit Plans We provide defined-benefit pension plans in certain countries, most significantly Ireland, the US, Israel, and Germany. The majority of the plans' benefits have been frozen. Benefit Obligation and Plan Assets for Pension Benefit Plans The vested benefit obligation for a defined-benefit pension plan is the actuarial present value of the vested benefits to which the employee is currently entitled based on the employee's expected date of separation or retirement. Dec 25, 2021 Dec 26, 2020 Changes in projected benefit obligation: Beginning projected benefit obligation $ 4,929 $ 4,284 Service cost 54 49 Interest cost 91 97 Actuarial (gain) loss (284) 373 Currency exchange rate changes (150) 261 Plan settlements (126) (79) Other (58) (56) Ending projected benefit obligation 1 4,456 4,929 Changes in fair value of plan assets: Beginning fair value of plan assets 2,878 2,654 Actual return on plan assets 145 203 Currency exchange rate changes (63) 113 Plan settlements (126) (79) Other (17) (13) Ending fair value of plan assets 2 2,817 2,878 Net unfunded status $ 1,639 $ 2,051 Amounts recognized in the Consolidated Balance Sheets Other long-term liabilities $ 1,639 $ 2,051 Accumulated other comprehensive loss (income), before tax 3 $ 1,445 $ 1,911 Accumulated benefit obligation 4 $ 4,086 $ 4,429 1 The projected benefit obligation was approximately 30% in the US and 70% outside of the US as of December 25, 2021 and approximately 35% in the US and 65% outside of the US as of December 26, 2020. 2 The fair value of plan assets was approximately 50% in the US and 50% outside of the US as of December 25, 2021 and approximately 55% in the US and 45% outside of the US as of December 26, 2020. 3 The accumulated other comprehensive loss (income), before tax, was approximately 30% in the US and 70% outside of the US as of December 25, 2021 and approximately 35% in the US and 65% outside of the US as of December 26, 2020. 4 All plans had accumulated benefit obligations and projected benefit obligations in excess of plan assets for all periods presented. Changes in actuarial gains and losses in the projected benefit obligation are generally driven by discount rate movement. We use the corridor approach to amortize actuarial gains and losses. Under this approach, net actuarial gains or losses in excess of 10% of the larger of the projected benefit obligation or the fair value of plan assets are amortized on a straight-line basis. Assumptions for Pension Benefit Plans Dec 25, 2021 Dec 26, 2020 Weighted average actuarial assumptions used to determine benefit obligations Discount rate 2.2 % 1.9 % Rate of compensation increase 3.2 % 3.2 % 2021 2020 2019 Weighted average actuarial assumptions used to determine costs Discount rate 1.9 % 2.3 % 3.4 % Expected long-term rate of return on plan assets 2.7 % 3.3 % 4.7 % Rate of compensation increase 3.2 % 3.2 % 3.5 % We establish the discount rate for each pension plan by analyzing current market long-term bond rates and matching the bond maturity with the average duration of the pension liabilities. We establish the long-term expected rate of return by developing a forward-looking, long-term return assumption for each pension fund asset class, taking into account factors such as the expected real return for the specific asset class and inflation. A single, long-term rate of return is then calculated as the weighted average of the target asset allocation percentages and the long-term return assumption for each asset class. Funding Our practice is to fund the various pension plans in amounts sufficient to meet the minimum requirements of applicable local laws and regulations. Additional funding may be provided as deemed appropriate. Funding for the US Retiree Medical Plan is discretionary under applicable laws and regulations; additional funding may be provided as deemed appropriate. On a worldwide basis, our pension and retiree medical plans were 68% funded as of December 25, 2021. The US Pension Plan, which accounts for 28% of the worldwide pension and retiree medical benefit obligations, was 99% funded. Funded status is not indicative of our ability to pay ongoing pension benefits or of our obligation to fund retirement trusts. Required pension funding for US retirement plans is determined in accordance with ERISA, which sets required minimum contributions. Cumulative company funding to the US Pension Plan currently exceeds the minimum ERISA funding requirements. Net Periodic Benefit Cost The net periodic benefit cost for pension and US retiree medical benefits was $162 million in 2021 ($164 million in 2020 and $135 million in 2019). Pension Plan Assets December 25, 2021 Dec 26, 2020 Fair Value Measured at Reporting Date Using (In Millions) Level 1 Level 2 Level 3 Total Total Equity securities $ — $ 342 $ — $ 342 $ 320 Fixed income — 122 20 142 135 Assets measured by fair value hierarchy $ — $ 464 $ 20 $ 484 $ 455 Assets measured at net asset value 2,311 2,401 Cash and cash equivalents 22 22 Total pension plan assets at fair value $ 2,817 $ 2,878 US Plan Assets The investment strategy for US Pension Plan assets is to manage the funded status volatility, taking into consideration the investment horizon and expected volatility to help ensure that sufficient assets are available to pay pension benefits as they come due. The allocation to each asset class will fluctuate with market conditions, such as volatility and liquidity concerns, and will typically be rebalanced when outside the target ranges, which are 90% fixed income and 10% equity investments. During 2021, the US Pension Plan assets were invested in collective investment trust funds, which are measured at net asset value. Non-US Plan Assets The investments of the non-US plans are managed by insurance companies, pension funds, or third-party trustees, consistent with regulations or market practice of the country where the assets are invested. The investment manager makes investment decisions within the guidelines set by Intel or local regulations. Investments managed by qualified insurance companies or pension funds under standard contracts follow local regulations, and we are not actively involved in their investment strategies. For the assets that we have discretion to set investment guidelines, the assets are invested in developed country equity investments and fixed-income investments, either through index funds or direct investment. In general, the investment strategy is designed to accumulate a diversified portfolio among markets, asset classes, or individual securities to reduce market risk and to help ensure that the pension assets are available to pay benefits as they come due. The target allocation of the non-US plan assets that we have control over was approximately 45% fixed income, 35% equity, and 20% hedge fund investments in 2021. The equity investments in the non-US plan assets are invested in a diversified mix of equities of developed countries, including the US, and emerging markets throughout the world. We have control over the investment strategy related to the majority of the assets measured at net asset value, which are invested in hedge funds, bond index funds, and equity index funds. Estimated Future Benefit Payments for Pension Benefit Plans Estimated benefit payments over the next 10 years are as follows: (In Millions) 2022 2023 2024 2025 2026 2027-2031 Pension benefits $ 147 $ 144 $ 141 $ 142 $ 146 $ 765

Employee Equity Incentive Plans

Employee Equity Incentive Plans	12 Months Ended
	Dec. 25, 2021
Employee Benefit and Share-based Payment Arrangement, Noncash Expense [Abstract]
Employee Equity Incentive Plans [Text Block]	Note 18 : Employee Equity Incentive Plans Our equity incentive plans are broad-based, long-term programs intended to attract and retain talented employees and align stockholder and employee interests. Our plans include our 2006 Plan and our 2006 ESPP. Under the 2006 Plan, 866 million shares of common stock have been authorized for issuance as equity awards to employees and non-employee directors through June 2023. As of December 25, 2021, 128 million shares of common stock remained available for future grants. Under the 2006 Plan, we grant RSUs and stock options. We grant RSUs with a service condition as well as RSUs with a market condition, performance condition, and a service condition, which we call PSUs. PSUs are granted to a group of senior officers and employees. For PSUs granted in 2021, the number of shares of our common stock to be received at vesting will range from 0% to 200% of the target grant amount, equally based on two metrics: our three-year cumulative non-GAAP EPS growth relative to a target rate and TSR of our common stock measured against the benchmark TSR of the S&P 500 IT Sector Index over a three-year period. TSR is a measure of stock price appreciation plus any dividends paid in this performance period. As of December 25, 2021, 15 million PSUs were outstanding. PSUs vest three years from the grant date. Other RSU awards and option awards generally vest over four years from the grant date. Stock options generally expire 10 years from the date of grant. Share-Based Compensation Share-based compensation recognized in 2021 was $2.0 billion ($1.9 billion in 2020 and $1.7 billion in 2019). During 2021, the tax benefit that we realized for the tax deduction from share-based awards totaled $377 million ($380 million in 2020 and $359 million in 2019). We estimate the fair value of RSUs with a service condition or performance condition using the value of our common stock on the date of grant, reduced by the present value of dividends expected to be paid on our shares of common stock prior to vesting. We estimate the fair value of RSUs with a market condition using a Monte Carlo simulation model as of the date of grant using historical volatility. Restricted Stock Units Weighted average assumptions used in estimating grant values were as follows: Dec 25, 2021 Dec 26, 2020 Dec 28, 2019 Estimated values $ 50.82 $ 54.82 $ 48.06 Risk-free interest rate 0.2 % 0.4 % 2.3 % Dividend yield 2.6 % 2.3 % 2.5 % Volatility 37 % 30 % 25 % Summary of activities: Number of Stock Units (In Millions) Weighted Average Grant-Date Fair Value December 26, 2020 82.7 $ 50.14 Granted 76.8 $ 50.82 Vested (30.2) $ 47.64 Forfeited (11.3) $ 49.48 December 25, 2021 118.0 $ 51.29 Expected to vest 105.9 $ 51.47 The aggregate fair value of awards that vested in 2021 was $1.7 billion ($1.9 billion in 2020 and $1.9 billion in 2019), which represents the market value of our common stock on the date that the RSUs vested. The grant-date fair value of awards that vested in 2021 was $1.4 billion ($1.3 billion in 2020 and $1.3 billion in 2019). The number of RSUs vested includes shares of common stock that we withheld on behalf of employees to satisfy the minimum statutory tax withholding requirements. RSUs that are expected to vest are net of estimated future forfeitures. As of December 25, 2021, unrecognized compensation costs related to RSUs granted under our equity incentive plans were $3.8 billion. We expect to recognize those costs over a weighted average period of 1.5 years. Stock Purchase Plan The 2006 ESPP allows eligible employees to purchase shares of our common stock at 85% of the value of our common stock on specific dates. Under the 2006 ESPP, 523 million shares of common stock are authorized for issuance through August 2026. As of December 25, 2021, 227 million shares of common stock remained available for issuance.

Commitments and Contingencies

Commitments and Contingencies	12 Months Ended
	Dec. 25, 2021
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies Disclosure [Text Block]	Note 19 : Commitments and Contingencies Leases We recognized operating leased assets in other long-term assets of $549 million and corresponding accrued liabilities of $180 million, and other long-term liabilities of $295 million as of December 25, 2021. Our operating leases have remaining terms of 1 to 14 years and may include options to extend the leases for up to 37 years. The weighted average remaining lease term was 3.8 years, and the weighted average discount rate was 2.5% as of December 25, 2021 for our operating leases. Operating lease expense was $798 million in 2021 ($416 million in 2020 and $185 million in 2019), including $620 million in variable lease expense in 2021. In 2021, we signed finance leases for supplier capacity extending over approximately eight years. The leases will commence upon start of supplier production expected in 2023 with prepayments totaling approximately $980 million in 2022 and 2023. These prepayments will be recognized in property, plant and equipment upon payment. Discounted and undiscounted lease payments under non-cancelable leases as of December 25, 2021, excluding non-lease components, were as follows: (In Millions) 2022 2023 2024 2025 2026 Thereafter Total Operating lease payments $ 183 $ 139 $ 79 $ 55 $ 16 $ 27 $ 499 Finance lease payments $ 451 $ 529 $ 980 Present value of lease payments $ 1,455 Commitments Commitments for capital expenditures totaled $27.0 billion as of December 25, 2021 ($8.6 billion as of December 26, 2020), a substantial majority of which will be due within the next 12 months. Other purchase obligations and commitments totaled approximately $12.4 billion as of December 25, 2021 (approximately $2.6 billion as of December 26, 2020). Other purchase obligations and commitments include payments due under supply agreements and various types of licenses and agreements to purchase goods or services. Contractual obligations for purchases of goods or services relate to agreements that are enforceable and legally binding and that specify all significant terms, including fixed or minimum quantities, fixed, minimum, or variable price provisions, and the approximate timing of the transaction. For obligations with cancellation provisions, amounts are limited to the non-cancelable portion or the minimum cancellation fee under the agreement. Legal Proceedings We are regularly party to various ongoing claims, litigation, and other proceedings, including those noted in this section. In the first quarter of 2021, we accrued a charge of $2.2 billion related to litigation involving VLSI, described below. Excluding this charge, management at present believes that the ultimate outcome of these proceedings, individually and in the aggregate, will not materially harm our financial position, results of operations, cash flows, or overall trends; however, legal proceedings and related government investigations are subject to inherent uncertainties, and unfavorable rulings, excessive verdicts, or other events could occur. Unfavorable resolutions could include substantial monetary damages, fines, or penalties. Certain of these outstanding matters include speculative, substantial or indeterminate monetary awards. In addition, in matters for which injunctive relief or other conduct remedies are sought, unfavorable resolutions could include an injunction or other order prohibiting us from selling one or more products at all or in particular ways, precluding particular business practices, or requiring other remedies. An unfavorable outcome may result in a material adverse impact on our business, results of operations, financial position, and overall trends. We might also conclude that settling one or more such matters is in the best interests of our stockholders, employees, and customers, and any such settlement could include substantial payments. Except as specifically described below, we have not concluded that settlement of any of the legal proceedings noted in this section is appropriate at this time. European Commission Competition Matter In 2001, the EC commenced an investigation regarding claims by Advanced Micro Devices, Inc. (AMD) that we used unfair business practices to persuade customers to buy our microprocessors. We received numerous requests for information and documents from the EC and we responded to each of those requests. The EC issued a Statement of Objections in July 2007 and held a hearing on that Statement in March 2008. The EC issued a Supplemental Statement of Objections in July 2008. In May 2009, the EC issued a decision finding that we had violated Article 82 of the EC Treaty and Article 54 of the European Economic Area Agreement. In general, the EC found that we violated Article 82 (later renumbered as Article 102 by a new treaty) by offering alleged "conditional rebates and payments" that required our customers to purchase all or most of their x86 microprocessors from us. The EC also found that we violated Article 82 by making alleged "payments to prevent sales of specific rival products." The EC imposed a fine in the amount of €1.1 billion ($1.4 billion as of May 2009), which we subsequently paid during the third quarter of 2009, and ordered us to "immediately bring to an end the infringement referred to in" the EC decision. The EC decision contained no specific direction on whether or how we should modify our business practices. Instead, the decision stated that we should "cease and desist" from further conduct that, in the EC's opinion, would violate applicable law. We took steps, which are subject to the EC's ongoing review, to comply with that decision pending appeal. We had discussions with the EC to better understand the decision and to explain changes to our business practices. We appealed the EC decision to the Court of First Instance (which has been renamed the General Court) in July 2009. The hearing of our appeal took place in July 2012. In June 2014, the General Court rejected our appeal in its entirety. In August 2014, we filed an appeal with the European Court of Justice. In November 2014, Intervener Association for Competitive Technologies filed comments in support of Intel's grounds of appeal. The EC and interveners filed briefs in November 2014, we filed a reply in February 2015, and the EC filed a rejoinder in April 2015. The Court of Justice held oral argument in June 2016. In October 2016, Advocate General Wahl, an advisor to the Court of Justice, issued a non-binding advisory opinion that favored Intel on a number of grounds. The Court of Justice issued its decision in September 2017, setting aside the judgment of the General Court and sending the case back to the General Court to examine whether the rebates at issue were capable of restricting competition. The General Court appointed a panel of five judges to consider our appeal of the EC's 2009 decision in light of the Court of Justice's clarifications of the law. In November 2017, the parties filed initial "Observations" about the Court of Justice's decision and the appeal and were invited by the General Court to offer supplemental comments to each other's "Observations," which the parties submitted in March 2018. Responses to other questions posed by the General Court were filed in May and June 2018. The General Court heard oral argument in March 2020, and on January 26, 2022 issued a decision annulling the EC’s finding against Intel regarding rebates as well as the fine on Intel. Any appeal of the General Court’s decision must be brought before the Court of Justice by early April 2022. Litigation Related to Security Vulnerabilities In June 2017, a Google research team notified us and other companies that it had identified security vulnerabilities (now commonly referred to as "Spectre" and "Meltdown") that affect many types of microprocessors, including our products. As is standard when findings like these are presented, we worked together with other companies in the industry to verify the research and develop and validate software and firmware updates for impacted technologies. On January 3, 2018, information on the security vulnerabilities was publicly reported, before software and firmware updates to address the vulnerabilities were made widely available. Numerous lawsuits have been filed against Intel and, in certain cases, our current and former executives and directors, in US federal and state courts and in certain courts in other countries relating to the Spectre and Meltdown security vulnerabilities, as well as other variants of these vulnerabilities that have since been identified. As of January 25, 2022, consumer class action lawsuits relating to the above class of security vulnerabilities publicly disclosed since 2018 were pending in the United States, Canada, and Israel. The plaintiffs, who purport to represent various classes of purchasers of our products, generally claim to have been harmed by Intel's actions and/or omissions in connection with the security vulnerabilities and assert a variety of common law and statutory claims seeking monetary damages and equitable relief. In the United States, numerous individual class action suits filed in various jurisdictions were consolidated in April 2018 for all pretrial proceedings in the US District Court for the District of Oregon. In March 2020, the court granted Intel's motion to dismiss the complaint in that consolidated action but granted plaintiffs leave to amend. In March 2021, the court granted Intel's motion to dismiss the amended complaint but granted plaintiffs leave to further amend in part. Plaintiffs filed a further amended complaint in May 2021, which Intel moved to dismiss in July 2021. In Canada, in one case pending in the Superior Court of Justice of Ontario, an initial status conference has not yet been scheduled. In a second case pending in the Superior Court of Justice of Quebec, a stay of the case was in effect until December 2021, and the parties' joint request for a further stay to May 2022 is pending with the court. In Israel, two consumer class action lawsuits were filed in the District Court of Haifa. The plaintiff voluntarily dismissed the first lawsuit in July 2021. Intel filed a motion to stay the second case pending resolution of the consolidated proceeding in the US, and a hearing on that motion has been scheduled for April 2022. Additional lawsuits and claims may be asserted seeking monetary damages or other related relief. We dispute the pending claims described above and intend to defend those lawsuits vigorously. Given the procedural posture and the nature of those cases, including that the pending proceedings are in the early stages, that alleged damages have not been specified, that uncertainty exists as to the likelihood of a class or classes being certified or the ultimate size of any class or classes if certified, and that there are significant factual and legal issues to be resolved, we are unable to make a reasonable estimate of the potential loss or range of losses, if any, that might arise from those matters. In addition to these lawsuits, Intel stockholders filed multiple shareholder derivative lawsuits since January 2018 against certain current and former members of our Board of Directors and certain current and former officers, alleging that the defendants breached their duties to Intel in connection with the disclosure of the security vulnerabilities and the failure to take action in relation to alleged insider trading. The complaints sought to recover damages from the defendants on behalf of Intel. Some of the derivative actions were filed in the US District Court for the Northern District of California and were consolidated, and the others were filed in the Superior Court of the State of California in San Mateo County and were consolidated. The federal court granted defendants' motion to dismiss in August 2018 on the ground that plaintiffs failed to plead facts sufficient to show they were excused from making a pre-lawsuit demand on the Board. The federal court granted plaintiffs leave to amend their complaint, but subsequently dismissed the cases in January 2019 at plaintiffs' request. The California Superior Court entered judgment in defendants' favor in August 2020 after granting defendants' motions to dismiss plaintiffs' consolidated complaint and three successive amended complaints, all for failure to plead facts sufficient to show plaintiffs were excused from making a pre-lawsuit demand on the Board. Plaintiffs filed a notice of appeal of the California court's judgment in October 2020. In January 2021, another Intel stockholder filed a derivative lawsuit in the Superior Court in San Mateo County against certain current and former officers and members of our Board of Directors. The lawsuit asserts claims similar to those dismissed in August 2020, except that it alleges that the stockholder made a pre-lawsuit demand on our Board of Directors and that the demand was wrongfully refused. In May 2021, the court granted defendants' motion to stay the action pending the outcome of any litigation plaintiff may choose to file in Delaware where Intel's bylaws require such claims to be filed. Litigation Related to 7nm Product Delay Announcement Starting in July 2020, five securities class action lawsuits were filed in the United States District Court for the Northern District of California against Intel and certain current and former officers based on Intel’s July 2020 announcement of 7nm product delays. The plaintiffs, who purport to represent classes of acquirers of Intel stock between October 2019 and July 2020, generally allege that the defendants violated securities laws by making false or misleading statements about the timeline for 7nm products in light of subsequently announced delays. In October 2020, the court consolidated the lawsuits and appointed lead plaintiffs, and in January 2021 the lead plaintiffs filed a consolidated complaint. Defendants moved to dismiss the consolidated complaint in March 2021. We dispute the claims described above and intend to defend the lawsuits vigorously. Given the procedural posture and the nature of those cases, including that the pending proceedings are in the early stages, that alleged damages have not been specified, that uncertainty exists as to the likelihood of a class or classes being certified or the ultimate size of any class or classes if certified, and that there are significant factual and legal issues to be resolved, we are unable to make a reasonable estimate of the potential loss or range of losses, if any, that might arise from those matters. In July 2021, Intel introduced a new process node naming structure, and the 7nm process is now Intel 4. Litigation Related to Patent and IP Claims We have had IP infringement lawsuits filed against us, including but not limited to those discussed below. Most involve claims that certain of our products, services, and technologies infringe others' IP rights. Adverse results in these lawsuits may include awards of substantial fines and penalties, costly royalty or licensing agreements, or orders preventing us from offering certain features, functionalities, products, or services. As a result, we may have to change our business practices, and develop non-infringing products or technologies, which could result in a loss of revenues for us and otherwise harm our business. In addition, certain agreements with our customers require us to indemnify them against certain IP infringement claims, which can increase our costs as a result of defending such claims, and may require that we pay significant damages, accept product returns, or supply our customers with non-infringing products if there were an adverse ruling in any such claims. In addition, our customers and partners may discontinue the use of our products, services, and technologies, as a result of injunctions or otherwise, which could result in loss of revenues and adversely affect our business. Institute of Microelectronics, Chinese Academy of Sciences v. Intel China, Ltd., et al. In February 2018, the Institute of Microelectronics of the Chinese Academy of Sciences (IMECAS) sued Intel China, Ltd., Dell China, Ltd. (Dell), and Beijing Jingdong Century Information Technology, Ltd. (JD) for patent infringement in the Beijing Higher People's Court. IMECAS alleges that Intel's Core series processors infringe Chinese patent CN 102956457 ('457 Patent). The complaint demands an injunction and damages of at least RMB 200 million plus the cost of litigation. Intel is indemnifying Dell and JD. The Beijing Higher People's Court held a final trial hearing in September 2021. No ruling has been issued. In March 2018, Intel filed an invalidation request on the '457 patent with the China National Intellectual Property Administration (CNIPA). The CNIPA held an oral hearing in September 2018 and in February 2019 upheld the validity of the challenged claims. Intel filed a complaint in April 2019 with the Beijing Intellectual Property (IP) Court challenging the February 2019 CNIPA ruling. The Beijing IP Court held oral arguments in July and October 2021 and in November 2021 affirmed the CNIPA ruling. In December 2021, Intel filed an appeal with the Supreme People's Court challenging the Beijing IP Court's affirmance of the CNIPA ruling. In January 2020, Intel filed a second invalidation request on the '457 patent with the CNIPA, for which the CNIPA heard oral argument in July 2020 and in November 2020 held the challenged apparatus claims invalid. IMECAS filed a complaint in February 2021 with the Beijing IP Court challenging the November 2020 CNIPA ruling. In December 2020, Intel filed a third invalidation request on the '457 patent with the CNIPA. The CNIPA held an oral hearing in June 2021 and in September 2021 upheld the validity of the challenged claims. Intel filed a complaint in December 2021 with the Beijing IP Court challenging the September 2021 CNIPA ruling. In September 2018 and March 2019, Intel filed petitions with the US Patent and Trademark Office (USPTO) requesting institution of inter partes review (IPR) of US Patent No. 9,070,719, the US counterpart to the '457 patent. The USPTO denied institution of Intel's petitions in March and October 2019, respectively. In April 2019, Intel filed a request for rehearing and a petition for a Precedential Opinion Panel (POP) in the USPTO to challenge the denial of its first IPR petition, and in November 2019 Intel filed a request for rehearing on the second IPR petition. In January 2020, the USPTO denied the POP petition on the first IPR petition. In June 2020, the Patent Trial and Appeal Board (PTAB) denied Intel's rehearing requests on both petitions. In October 2019, IMECAS filed second and third lawsuits in the Beijing IP Court, alleging infringement of Chinese Patent No. CN 102386226 ('226 Patent) based on the manufacturing and sale of Intel ® Core i3 microprocessors. Defendants in the second case are Lenovo (Beijing) Co., Ltd. (Lenovo) and Beijing Jiayun Huitong Technology Development Co. Ltd. (BJHT). Defendants in the third case are Intel Corp., Intel China Co., Ltd., the Intel China Beijing Branch, Beijing Digital China Co., Ltd. (Digital China), and JD. The complaint in the second lawsuit demands an injunction plus litigation costs and reserves the right to claim damages in unspecified amounts. Intel is indemnifying Lenovo in the second lawsuit. The Beijing IP Court held a trial hearing in the second lawsuit in November 2021, but no ruling has been issued. The complaint in the third lawsuit demands an injunction plus litigation costs and claims damages of RMB 10 million. Intel China's jurisdictional challenge in the third lawsuit was denied in June 2021 by the Beijing IP Court and in November 2021 by the Supreme People's Court. A trial hearing in the third lawsuit was held in January 2022, but no ruling has been issued. In July 2020, Intel and Lenovo filed invalidation requests on the '226 patent with the CNIPA. The CNIPA heard oral arguments in December 2020, during which IMECAS proposed amendments to two claims. In April 2021, the CNIPA upheld the validity of the challenged and amended claims on both invalidation requests. Intel and Lenovo filed complaints in July 2021 with the Beijing IP Court challenging the April 2021 CNIPA rulings; the Beijing IP Court held oral arguments in October 2021. Given the procedural posture and the nature of these cases, the unspecified nature and extent of damages claimed by IMECAS, and uncertainty regarding the availability of injunctive relief under applicable law, we are unable to make a reasonable estimate of the potential loss or range of losses, if any, arising from these matters. We dispute IMECAS's claims and intend to vigorously defend against them. VLSI Technology LLC v. Intel In October 2017, VLSI filed a complaint against Intel in the US District Court for the Northern District of California alleging infringement of eight patents acquired from NXP Semiconductors, N.V. (NXP). The patents, which originated at Freescale Semiconductor, Inc. and NXP B.V., are US Patent Nos. 7,268,588; 7,675,806; 7,706,207; 7,709,303; 8,004,922; 8,020,014; 8,268,672; and 8,566,836. VLSI accuses various FPGA and processor products of infringement. VLSI estimated its damages to be at least $5.5 billion, and its complaint further sought enhanced damages, future royalties, attorneys' fees, costs, and interest. In May, June, September, and October 2018, Intel filed IPR petitions challenging the patentability of certain claims in all eight of the patents in-suit. The PTAB instituted review of six patents and denied institution on two patents. As a result of the institution decisions, the parties stipulated to stay the District Court action in March 2019. In December 2019 and February 2020, the PTAB found all claims of the '588 and '303 patents, and some claims of the '922 patent, to be unpatentable. The PTAB found the challenged claims of the '014, '672 and '207 patents to be patentable. Intel appealed the PTAB’s decision as to ‘014, ‘672 and ‘207 patents. The Federal Circuit affirmed the PTAB’s decision as to the ‘672 and ‘207 patents, but reversed and remanded as to the ‘014 patent. Intel moved for a continuation of the stay in March 2020 pending the appeal. In June 2020, the District Court issued an order continuing the stay through August 2021. The court lifted the stay in September 2021 and scheduled a trial for March 2024. In June 2018, VLSI filed a second suit against Intel, in US District Court for the District of Delaware, alleging infringement by various Intel processors of five additional patents acquired from NXP: US Patent Nos. 6,212,663; 7,246,027; 7,247,552; 7,523,331; and 8,081,026. VLSI accused Intel of willful infringement and seeks an injunction or, in the alternative, ongoing royalties, enhanced damages, attorneys' fees and costs, and interest. In March 2019, the District Court dismissed VLSI's claims for willful infringement as to all the patents-in-suit except the '027 patent, and also dismissed VLSI's allegations of indirect infringement as to the '633, '331, and '026 patents. In June 2019, Intel filed IPR petitions challenging the patentability of certain claims in all five patents-in-suit. In January 2020, VLSI said that it was no longer asserting any claims of the '633 patent. In January and February 2020, the PTAB instituted review of the '552, '633, '331 and '026 patents, but declined to institute review of the '027 patent. As a result, the District Court stayed the case as to the '026 and '552 patents but allowed the case to proceed on the '027 and '331 patents. In January 2021, the PTAB invalidated certain asserted claims of the '026 patent, and in February the PTAB invalidated all asserted claims of the '552 patent. Both parties filed notices of appeal regarding the PTAB's decision as to the '026 patent in March 2021, and in April 2021, VLSI filed a notice of appeal of the PTAB's decision as to the '552 patent. The case remains stayed as to both of those patents. For the '027 and '331 patents, VLSI is seeking damages of approximately $4.13 billion plus enhanced damages for the '027 patent. Intel is filing summary judgment motions and challenges to expert witnesses in accordance with the court's January 2022 deadline. In March 2019, VLSI filed a third suit against Intel, also in US District Court for the District of Delaware, alleging infringement of six more patents acquired from NXP: US Patent Nos. 6,366,522; 6,663,187; 7,292,485; 7,606,983; 7,725,759; and 7,793,025. In April 2019, VLSI voluntarily dismissed this Delaware case without prejudice. In April 2019, VLSI filed three new infringement suits against Intel in the US District Court for the Western District of Texas (WDTX) accusing various Intel processors of infringement. The three suits collectively assert the same six patents from the voluntarily dismissed Delaware case plus two additional patents acquired from NXP, US Patent Nos. 7,523,373 and 8,156,357. VLSI accuses Intel of willful infringement and seeks an injunction or, in the alternative, ongoing royalties, enhanced damages, attorneys' fees and costs, and interest. In the first Texas case, VLSI asserted the '373 and '759 patents (in December 2020, the court granted Intel summary judgment of non-infringement on the '357 patent, which had also been asserted in the first Texas case). That case went to trial in February 2021, and the jury awarded a “lump sum” to VLSI of $1.5 billion for literal infringement of the ‘373 patent and $675 million for infringement under the doctrine of equivalents of the ‘759 patent. The jury found that Intel had not willfully infringed either patent. Intel has challenged the verdict with post-trial motions, including filing in May 2021 a motion for a new trial and a motion for judgment as a matter of law that the ‘373 and ‘759 patents are not infringed and the ‘759 patent is invalid. The court denied the motion for new trial in August 2021, but other post-trial motions, including the motion for judgment as a matter of law, remain pending. If the court does not vacate the verdict, Intel will challenge it on appeal. The second Texas case went to trial in April 2021, and the jury found that Intel does not infringe the ‘522 and ‘187 patents. VLSI had sought approximately $3.0 billion for alleged infringement of those patents, plus enhanced damages for willful infringement. The court has not yet entered a judgment following the first or second trials in Texas. The third Texas case has been postponed and is not currently set for trial. In that case, VLSI seeks approximately $2.2 billion to $2.4 billion for alleged infringement of the ‘983, ‘025 and ‘485 patents, plus enhanced damages for willful infringement. In October and November 2019 and in February 2020, Intel filed IPR petitions on certain asserted claims across six of the patents-in-suit in WDTX. Between May and October 2020, the PTAB denied all of these petitions on a discretionary basis and without reviewing the merits. Intel requested a rehearing, as well as review from the POP, as to all petitions. All requests for POP review and rehearing were denied. Intel filed notices of appeal regarding the discretionary denials for all petitions in February and March of 2021. The Federal Circuit dismissed the appeals in May 2021 for lack of jurisdiction. The Federal Circuit denied Intel's petition for hearing en banc in August 2021. In December 2021, Intel petitioned the Supreme Court to hear its appeal as to whether the Federal Circuit has jurisdiction to review the PTAB’s discretionary denials of Intel’s IPRs. In May 2019, VLSI filed a case in Shenzhen Intermediate People’s Court against Intel, Intel (China) Co., Ltd., Intel Trading (Shanghai) Co., Ltd., and Intel Products (Chengdu) Co., Ltd. VLSI asserts Chinese Patent 201410094015.9, accusing certain Intel Core processors of infringement. VLSI requests an injunction as well as RMB 1 million in damages and RMB 300 thousand in expenses. Defendants filed an invalidation petition in October 2019 with the CNIPA, which held a hearing in September 2021. In May 2020, defendants filed a motion to stay the trial court proceedings pending a determination on invalidity. The court held the first evidentiary hearing in November 2020 and the second in July 2021. The court also held trial proceedings in the hearing in July 2021 and concluded that further trial proceedings were needed but indicated those would be stayed pending the outcome of defendants’ invalidity challenge at the CNIPA. In July 2021, VLSI dismissed its case, but refiled it in August 2021. In November 2021, Intel moved for a stay of the August 2021 action pending a ruling on invalidity. The court has not yet ruled on that motion. In May 2019, VLSI filed a second case in Shanghai Intellectual Property Court against Intel (China) Co., Ltd., Intel Trading (Shanghai) Co., Ltd., and Intel Products (Chengdu) Co., Ltd. VLSI asserts Chinese Patent 201080024173.7. VLSI accuses certain Intel Core processors and seeks an injunction, as well as RMB 1 million in damages and RMB 300 thousand in expenses. Defendants filed with the CNIPA an invalidation petition in October 2019 and the CNIPA held a hearing in September 2021, but has not yet issued a decision. In June 2020, defendants filed a motion to stay the trial court proceedings pending a determination on invalidity. The court held its first evidentiary hearing in September 2020. The court held a second evidentiary hearing in December 2020, and a trial the same month. At trial, VLSI dropped its monetary damages claim, but still requested expenses (RMB 300 thousand) and an injunction. The court has not yet issued a decision following the trial. Rather, the court stayed the case in December 2020 pending a determination on invalidity by the CNIPA. In November 2019, Intel, along with Apple Inc., filed a complaint against Fortress Investment Group LLC, Fortress Credit Co. LLC, Uniloc 2017 LLC, Uniloc USA, Inc., Uniloc Luxembourg S.A.R.L., VLSI, INVT SPE LLC, Inventergy Global, Inc., DSS Technology Management, Inc., IXI IP, LLC, and Seven Networks, LLC. Plaintiffs allege violations of Section 1 of the Sherman Act by certain defendants, Section 7 of the Clayton Act by certain defendants, and California Business and Professions Code section 17200 by all defendants based on defendants' unlawful aggregation of patents. In 2020 and 2021, the court twice dismissed plaintiffs' complaint with leave to amend. In December 2020, the court granted a joint motion by Apple and Seven Networks to dismiss with prejudice Apple’s claims against Seven Networks. Plaintiffs filed a second amended complaint in March 2021. Defendants moved to dismiss the Second Amended Complaint in May 2021. Apple withdrew from the case and dismissed its claims in June 2021. The court heard defendants’ motion to dismiss the Second Amended Complaint in September 2021, and dismissed Intel’s claims with prejudice that same month, entering judgment in favor of defendants. Intel filed a notice of appeal in December 2021. In June 2020, affiliates controlled by Fortress Investment Group, which also controls VLSI, acquired Finjan Holdings, Inc. Intel had signed a "Settlement, Release and Patent License Agreement" with Finjan in 2012, acquiring a license to the patents of Finjan and its affiliates, current or future, through a capture period of November 20, 2022. The agreement also contains covenants wherein Finjan agrees to cause its affiliates to comply with the agreement. As such, Intel maintains that it now has a license to the patents of VLSI, which has become a Finjan affiliate, and that Finjan must cause VLSI to dismiss its suits against Intel. In August 2020, Intel started dispute resolution proceedings under the agreement. As a part of this dispute resolution process, Intel and Finjan held a mediation in December 2020, but failed to resolve their differences. Intel filed suit to enforce its rights under the License Agreement with Finjan in January 2021 in Delaware Chancery Court . In March 2021, defendants filed motions to dismiss the Chancery Court proceedings. The court heard those motions in May 2021, and dismissed all of Intel’s claims—except the breach of contract claim—with prejudice in September 2021 for lack of jurisdiction because, the court reasoned, Intel’s license defense has been raised in the other US suits between Intel and VLSI and could be adjudicated in one of those actions. The court stayed Intel’s breach of contract claim pending a determination on whether Intel is licensed to VLSI’s patents. In September 2020, Intel filed motions to stay the Texas, De

Accounting Policies (Policies)

Accounting Policies (Policies)	12 Months Ended
	Dec. 25, 2021
Accounting Policies [Abstract]
Revenue Recognition [Policy Text Block]	Revenue Recognition We recognize net product revenue when we satisfy performance obligations as evidenced by the transfer of control of our products or services to customers. Substantially all of our revenue is derived from product sales. In accordance with contract terms, revenue for product sales is recognized at the time of product shipment from our facilities or delivery to the customer location, as determined by the agreed upon shipping terms. We measure revenue based on the amount of consideration we expect to be entitled to in exchange for products or services. Variable consideration is estimated and reflected as an adjustment to the transaction price. We determine variable consideration, which consists primarily of various sales price concessions, by estimating the most likely amount of consideration we expect to receive from the customer based on historical analysis of customer purchase volumes. Sales rebates earned by customers are offset against their receivable balances. Rebates earned by customers when they do not have outstanding receivable balances are recorded within other accrued liabilities. We make payments to our customers through cooperative advertising programs for marketing activities for some of our products. We generally record the payment as a reduction in revenue in the period that the revenue is earned, unless the payment is for a distinct service, which we record as expense when the marketing activities occur.
Inventories [Policy Text Block]	Inventories We compute inventory cost on a first-in, first-out basis. Our process and product development life cycle corresponds with substantive engineering milestones. These engineering milestones are regularly and consistently applied in assessing the point at which our activities and associated costs change in nature from R&D to cost of sales, and when cost of sales can be capitalized as inventory. For a product to be manufactured in high volumes and sold to our customers under our standard warranty, it must meet our rigorous technical quality specifications. This milestone is known as PRQ. We have identified PRQ as the point at which the costs incurred to manufacture our products are included in the valuation of inventory. A single PRQ has previously valued inventory up to $870 million in the quarter the PRQ milestone was achieved. Prior to PRQ, costs that do not meet the criteria for R&D are included in cost of sales in the period incurred. The valuation of inventory includes determining which fixed production overhead costs can be included in inventory based on the normal capacity of our manufacturing and assembly and test facilities. We apply our historical loadings compared to our total available capacity in a statistical model to determine our normal capacity level. If the factory loadings are below the established normal capacity level, a portion of our fixed production overhead costs would not be included in the cost of inventory; instead, it would be recognized as cost of sales in that period. We refer to these costs as excess capacity charges. Excess capacity charges are insignificant in the years presented. Charges in years prior to those presented have ranged up to $1.1 billion taken in connection with the 2009 economic recession. Inventory is valued at the lower of cost or net realizable value, based upon assumptions about future demand and market conditions. Product-specific facts and circumstances reviewed in the inventory valuation process include a review of our customer base, the stage of the product life cycle, variations in market pricing, and an assessment of selling price in relation to product cost. Lower of cost or net realizable value inventory reserves fluctuate as we ramp new process technologies, with costs improving over time due to scale and improved yields. Additionally, inventory valuation is impacted by cyclical changes in market conditions and the associated pricing environment.
Property, Plant and Equipment [Policy Text Block]	Property, Plant and Equipment We compute depreciation using the straight-line method over the estimated useful life of assets. We also capitalize interest on borrowings related to eligible capital expenditures. Capitalized interest is added to the cost of qualified assets and depreciated together with that asset cost. We record capital-related government grants earned as a reduction to property, plant and equipment. We evaluate the period over which we expect to recover the economic value of our property, plant and equipment, considering factors such as the process technology cadence between node transitions, changes in machinery and equipment technology, and re-use of machinery and tools across each generation of process technology. As we make manufacturing process conversions and other factory planning decisions, we use assumptions involving the use of management judgments regarding the remaining useful lives of assets, primarily process-specific semiconductor manufacturing tools and building improvements. When we determine that the useful lives of assets are shorter or longer than we had originally estimated, we adjust the rate of depreciation to reflect the assets' revised useful lives.
Fair Value [Policy Text Block]	Fair Value When determining fair value, we consider the principal or most advantageous market in which we would transact, as well as assumptions that market participants would use when pricing the asset or liability. Our financial assets are measured and recorded at fair value on a recurring basis, except for equity securities measured using the measurement alternative, equity method investments, and grants receivable. We assess fair value hierarchy levels for our issued debt and fixed-income investment portfolio based on the underlying instrument type. The three levels of inputs that may be used to measure fair value are: ▪ Level 1 . Quoted prices in active markets for identical assets or liabilities. We evaluate security-specific market data when determining whether a market is active. ▪ Level 2. Observable inputs other than Level 1 prices, such as quoted prices for similar assets or liabilities, quoted prices in less active markets, or model-derived valuations. All significant inputs used in our valuations, such as discounted cash flows, are observable or can be derived principally from or corroborated with observable market data for substantially the full term of the assets or liabilities. We use LIBOR-based yield curves, overnight indexed swap curves, currency spot and forward rates, and credit ratings as significant inputs in our valuations. Level 2 inputs also include non-binding market consensus prices, as well as quoted prices that were adjusted for security-specific restrictions. When we use non-binding market consensus prices, we corroborate them with quoted market prices for similar instruments or compare them to output from internally developed pricing models such as discounted cash flow models. ▪ Level 3. Unobservable inputs to the valuation methodology that are significant to the measurement of the fair value of assets or liabilities. We monitor and review the inputs and results of these valuation models to help ensure the fair value measurements are reasonable and consistent with market experience in similar asset classes. Level 3 inputs also include non-binding market consensus prices or non-binding broker quotes that we were unable to corroborate with observable market data.
Cash Equivalents [Policy Text Block]	Cash equivalents can include investments such as corporate debt, financial institution instruments, government debt, and reverse repurchase agreements.
Debt Investments and Equity Investments [Policy Text Block]	Debt Investments We consider all highly liquid debt investments with original maturities from the date of purchase of three months or less as cash equivalents. Cash equivalents can include investments such as corporate debt, financial institution instruments, government debt, and reverse repurchase agreements. Marketable debt investments are generally designated as trading assets when a market risk is economically hedged at inception with a related derivative instrument, or when the marketable debt investment itself is used to economically hedge currency exchange rate risk from remeasurement. Investments designated as trading assets are reported at fair value. Gains or losses on these investments arising from changes in fair value due to interest rate and currency market fluctuations and credit market volatility, largely offset by losses or gains on the related derivative instruments and balance sheet remeasurement, are recorded in interest and other, net. Marketable debt investments are considered available-for-sale investments when the interest rate and foreign currency risks are not hedged at the inception of the investment or when our criteria for designation as trading assets are not met. Available-for-sale debt investments with original maturities of approximately three months or less from the date of purchase are classified within cash and cash equivalents. Available-for-sale debt investments with original maturities at the date of purchase greater than approximately three months and remaining maturities of less than one year are classified as short-term investments. Available-for-sale debt investments with remaining maturities beyond one year are classified as other long-term investments. Available-for-sale debt investments are reported at fair value, with unrealized gains or losses, net of tax, recorded in accumulated other comprehensive income (loss). We determine the cost of the investment sold based on an average cost basis at the individual security level, and record the interest income and realized gains or losses on the sale of these investments in interest and other, net. Our available-for-sale debt investments are subject to periodic impairment reviews. For investments in an unrealized loss position, we determine whether a credit loss exists by considering information about the collectability of the instrument, current market conditions, and reasonable and supportable forecasts of economic conditions. We recognize an allowance for credit losses, up to the amount of the unrealized loss when appropriate, and write down the amortized cost basis of the investment if it is more likely than not we will be required or we intend to sell the investment before recovery of its amortized cost basis. Allowances for credit losses and write-downs are recognized in interest and other, net, and unrealized losses not related to credit losses are recognized in other comprehensive income (loss). Equity Investments We regularly invest in equity securities of public and private companies to promote business and strategic objectives. Equity investments are measured and recorded as follows: ▪ Marketable equity securities are equity securities with RDFV that are measured and recorded at fair value on a recurring basis with changes in fair value, whether realized or unrealized, recorded through the income statement. ▪ Non-marketable equity securities are equity securities without RDFV that are measured and recorded using a measurement alternative that measures the securities at cost minus impairment, if any, plus or minus changes resulting from qualifying observable price changes. ▪ Equity method investments are equity securities in investees we do not control but over which we have the ability to exercise significant influence. Equity method investments are measured at cost minus impairment, if any, plus or minus our share of equity method investee income or loss. Our proportionate share of the income or loss from equity method investments is recognized on a one-quarter lag. Realized and unrealized gains and losses resulting from changes in fair value or the sale of our equity investments are recorded in gains (losses) on equity investments, net. The carrying value of our non-marketable equity securities is adjusted for qualifying observable price changes resulting from the issuance of similar or identical securities in an orderly transaction by the same issuer. Determining whether an observed transaction is similar to a security within our portfolio requires judgment based on the rights and preferences of the securities. Recording upward and downward adjustments to the carrying value of our equity securities as a result of observable price changes requires quantitative assessments of the fair value of our securities using various valuation methodologies and involves the use of estimates. Non-marketable equity securities and equity method investments (collectively referred to as non-marketable equity investments) are also subject to periodic impairment reviews. Our quarterly impairment analysis considers both qualitative and quantitative factors that may have a significant impact on the investee's fair value. Qualitative factors considered include the investee's financial condition and business outlook, industry and sector performance, market for technology, operational and financing cash flow activities, and other relevant events and factors affecting the investee. When indicators of impairment exist, we prepare quantitative assessments of the fair value of our non-marketable equity investments using both the market and income approaches, which require judgment and the use of estimates, including discount rates, investee revenue and costs, and comparable market data of private and public companies, among others. ▪ Non-marketable equity securities are tested for impairment using a qualitative model similar to the model used for goodwill and long-lived assets. Upon determining that an impairment may exist, the security's fair value is calculated and compared to its carrying value and an impairment is recognized immediately if the carrying value exceeds the fair value. ▪ Equity method investments are subject to periodic impairment reviews using the other-than-temporary impairment model, which considers the severity and duration of a decline in fair value below cost and our ability and intent to hold the investment for a sufficient period of time to allow for recovery. Impairments of equity investments are recorded in gains (losses) on equity investments, net.
Derivative Financial Instruments [Policy Text Block]	Derivative Financial Instruments Our primary objective for holding derivative financial instruments is to manage currency exchange rate risk and interest rate risk, and, to a lesser extent, equity market risk, commodity price risk, and credit risk. We enter into master netting arrangements to mitigate credit risk in derivative transactions by permitting net settlement of transactions with the same counterparty. We also enter into collateral security arrangements with certain of our counterparties to exchange cash collateral when the net fair value of certain derivative instruments fluctuates from contractually established thresholds. For presentation on our Consolidated Balance Sheets, we do not offset fair value amounts recognized for derivative instruments under master netting arrangements. Our derivative financial instruments, including related collateral amounts, are presented at fair value on a gross basis and are included in other current assets, other long-term assets, other accrued liabilities, or other long-term liabilities. Cash flow hedges use foreign currency contracts, such as currency forwards and currency interest rate swaps, to hedge exposures for variability in the US-dollar equivalent of non-US-dollar-denominated cash flows associated with our forecasted operating and capital purchases spending. The after-tax gains or losses from the effective portion of a cash flow hedge is reported as a component of accumulated other comprehensive income (loss) and reclassified into earnings in the same period or periods in which the hedged transaction affects earnings, and in the same line item on the Consolidated Statements of Income as the impact of the hedge transaction. For foreign currency contracts hedging our capital purchases, forward points are excluded from the hedge effectiveness assessment, and are recognized in earnings in the same income statement line item used to present the earnings effect of the hedged item. If the cash flow hedge transactions become improbable, the corresponding amounts deferred in accumulated other comprehensive income (loss) would be immediately reclassified to interest and other, net. These derivatives are classified in the Consolidated Statements of Cash Flows in the same section as the underlying item. Fair value hedges use interest rate contracts, such as interest rate swaps, to hedge against changes in the fair value on certain of our fixed-rate indebtedness attributable to changes in the benchmark interest rate. The gains or losses on these hedges, as well as the offsetting losses or gains related to the changes in the fair value of the underlying hedged item attributable to the hedged risk, are recognized in earnings in the current period, primarily in interest and other, net. These derivatives are classified in the Consolidated Statements of Cash Flows in the same section as the underlying item, primarily within cash flows from financing activities.
Loans Receivable [Policy Text Block]	Loans ReceivableWe elect the fair value option when the interest rate or foreign currency exchange rate risk is economically hedged at the inception of the loan with a related derivative instrument. When the fair value option is not elected, the loans are carried at amortized cost. We measure interest income for all loans receivable using the interest method, which is based on the effective yield of the loans rather than the stated coupon rate. We classify our loans within other current and long-term assets.
Credit Risk [Policy Text Block]	Credit Risk Financial instruments that potentially subject us to concentrations of credit risk consist principally of investments in debt instruments, derivative financial instruments, loans receivable, reverse repurchase agreements, and trade receivables. We generally place investments with high-credit-quality counterparties and, by policy, we limit the amount of credit exposure to any one counterparty based on our analysis of that counterparty's relative credit standing. As required per our investment policy, substantially all of our investments in debt instruments are in investment-grade instruments. Credit-rating criteria for derivative instruments are similar to those for other investments. We enter into master netting arrangements to mitigate credit risk in derivative transactions by permitting net settlement of transactions with the same counterparty. Due to master netting arrangements, the amounts subject to credit risk related to derivative instruments are generally limited to the amounts, if any, by which the counterparty's obligations exceed our obligations with that counterparty. As of December 25, 2021, our total credit exposure to any single counterparty, excluding money market funds invested in US treasury and US agency securities and reverse repurchase agreements collateralized by treasury and agency securities, did not exceed $2.6 billion. To further reduce credit risk, we enter into collateral security arrangements with certain of our derivative counterparties and obtain and secure collateral from counterparties against obligations, including securities lending transactions when we deem it appropriate. Cash collateral exchanged under our collateral security arrangements are included in other current assets, other long-term assets, other accrued liabilities, or other long-term liabilities. For reverse repurchase agreements collateralized by other securities, we do not record the collateral as an asset or a liability unless the collateral is repledged. A substantial majority of our trade receivables are derived from sales to OEMs and ODMs. We also have accounts receivable derived from sales to industrial and communications equipment manufacturers in the computing and communications industries. We believe the net accounts receivable balances from our three largest customers (42% as of December 25, 2021) do not represent a significant credit risk, based on cash flow forecasts, balance sheet analysis, and past collection experience. We have adopted credit policies and standards intended to accommodate industry growth and inherent risk. We believe credit risks are moderated by the financial stability of our major customers. We assess credit risk through quantitative and qualitative analysis. From this analysis, we establish shipping and credit limits, and determine whether we will seek to use one or more credit support protection devices, such as obtaining a parent guarantee, standby letter of credit, or credit insurance.
Business Combinations Policy [Policy Text Block]	Business Combinations We allocate the purchase price paid for assets acquired and liabilities assumed in connection with our acquisitions based on their estimated fair values at the time of acquisition. This allocation involves a number of assumptions, estimates, and judgments in determining the fair value of the following: ▪ inventory; property, plant and equipment; pre-existing liabilities or legal claims; and contingent consideration, each as may be applicable; ▪ intangible assets, including the valuation methodology, estimations of future cash flows, discount rates, market segment growth rates, and our assumed market segment share, as well as the estimated useful life of intangible assets; ▪ deferred tax assets and liabilities, uncertain tax positions, and tax-related valuation allowances, which are initially estimated as of the acquisition date; and ▪ goodwill as measured as the excess of consideration transferred over the net of the acquisition date fair values of the assets acquired and the liabilities assumed. Our assumptions and estimates are based upon comparable market data and information obtained from our management and the management of the acquired companies. We allocate goodwill to the reporting units of the business that are expected to benefit from the business combination.
Goodwill and Intangible Assets, Goodwill, Policy [Policy Text Block]	Goodwill We perform an annual impairment assessment of goodwill at the reporting unit level in the fourth quarter of each year, or more frequently if indicators of potential impairment exist. The analysis may include both qualitative and quantitative factors to assess the likelihood of an impairment. The reporting unit's carrying value used in an impairment test represents the assignment of various assets and liabilities, excluding certain corporate assets and liabilities, such as cash, investments, and debt. Qualitative factors include industry and market considerations, overall financial performance, and other relevant events and factors affecting the reporting unit. Additionally, as part of this assessment, we may perform a quantitative analysis to support the qualitative factors above by applying sensitivities to assumptions and inputs used in measuring a reporting unit's fair value. Our quantitative impairment test considers both the income approach and the market approach to estimate a reporting unit's fair value. Significant estimates include market segment growth rates, our assumed market segment share, estimated gross margins, operating expenses, and discount rates based on a reporting unit's weighted average cost of capital.
Identified Intangible Assets [Policy Text Block]	Identified Intangible Assets We amortize acquisition-related intangible assets that are subject to amortization over their estimated useful life. Acquisition-related in-process R&D assets represent the fair value of incomplete R&D projects that had not reached technological feasibility as of the date of acquisition; initially, these are classified as in-process R&D and are not subject to amortization. Once these R&D projects are completed, the asset balances are transferred from in-process R&D to acquisition-related developed technology and are subject to amortization from that point forward. The asset balances relating to projects that are abandoned after acquisition are impaired and expensed to R&D.
Employee Equity Incentive Plans [Policy Text Block]	Employee Equity Incentive Plans We use the straight-line amortization method to recognize share-based compensation expense over the service period of the award, net of estimated forfeitures. Upon exercise, cancellation, forfeiture, or expiration of stock options, or upon vesting or forfeiture of RSUs, we eliminate deferred tax assets for options and RSUs with multiple vesting dates for each vesting period on a first-in, first-out basis as if each vesting period were a separate award.
Income Taxes [Policy Text Block]	Income Taxes We compute the provision for income taxes using the asset and liability method, under which deferred tax assets and liabilities are recognized for the expected future tax consequences of temporary differences between the financial reporting and tax bases of assets and liabilities, and for operating losses and tax credit carryforwards. We measure deferred tax assets and liabilities using the currently enacted tax rates that apply to taxable income in effect for the years in which those tax assets are expected to be realized or settled. We assess the likelihood that we will be able to recover our deferred tax assets. If recovery is not likely, we must increase our provision for taxes by recording a valuation allowance against the deferred tax assets that we estimate will not ultimately be recoverable. We believe that we will ultimately recover the deferred tax assets recorded on our Consolidated Balance Sheets. Recovery of a portion of our deferred tax assets is affected by management's plans with respect to holding or disposing of certain investments; therefore, such changes could also affect our future provision for taxes. We recognize tax benefits from uncertain tax positions only if (based on the technical merits of the position) it is more likely than not that the tax positions will be sustained on examination by the tax authority. The tax benefits recognized in the financial statements from such positions are measured based on the largest amount that is more than 50% likely to be realized upon ultimate settlement. We recognize interest and penalties related to unrecognized tax benefits within the provision for taxes on the Consolidated Statements of Income.
Leases	Leases Leases consist of real property and machinery and equipment. Our lease terms may include options to extend when it is reasonably certain that we will exercise that option. We have lease agreements with lease and non-lease components, and the non-lease components are accounted for separately and not included in our leased assets and corresponding liabilities. Payments on leases may be fixed or variable, and variable lease payments are based on output of the underlying leased assets.
Loss Contingencies [Policy Text Block]	Loss Contingencies We are subject to loss contingencies, including various legal and regulatory proceedings, asserted and potential claims, liabilities related to repair or replacement of parts in connection with product defects, as well as product warranties and potential asset impairments that arise in the ordinary course of business. An estimated loss from such contingencies is recognized as a charge to income if it is probable that a liability has been incurred and the amount of the loss can be reasonably estimated. We evaluate developments that could affect the amount of liability that has been previously accrued and reasonably possible losses disclosed, and make adjustments as appropriate. Significant judgment is required to determine both likelihood of there being, and the estimated amount of, a loss related to such matters.

Operating Segments (Tables)

Operating Segments (Tables)	12 Months Ended
	Dec. 25, 2021
Segment Reporting [Abstract]
Schedule of Segment Reporting Information, by Segment [Table Text Block]	Net revenue and operating income (loss) for each period were as follows: Years Ended (In Millions) Dec 25, 2021 Dec 26, 2020 Dec 28, 2019 Net revenue: Client Computing Group Platform $ 37,376 $ 35,642 $ 32,681 Adjacent 3,135 4,415 4,465 40,511 40,057 37,146 Data Center Group Platform 22,703 23,056 21,441 Adjacent 3,118 3,047 2,040 25,821 26,103 23,481 Internet of Things IOTG 3,998 3,007 3,821 Mobileye 1,386 967 879 5,384 3,974 4,700 Non-Volatile Memory Solutions Group 4,306 5,358 4,362 Programmable Solutions Group 1,934 1,853 1,987 All other 1,068 522 289 Total net revenue $ 79,024 $ 77,867 $ 71,965 Operating income (loss): Client Computing Group $ 14,672 $ 15,129 $ 15,202 Data Center Group 6,997 10,571 10,227 Internet of Things IOTG 1,045 497 1,097 Mobileye 460 241 245 1,505 738 1,342 Non-Volatile Memory Solutions Group 1,369 361 (1,176) Programmable Solutions Group 297 260 318 All other (5,384) (3,381) (3,878) Total operating income $ 19,456 $ 23,678 $ 22,035
Revenue from External Customers by Products and Services [Table Text Block]	Disaggregated net revenue for each period was as follows: Years Ended (In Millions) Dec 25, 2021 Dec 26, 2020 Dec 28, 2019 Platform revenue CCG notebook platform $ 25,475 $ 24,903 $ 20,779 CCG desktop platform 11,835 10,692 11,822 CCG other platform 1 66 47 80 DCG platform 22,703 23,056 21,441 IOTG platform 3,658 2,705 3,440 63,737 61,403 57,562 Adjacent revenue 2 15,287 16,464 14,403 Total revenue $ 79,024 $ 77,867 $ 71,965 1 Includes our tablet and service provider revenue.
Revenue from External Customers by Geographic Areas [Table Text Block]	Net revenue by region, based on the billing location of the customer, was as follows: Years Ended (In Millions) Dec 25, 2021 Dec 26, 2020 Dec 28, 2019 China $ 21,141 $ 20,257 $ 20,026 Singapore 14,254 17,845 15,650 United States 14,107 16,573 15,617 Taiwan 13,461 11,605 10,058 Other regions 16,061 11,587 10,614 Total net revenue $ 79,024 $ 77,867 $ 71,965

Earnings Per Share (Tables)

Earnings Per Share (Tables)	12 Months Ended
	Dec. 25, 2021
Earnings Per Share [Abstract]
Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]	Years Ended (In Millions, Except Per Share Amounts) Dec 25, 2021 Dec 26, 2020 Dec 28, 2019 Net income available to common stockholders $ 19,868 $ 20,899 $ 21,048 Weighted average shares of common stock outstanding—basic 4,059 4,199 4,417 Dilutive effect of employee incentive plans 31 33 41 Dilutive effect of convertible debt — — 15 Weighted average shares of common stock outstanding—diluted 4,090 4,232 4,473 Earnings per share—basic $ 4.89 $ 4.98 $ 4.77 Earnings per share—diluted $ 4.86 $ 4.94 $ 4.71

Contract Liabilities (Tables)

Contract Liabilities (Tables)	12 Months Ended
	Dec. 25, 2021
Revenue from Contract with Customer [Abstract]
Contract with Customer, Asset and Liability	The following table shows the changes in contract liability balances relating to long-term prepaid customer supply agreements during 2021: (In Millions) Prepaid customer supply agreements balance as of December 26, 2020 $ 1,625 Concession payment (950) Prepaids utilized (633) Prepaid customer supply agreements balance as of December 25, 2021 $ 42

Other Financial Statement Det_2

Other Financial Statement Details (Tables)	12 Months Ended
	Dec. 25, 2021
Other Financial Statement Details [Abstract]
Inventories [Table Text Block]	(In Millions) Dec 25, 2021 Dec 26, 2020 Raw materials $ 1,441 $ 908 Work in process 6,656 5,693 Finished goods 2,679 1,826 Total inventories $ 10,776 $ 8,427
Property, Plant and Equipment [Table Text Block]	(In Millions) Dec 25, 2021 Dec 26, 2020 Land and buildings $ 40,039 $ 37,536 Machinery and equipment 86,955 79,384 Construction in progress 21,545 17,309 Total property, plant and equipment, gross 148,539 134,229 Less: accumulated depreciation (85,294) (77,645) Total property, plant and equipment, net $ 63,245 $ 56,584
Long-lived Assets by Geographic Areas [Table Text Block]	Net property, plant and equipment by country at the end of each period was as follows: (In Millions) Dec 25, 2021 Dec 26, 2020 United States $ 43,428 $ 38,829 Israel 7,754 7,837 Ireland 7,503 5,828 Other countries 4,560 4,090 Total property, plant and equipment, net $ 63,245 $ 56,584
Interest and Other, Net [Table Text Block]	Years Ended (In Millions) Dec 25, 2021 Dec 26, 2020 Dec 28, 2019 Interest income $ 144 $ 272 $ 483 Interest expense (597) (629) (489) Other, net (29) (147) 490 Total interest and other, net $ (482) $ (504) $ 484

Restructuring and Other Charg_2

Restructuring and Other Charges (Tables) - USD ($) $ in Millions	12 Months Ended
	Dec. 25, 2021	Dec. 26, 2020
Restructuring Cost and Reserve [Line Items]
Restructuring and Related Cost, Incurred Cost	$ 2,626	$ 198

Income Taxes (Tables)

Income Taxes (Tables)	12 Months Ended
	Dec. 25, 2021
Income Tax Disclosure [Abstract]
Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]	Years Ended (In Millions) Dec 25, 2021 Dec 26, 2020 Dec 28, 2019 Income before taxes: US $ 9,361 $ 15,452 $ 13,729 Non-US 12,342 9,626 10,329 Total income before taxes 21,703 25,078 24,058 Provision for taxes: Current: Federal 1,304 1,120 1,391 State 75 46 37 Non-US 1,198 1,244 1,060 Total current provision for taxes 2,577 2,410 2,488 Deferred: Federal (863) 1,369 597 State (25) 25 1 Non-US 146 375 (76) Total deferred provision for taxes (742) 1,769 522 Total provision for taxes $ 1,835 $ 4,179 $ 3,010 Effective tax rate 8.5 % 16.7 % 12.5 %
Schedule of Income before Income Tax, Domestic and Foreign [Table Text Block]	Years Ended (In Millions) Dec 25, 2021 Dec 26, 2020 Dec 28, 2019 Income before taxes: US $ 9,361 $ 15,452 $ 13,729 Non-US 12,342 9,626 10,329 Total income before taxes 21,703 25,078 24,058 Provision for taxes: Current: Federal 1,304 1,120 1,391 State 75 46 37 Non-US 1,198 1,244 1,060 Total current provision for taxes 2,577 2,410 2,488 Deferred: Federal (863) 1,369 597 State (25) 25 1 Non-US 146 375 (76) Total deferred provision for taxes (742) 1,769 522 Total provision for taxes $ 1,835 $ 4,179 $ 3,010 Effective tax rate 8.5 % 16.7 % 12.5 %
Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]	The difference between the tax provision at the statutory federal income tax rate and the tax provision as a percentage of income before income taxes (effective tax rate) for each period was as follows: Years Ended Dec 25, 2021 Dec 26, 2020 Dec 28, 2019 Statutory federal income tax rate 21.0 % 21.0 % 21.0 % Increase (reduction) in rate resulting from: Non-US income taxed at different rates (5.9) (3.7) (3.7) Research and development tax credits (2.4) (2.1) (2.3) Restructuring of certain non-U.S. subsidiaries (3.4) — — Foreign derived intangible income benefit (2.2) (1.9) (3.2) Change in permanent reinvestment assertion — 1.6 — Other 1.4 1.8 0.7 Effective tax rate 8.5 % 16.7 % 12.5 %
Schedule of Deferred Tax Assets and Liabilities [Table Text Block]	Deferred income taxes reflect the net tax effects of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts for income tax purposes. Significant components of our deferred tax assets and liabilities at the end of each period were as follows: (In Millions) Dec 25, 2021 Dec 26, 2020 Deferred tax assets: Accrued compensation and other benefits $ 1,019 $ 865 Share-based compensation 477 324 Litigation charge 467 — Inventory 914 835 R&D expenditures capitalization 519 — State credits and net operating losses 2,010 1,829 Other, net 819 617 Gross deferred tax assets 6,225 4,470 Valuation allowance (2,259) (1,963) Total deferred tax assets 3,966 2,507 Deferred tax liabilities: Property, plant and equipment (4,213) (3,109) Licenses and intangibles (486) (725) Unrealized gains on investments and derivatives (819) (735) Unremitted earnings of non-US subsidiaries — (403) Other, net (241) (146) Total deferred tax liabilities (5,759) (5,118) Net deferred tax assets (liabilities) $ (1,793) $ (2,611) Reported as: Deferred tax assets 874 1,232 Deferred tax liabilities (2,667) (3,843) Net deferred tax assets (liabilities) $ (1,793) $ (2,611)
Summary of Valuation Allowance [Table Text Block]	Change in valuation allowance for deferred tax assets were as follows: Years Ended (In Millions) Balance at Beginning of Year Additions Charged to Expenses/ Net Balance at Valuation allowance for deferred tax assets December 25, 2021 $ 1,963 $ 442 $ (146) $ 2,259 December 26, 2020 $ 1,534 $ 378 $ 51 $ 1,963 December 28, 2019 $ 1,302 $ 239 $ (7) $ 1,534
Schedule of Unrecognized Tax Benefits Roll Forward	Uncertain Tax Positions (In Millions) Dec 25, 2021 Dec 26, 2020 Dec 28, 2019 Beginning gross unrecognized tax benefits $ 828 $ 548 $ 283 Settlements and effective settlements with tax authorities (25) (142) (4) Changes in balances related to tax position taken during prior periods (26) 165 122 Changes in balances related to tax position taken during current period 243 257 147 Ending gross unrecognized tax benefits $ 1,020 $ 828 $ 548

Investments (Tables)

Investments (Tables)	12 Months Ended
	Dec. 25, 2021
Debt Securities, Available-for-sale [Line Items]
Investment [Table Text Block]	(In Millions) Dec 25, 2021 Dec 26, 2020 Marketable equity securities $ 2,171 $ 1,830 Non-marketable equity securities 4,111 3,304 Equity method investments 16 18 Total $ 6,298 $ 5,152
Gain (Loss) on Securities [Table Text Block]	The components of gains (losses) on equity investments, net for each period were as follows: Years Ended (In Millions) Dec 25, 2021 Dec 26, 2020 Dec 28, 2019 Ongoing mark-to-market adjustments on marketable equity securities $ (130) $ (133) $ 277 Observable price adjustments on non-marketable equity securities 750 176 293 Impairment charges (154) (303) (122) Sale of equity investments and other 1 2,263 2,164 1,091 Total gains (losses) on equity investments, net $ 2,729 $ 1,904 $ 1,539 1 Sale of equity investments and other includes initial fair value adjustments recorded upon a security becoming marketable, realized gains (losses) on sales of non-marketable equity investments, and our share of equity method investee gains (losses) and distributions. (In Millions) Dec 25, 2021 Dec 26, 2020 Dec 28, 2019 Net gains (losses) recognized during the period on equity securities $ 1,210 $ 1,679 $ 734 Less: Net (gains) losses recognized during the period on equity securities sold during the period (259) (254) (424) Net unrealized gains (losses) recognized during the period on equity securities still held at the reporting date $ 951 $ 1,425 $ 310
Available-for-sale Securities [Member]
Debt Securities, Available-for-sale [Line Items]
Investments Classified by Contractual Maturity Date [Table Text Block]	The fair values of available-for-sale debt investments by contractual maturity as of December 25, 2021 were as follows: (In Millions) Fair Value Due in 1 year or less $ 2,931 Due in 1–2 years 559 Due in 2–5 years 281 Due after 5 years — Instruments not due at a single maturity date 1,216 Total $ 4,987

Acquisitions & Divestitures (Ta

Acquisitions & Divestitures (Tables)	12 Months Ended
	Dec. 25, 2021
Business Combinations [Abstract]
Disposal Groups, Including Discontinued Operations [Table Text Block]	The carrying amounts of the major classes of NAND assets held for sale included the following: (In Millions) Dec 25, 2021 Dec 26, 2020 Inventories $ 953 $ 962 Property, plant and equipment, net 5,989 4,363 Total assets $ 6,942 $ 5,325

Goodwill (Tables)

Goodwill (Tables)	12 Months Ended
	Dec. 25, 2021
Business Combination, Goodwill [Abstract]
Schedule of Goodwill [Table Text Block]	Dec 26, 2020 Acquisitions Other Dec 25, 2021 Client Computing Group $ 4,360 $ 73 $ — $ 4,433 Data Center Group 7,232 123 — 7,355 Internet of Things Group 1,591 — — 1,591 Mobileye 10,928 — — 10,928 Programmable Solutions Group 2,622 — 34 2,656 All other 238 — (238) — Total $ 26,971 $ 196 $ (204) $ 26,963 (In Millions) Dec 28, 2019 Acquisitions Other Dec 26, 2020 Client Computing Group $ 4,333 $ 27 $ — $ 4,360 Data Center Group 7,182 50 — 7,232 Internet of Things Group 1,579 12 — 1,591 Mobileye 10,290 638 — 10,928 Programmable Solutions Group 2,654 2 (34) 2,622 All other 238 — — 238 Total $ 26,276 $ 729 $ (34) $ 26,971

Identified Intangible Assets (T

Identified Intangible Assets (Tables)	12 Months Ended
	Dec. 25, 2021
Intangible Assets, Net (Excluding Goodwill) [Abstract]
Schedule of Finite-Lived Intangible Assets [Table Text Block]	December 25, 2021 December 26, 2020 (In Millions) Gross Assets Accumulated Amortization Net Gross Assets Accumulated Amortization Net Developed technology $ 11,102 $ (6,026) $ 5,076 $ 10,188 $ (4,880) $ 5,308 Customer relationships and brands 2,110 (1,063) 1,047 2,110 (854) 1,256 Licensed technology and patents 2,893 (1,746) 1,147 2,836 (1,629) 1,207 In-process R&D — — — 954 — 954 Other non-amortizing intangibles — — — 301 — 301 Total identified intangible assets $ 16,105 $ (8,835) $ 7,270 $ 16,389 $ (7,363) $ 9,026
Schedule of Indefinite-Lived Intangible Assets [Table Text Block]	December 25, 2021 December 26, 2020 (In Millions) Gross Assets Accumulated Amortization Net Gross Assets Accumulated Amortization Net Developed technology $ 11,102 $ (6,026) $ 5,076 $ 10,188 $ (4,880) $ 5,308 Customer relationships and brands 2,110 (1,063) 1,047 2,110 (854) 1,256 Licensed technology and patents 2,893 (1,746) 1,147 2,836 (1,629) 1,207 In-process R&D — — — 954 — 954 Other non-amortizing intangibles — — — 301 — 301 Total identified intangible assets $ 16,105 $ (8,835) $ 7,270 $ 16,389 $ (7,363) $ 9,026
Finite-lived Intangible Assets Amortization Expense [Table Text Block]	Amortization expenses recorded for identified intangible assets in the Consolidated Statements of Income for each period and the weighted average useful life were as follows: Years Ended (In Millions) Location Dec 25, 2021 Dec 26, 2020 Dec 28, 2019 Weighted Average Useful Life 1 Developed technology Cost of sales $ 1,283 $ 1,211 $ 1,124 9 years Customer relationships and brands Marketing, general and administrative 209 205 200 11 years Licensed technology and patents Cost of sales 347 341 298 13 years Total amortization expenses $ 1,839 $ 1,757 $ 1,622
Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block]	We expect future amortization expense for the next five years and thereafter to be as follows: (In Millions) 2022 2023 2024 2025 2026 Thereafter Total Future amortization expenses $ 1,854 $ 1,622 $ 1,188 $ 779 $ 598 $ 1,229 $ 7,270

Borrowings (Tables)

Borrowings (Tables)	12 Months Ended
	Dec. 25, 2021
Debt Disclosure [Abstract]
Schedule of Long-term Debt Instruments [Table Text Block]	Long-Term Debt Dec 25, 2021 Dec 26, 2020 (In Millions) Effective Interest Rate Amount Amount Floating-rate senior note: Three-month LIBOR plus 0.35%, due May 2022 0.55% $ 800 $ 800 Fixed-rate senior notes: 1.70%, due May 2021 —% — 500 3.30%, due October 2021 —% — 2,000 2.35%, due May 2022 1.96% 750 750 3.10%, due July 2022 2.70% 1,000 1,000 4.00%, due December 2022 1 2.96% 398 417 2.70%, due December 2022 2.28% 1,500 1,500 4.10%, due November 2023 3.22% 400 400 2.88%, due May 2024 2.31% 1,250 1,250 2.70%, due June 2024 2.14% 600 600 3.40%, due March 2025 3.45% 1,500 1,500 3.70%, due July 2025 2.16% 2,250 2,250 2.60%, due May 2026 0.63% 1,000 1,000 3.75%, due March 2027 3.79% 1,000 1,000 3.15%, due May 2027 1.21% 1,000 1,000 1.60%, due August 2028 1.68% 1,000 — 2.45%, due November 2029 2.39% 2,000 2,000 3.90%, due March 2030 3.93% 1,500 1,500 2.00%, due August 2031 2.04% 1,250 — 4.00%, due December 2032 1.24% 750 750 4.60%, due March 2040 4.61% 750 750 2.80%, due August 2041 2.82% 750 — 4.80%, due October 2041 2.01% 802 802 4.25%, due December 2042 1.42% 567 567 4.90%, due July 2045 2.13% 772 772 4.10%, due May 2046 1.40% 1,250 1,250 4.10%, due May 2047 1.37% 1,000 1,000 4.10%, due August 2047 0.92% 640 640 3.73%, due December 2047 1.77% 1,967 1,967 3.25%, due November 2049 3.20% 2,000 2,000 4.75%, due March 2050 4.74% 2,250 2,250 3.05%, due August 2051 3.07% 1,250 — 3.10%, due February 2060 3.11% 1,000 1,000 4.95%, due March 2060 4.99% 1,000 1,000 3.20%, due August 2061 3.22% 750 — Oregon and Arizona bonds: 2.40% - 2.70%, due December 2035 - 2040 2.49% 423 423 5.00%, due March 2049 2.13% 138 138 5.00%, due June 2049 2.15% 438 438 Total senior notes and other borrowings 37,695 35,214 Unamortized premium/discount and issuance costs (405) (378) Hedge accounting fair value adjustments 811 1,565 Long-term debt 38,101 36,401 Current portion of long-term debt (4,591) (2,504) Total long-term debt $ 33,510 $ 33,897 1 To manage foreign currency risk associated with the Australian-dollar-denominated notes issued in 2015, we entered into currency interest rate swaps with an aggregate notional amount of $396 million at December 25, 2021, which effectively converted these notes to US-dollar-denominated notes. For further discussion on derivatives in cash flow hedging relationships, see "Note 16: Derivative Financial Instruments." Principal and unamortized discount/issuance costs for the Australian-dollar-denominated notes in the table above were calculated using foreign currency exchange rates as of December 25, 2021 and December 26, 2020.
Schedule of Maturities of Long-term Debt [Table Text Block]	Our aggregate debt maturities, excluding commercial paper and drafts payable, based on outstanding principal as of December 25, 2021, by year payable, are as follows: (In Millions) 2022 2023 2024 2025 2026 2027 and thereafter Total $ 4,586 $ 400 $ 1,850 $ 3,750 $ 1,000 $ 26,109 $ 37,695

Fair Value (Tables)

Fair Value (Tables)	12 Months Ended
	Dec. 25, 2021
Fair Value Disclosures [Abstract]
Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]	Assets and Liabilities Measured and Recorded at Fair Value on a Recurring Basis December 25, 2021 December 26, 2020 Fair Value Measured and Recorded at Reporting Date Using Total Fair Value Measured and Total (In Millions) Level 1 Level 2 Level 3 Level 1 Level 2 Level 3 Assets Cash equivalents: Corporate debt $ — $ 65 $ — $ 65 $ — $ 50 $ — $ 50 Financial institution instruments 1 1,216 763 — 1,979 2,781 636 — 3,417 Reverse repurchase — 1,595 — 1,595 — 1,900 — 1,900 Short-term investments: Corporate debt — 648 — 648 — 428 — 428 Financial institution instruments 1 — 1,243 — 1,243 — 1,179 — 1,179 Government debt 2 — 212 — 212 — 685 — 685 Trading assets: Corporate debt — 5,143 — 5,143 — 3,815 — 3,815 Financial institution instruments 1 154 3,729 — 3,883 131 2,847 — 2,978 Government debt 2 — 12,457 — 12,457 — 8,945 — 8,945 Other current assets: Derivative assets 80 576 — 656 48 644 — 692 Loans receivable 3 — 152 — 152 — 439 — 439 Marketable equity securities 1,854 317 — 2,171 136 1,694 — 1,830 Other long-term investments: Corporate debt — 576 — 576 — 1,520 — 1,520 Financial institution instruments 1 — 190 — 190 — 257 — 257 Government debt 2 50 24 — 74 — 415 — 415 Other long-term assets: Derivative assets — 772 7 779 — 1,520 30 1,550 Loans receivable 3 — 57 — 57 — 157 — 157 Total assets measured and recorded at fair value $ 3,354 $ 28,519 $ 7 $ 31,880 $ 3,096 $ 27,131 $ 30 $ 30,257 Liabilities Other accrued liabilities: Derivative liabilities $ 4 $ 516 $ — $ 520 $ — $ 810 $ — $ 810 Other long-term liabilities: Derivative liabilities — 9 — 9 — 5 — 5 Total liabilities measured and recorded at fair value $ 4 $ 525 $ — $ 529 $ — $ 815 $ — $ 815 1 Level 1 investments in financial institution instruments consist of money market funds. Level 2 investments consist primarily of commercial paper, certificates of deposit, time deposits, and notes and bonds issued by financial institutions. 2 Level 1 investments consist primarily of US Treasury securities. Level 2 investments in government debt consist primarily of non-US government debt, as well as marketable equity securities subject to security-specific restrictions. 3 The fair value of our loans receivable for which we elected the fair value option did not significantly differ from the contractual principal balance based on the contractual currency.

Other Comprehensive Income (L_2

Other Comprehensive Income (Loss) (Tables)	12 Months Ended
	Dec. 25, 2021
Equity [Abstract]
Schedule of Accumulated Other Comprehensive Income (Loss) [Table Text Block]	The changes in accumulated other comprehensive income (loss) by component and related tax effects for each period were as follows: (In Millions) Unrealized Holding Gains (Losses) on Derivatives Actuarial Valuation and Other Pension Expenses Translation Adjustments and Other Total December 29, 2018 $ (123) $ (818) $ (33) $ (974) Other comprehensive income (loss) before reclassifications (11) (753) 109 (655) Amounts reclassified out of accumulated other comprehensive income (loss) 195 67 (6) 256 Tax effects (7) 122 (22) 93 Other comprehensive income (loss) 177 (564) 81 (306) December 28, 2019 54 (1,382) 48 (1,280) Other comprehensive income (loss) before reclassifications 806 (323) 55 538 Amounts reclassified out of accumulated other comprehensive income (loss) (8) 89 (11) 70 Tax effects (121) 51 (9) (79) Other comprehensive income (loss) 677 (183) 35 529 December 26, 2020 731 (1,565) 83 (751) Other comprehensive income (loss) before reclassifications (434) 476 (58) (16) Amounts reclassified out of accumulated other comprehensive income (loss) (226) 101 (19) (144) Tax effects 140 (126) 17 31 Other comprehensive income (loss) (520) 451 (60) (129) December 25, 2021 $ 211 $ (1,114) $ 23 $ (880)

Derivative Financial Instrume_2

Derivative Financial Instruments (Tables)	12 Months Ended
	Dec. 25, 2021
Derivative [Line Items]
Schedule of Notional Amounts of Outstanding Derivative Positions [Table Text Block]	Total gross notional amounts for outstanding derivatives (recorded at fair value) at the end of each period were as follows: (In Millions) Dec 25, 2021 Dec 26, 2020 Dec 28, 2019 Foreign currency contracts $ 38,024 $ 31,209 $ 23,981 Interest rate contracts 15,209 14,461 14,302 Other 2,517 2,026 1,753 Total $ 55,750 $ 47,696 $ 40,036
Schedule of Derivative Instruments in Statement of Financial Position, Fair Value [Table Text Block]	Fair Value of Derivative Instruments in the Consolidated Balance Sheets December 25, 2021 December 26, 2020 (In Millions) Assets 1 Liabilities 2 Assets 1 Liabilities 2 Derivatives designated as hedging instruments: Foreign currency contracts 3 $ 80 $ 163 $ 551 $ 2 Interest rate contracts 774 — 1,498 — Total derivatives designated as hedging instruments 854 163 2,049 2 Derivatives not designated as hedging instruments: Foreign currency contracts 3 475 297 142 685 Interest rate contracts 26 65 3 128 Equity contracts 80 4 48 — Total derivatives not designated as hedging instruments 581 366 193 813 Total derivatives $ 1,435 $ 529 $ 2,242 $ 815 1 Derivative assets are recorded as other assets, current and long-term. 2 Derivative liabilities are recorded as other liabilities, current and long-term. 3 The majority of these instruments mature within 12 months. The amounts recorded on the Consolidated Balance Sheet related to cumulative basis adjustments for fair value hedges for each period were as follows: Line Item in the Consolidated Balance Sheet in Which the Hedged Item Is Included Carrying Amount of the Hedged Item Assets/(Liabilities) Cumulative Amount of Fair Value Hedging Adjustment Included in the Carrying Amount Assets/(Liabilities) Years Ended (In Millions) Dec 25, 2021 Dec 26, 2020 Dec 25, 2021 Dec 26, 2020 Long-term debt $ (12,772) $ (13,495) $ (775) $ (1,498)
Offsetting Assets [Table Text Block]	Agreements subject to master netting arrangements with various counterparties, and cash and non-cash collateral posted under such agreements at the end of each period were as follows: December 25, 2021 Gross Amounts Not Offset in the Balance Sheet (In Millions) Gross Amounts Recognized Gross Amounts Offset in the Balance Sheet Net Amounts Presented in the Balance Sheet Financial Instruments Cash and Non-Cash Collateral Received or Pledged Net Amount Assets: Derivative assets subject to master netting arrangements $ 1,427 $ — $ 1,427 $ (332) $ (986) $ 109 Reverse repurchase agreements 1,595 — 1,595 — (1,595) — Total assets 3,022 — 3,022 (332) (2,581) 109 Liabilities: Derivative liabilities subject to master netting arrangements 392 — 392 (332) (60) — Total liabilities $ 392 $ — $ 392 $ (332) $ (60) $ — December 26, 2020 Gross Amounts Not Offset in the Balance Sheet (In Millions) Gross Amounts Recognized Gross Amounts Offset in the Balance Sheet Net Amounts Presented in the Balance Sheet Financial Instruments Cash and Non-Cash Collateral Received or Pledged Net Amount Assets: Derivative assets subject to master netting arrangements $ 2,235 $ — $ 2,235 $ (264) $ (1,904) $ 67 Reverse repurchase agreements 1,900 — 1,900 — (1,900) — Total assets 4,135 — 4,135 (264) (3,804) 67 Liabilities: Derivative liabilities subject to master netting arrangements 711 — 711 (264) (447) — Total liabilities $ 711 $ — $ 711 $ (264) $ (447) $ —
Offsetting Liabilities [Table Text Block]	Agreements subject to master netting arrangements with various counterparties, and cash and non-cash collateral posted under such agreements at the end of each period were as follows: December 25, 2021 Gross Amounts Not Offset in the Balance Sheet (In Millions) Gross Amounts Recognized Gross Amounts Offset in the Balance Sheet Net Amounts Presented in the Balance Sheet Financial Instruments Cash and Non-Cash Collateral Received or Pledged Net Amount Assets: Derivative assets subject to master netting arrangements $ 1,427 $ — $ 1,427 $ (332) $ (986) $ 109 Reverse repurchase agreements 1,595 — 1,595 — (1,595) — Total assets 3,022 — 3,022 (332) (2,581) 109 Liabilities: Derivative liabilities subject to master netting arrangements 392 — 392 (332) (60) — Total liabilities $ 392 $ — $ 392 $ (332) $ (60) $ — December 26, 2020 Gross Amounts Not Offset in the Balance Sheet (In Millions) Gross Amounts Recognized Gross Amounts Offset in the Balance Sheet Net Amounts Presented in the Balance Sheet Financial Instruments Cash and Non-Cash Collateral Received or Pledged Net Amount Assets: Derivative assets subject to master netting arrangements $ 2,235 $ — $ 2,235 $ (264) $ (1,904) $ 67 Reverse repurchase agreements 1,900 — 1,900 — (1,900) — Total assets 4,135 — 4,135 (264) (3,804) 67 Liabilities: Derivative liabilities subject to master netting arrangements 711 — 711 (264) (447) — Total liabilities $ 711 $ — $ 711 $ (264) $ (447) $ —
Schedule of Fair Value Hedging Instruments, Statements of Financial Performance and Financial Position, Location [Table Text Block]	The effects of derivative instruments designated as fair value hedges, recognized in interest and other, net for each period were as follows: Gains (Losses) Recognized in Statement of Income on Derivatives Years Ended (In Millions) Dec 25, 2021 Dec 26, 2020 Dec 28, 2019 Interest rate contracts $ (723) $ 817 $ 1,071 Hedged items 723 (817) (1,071) Total $ — $ — $ —
Derivatives Not Designated as Hedging Instruments [Table Text Block]	The effects of derivative instruments not designated as hedging instruments on the Consolidated Statements of Income for each period were as follows: Years Ended (In Millions) Location of Gains (Losses) Dec 25, 2021 Dec 26, 2020 Dec 28, 2019 Foreign currency contracts Interest and other, net $ 677 $ (572) $ 204 Interest rate contracts Interest and other, net 31 (90) (32) Other Various 360 284 297 Total $ 1,068 $ (378) $ 469

Retirement Benefit Plans (Table

Retirement Benefit Plans (Tables)	12 Months Ended
	Dec. 25, 2021
Defined Benefit Plan Disclosure [Line Items]
Changes in Projected Benefit Obligations, Fair Value of Plan Assets, and Funded Status of Plan [Table Text Block]	The vested benefit obligation for a defined-benefit pension plan is the actuarial present value of the vested benefits to which the employee is currently entitled based on the employee's expected date of separation or retirement. Dec 25, 2021 Dec 26, 2020 Changes in projected benefit obligation: Beginning projected benefit obligation $ 4,929 $ 4,284 Service cost 54 49 Interest cost 91 97 Actuarial (gain) loss (284) 373 Currency exchange rate changes (150) 261 Plan settlements (126) (79) Other (58) (56) Ending projected benefit obligation 1 4,456 4,929 Changes in fair value of plan assets: Beginning fair value of plan assets 2,878 2,654 Actual return on plan assets 145 203 Currency exchange rate changes (63) 113 Plan settlements (126) (79) Other (17) (13) Ending fair value of plan assets 2 2,817 2,878 Net unfunded status $ 1,639 $ 2,051 Amounts recognized in the Consolidated Balance Sheets Other long-term liabilities $ 1,639 $ 2,051 Accumulated other comprehensive loss (income), before tax 3 $ 1,445 $ 1,911 Accumulated benefit obligation 4 $ 4,086 $ 4,429 1 The projected benefit obligation was approximately 30% in the US and 70% outside of the US as of December 25, 2021 and approximately 35% in the US and 65% outside of the US as of December 26, 2020. 2 The fair value of plan assets was approximately 50% in the US and 50% outside of the US as of December 25, 2021 and approximately 55% in the US and 45% outside of the US as of December 26, 2020. 3 The accumulated other comprehensive loss (income), before tax, was approximately 30% in the US and 70% outside of the US as of December 25, 2021 and approximately 35% in the US and 65% outside of the US as of December 26, 2020.
Defined Benefit Plan, Assumptions [Table Text Block]	Assumptions for Pension Benefit Plans Dec 25, 2021 Dec 26, 2020 Weighted average actuarial assumptions used to determine benefit obligations Discount rate 2.2 % 1.9 % Rate of compensation increase 3.2 % 3.2 % 2021 2020 2019 Weighted average actuarial assumptions used to determine costs Discount rate 1.9 % 2.3 % 3.4 % Expected long-term rate of return on plan assets 2.7 % 3.3 % 4.7 % Rate of compensation increase 3.2 % 3.2 % 3.5 %
Schedule of Allocation of Plan Assets [Table Text Block]	Pension Plan Assets December 25, 2021 Dec 26, 2020 Fair Value Measured at Reporting Date Using (In Millions) Level 1 Level 2 Level 3 Total Total Equity securities $ — $ 342 $ — $ 342 $ 320 Fixed income — 122 20 142 135 Assets measured by fair value hierarchy $ — $ 464 $ 20 $ 484 $ 455 Assets measured at net asset value 2,311 2,401 Cash and cash equivalents 22 22 Total pension plan assets at fair value $ 2,817 $ 2,878
Postretirement Health Coverage [Member]
Defined Benefit Plan Disclosure [Line Items]
Schedule of Expected Benefit Payments [Table Text Block]	The estimated benefit payments for this plan over the next 10 years are as follows: (In Millions) 2022 2023 2024 2025 2026 2027-2031 Postretirement Medical Benefits $ 37 $ 38 $ 39 $ 41 $ 42 $ 219
Pension Plan [Member]
Defined Benefit Plan Disclosure [Line Items]
Schedule of Expected Benefit Payments [Table Text Block]	Estimated benefit payments over the next 10 years are as follows: (In Millions) 2022 2023 2024 2025 2026 2027-2031 Pension benefits $ 147 $ 144 $ 141 $ 142 $ 146 $ 765

Employee Equity Incentive Pla_2

Employee Equity Incentive Plans (Tables)	12 Months Ended
	Dec. 25, 2021
Employee Benefit and Share-based Payment Arrangement, Noncash Expense [Abstract]
Restricted Stock Units Estimated Values And Weighted Average Assumptions [Table Text Block]	Restricted Stock Units Weighted average assumptions used in estimating grant values were as follows: Dec 25, 2021 Dec 26, 2020 Dec 28, 2019 Estimated values $ 50.82 $ 54.82 $ 48.06 Risk-free interest rate 0.2 % 0.4 % 2.3 % Dividend yield 2.6 % 2.3 % 2.5 % Volatility 37 % 30 % 25 %
Share-based Payment Arrangement, Restricted Stock Unit, Activity [Table Text Block]	Summary of activities: Number of Stock Units (In Millions) Weighted Average Grant-Date Fair Value December 26, 2020 82.7 $ 50.14 Granted 76.8 $ 50.82 Vested (30.2) $ 47.64 Forfeited (11.3) $ 49.48 December 25, 2021 118.0 $ 51.29 Expected to vest 105.9 $ 51.47

Commitments and Contingencies (

Commitments and Contingencies (Tables)	12 Months Ended
	Dec. 25, 2021
Commitments and Contingencies Disclosure [Abstract]
Lessee, Operating Lease, Liability, Maturity	Discounted and undiscounted lease payments under non-cancelable leases as of December 25, 2021, excluding non-lease components, were as follows: (In Millions) 2022 2023 2024 2025 2026 Thereafter Total Operating lease payments $ 183 $ 139 $ 79 $ 55 $ 16 $ 27 $ 499 Finance lease payments $ 451 $ 529 $ 980 Present value of lease payments $ 1,455

Accounting Policies (Detail)

Accounting Policies (Detail) $ in Millions	12 Months Ended
	Dec. 25, 2021USD ($)
Production Related Impairments or Charges [Abstract]
PRQ Max	$ 870
Credit Concentration Risk [Member]
Revenue, Major Customer [Line Items]
Concentration Risk, Credit Risk, Financial Instrument, Maximum Exposure	2,600
Maximum
Revenue, Major Customer [Line Items]
Manufacturing Costs	$ 1,100

Operating Segments and Geograph

Operating Segments and Geographic Information (Detail) - USD ($) $ in Millions	12 Months Ended
	Dec. 25, 2021	Dec. 26, 2020	Dec. 28, 2019
Segment Reporting Information [Line Items]
Net revenue	$ 79,024	$ 77,867	$ 71,965
Operating Income (Loss)	19,456	23,678	22,035
InternetofThings [Member]
Segment Reporting Information [Line Items]
Net revenue	5,384	3,974	4,700
Operating Income (Loss)	1,505	738	1,342
IOTG Platform [Member]
Segment Reporting Information [Line Items]
Net revenue	3,658	2,705	3,440
DCG Platform [Member]
Segment Reporting Information [Line Items]
Net revenue	22,703	23,056	21,441
CCG Notebook Platform [Member]
Segment Reporting Information [Line Items]
Net revenue	25,475	24,903	20,779
CCG Desktop Platform [Member]
Segment Reporting Information [Line Items]
Net revenue	11,835	10,692	11,822
Other Platform [Member]
Segment Reporting Information [Line Items]
Net revenue	66	47	80
Other Product Or Service [Member]
Segment Reporting Information [Line Items]
Net revenue	15,287	16,464	14,403
Platform [Member]
Segment Reporting Information [Line Items]
Net revenue	63,737	61,403	57,562
Data Center Group [Member]
Segment Reporting Information [Line Items]
Net revenue	25,821	26,103	23,481
Operating Income (Loss)	6,997	10,571	10,227
Data Center Group [Member] | Other Product Or Service [Member]
Segment Reporting Information [Line Items]
Net revenue	3,118	3,047	2,040
Internet of Things Group [Member]
Segment Reporting Information [Line Items]
Net revenue	3,998	3,007	3,821
Operating Income (Loss)	1,045	497	1,097
Mobileye [Member]
Segment Reporting Information [Line Items]
Net revenue	1,386	967	879
Operating Income (Loss)	460	241	245
Non-Volatile Memory Solutions Group [Member]
Segment Reporting Information [Line Items]
Net revenue	4,306	5,358	4,362
Operating Income (Loss)	1,369	361	(1,176)
Programmable Solutions Group [Member]
Segment Reporting Information [Line Items]
Net revenue	1,934	1,853	1,987
Operating Income (Loss)	297	260	318
Client Computing Group [Member]
Segment Reporting Information [Line Items]
Net revenue	40,511	40,057	37,146
Operating Income (Loss)	14,672	15,129	15,202
Client Computing Group [Member] | Other Product Or Service [Member]
Segment Reporting Information [Line Items]
Net revenue	3,135	4,415	4,465
Client Computing Group [Member] | Platform [Member]
Segment Reporting Information [Line Items]
Net revenue	37,376	35,642	32,681
All other [Member]
Segment Reporting Information [Line Items]
Net revenue	1,068	522	289
Operating Income (Loss)	$ (5,384)	$ (3,381)	$ (3,878)

Operating Segments and Geogra_2

Operating Segments and Geographic Information, Revenue by Major Customers (Detail)	12 Months Ended
	Dec. 25, 2021	Dec. 26, 2020	Dec. 28, 2019
Customer Concentration Risk [Member] | Revenue Benchmark [Member] | Three Largest Customers
Revenue, Major Customer [Line Items]
Concentration Risk, Percentage	43.00%	39.00%	41.00%
Customer Concentration Risk [Member] | Revenue Benchmark [Member] | Dell Inc. [Member]
Revenue, Major Customer [Line Items]
Concentration Risk, Percentage	21.00%	17.00%	17.00%
Customer Concentration Risk [Member] | Revenue Benchmark [Member] | Lenovo Group Limited [Member]
Revenue, Major Customer [Line Items]
Concentration Risk, Percentage	12.00%	12.00%	13.00%
Customer Concentration Risk [Member] | Revenue Benchmark [Member] | HP Inc. [Member]
Revenue, Major Customer [Line Items]
Concentration Risk, Percentage	10.00%	10.00%	11.00%
Credit Concentration Risk [Member] | Accounts Receivable [Member] | Three Largest Customers
Revenue, Major Customer [Line Items]
Concentration Risk, Percentage	42.00%	43.00%

Operating Segments and Geogra_3

Operating Segments and Geographic Information, Revenues from External Customers by Country (Detail) - USD ($) $ in Millions	12 Months Ended
	Dec. 25, 2021	Dec. 26, 2020	Dec. 28, 2019
Revenues from External Customers and Long-Lived Assets [Line Items]
Net revenue	$ 79,024	$ 77,867	$ 71,965
China (Including Hong Kong) [Member]
Revenues from External Customers and Long-Lived Assets [Line Items]
Net revenue	21,141	20,257	20,026
Singapore [Member]
Revenues from External Customers and Long-Lived Assets [Line Items]
Net revenue	14,254	17,845	15,650
UNITED STATES
Revenues from External Customers and Long-Lived Assets [Line Items]
Net revenue	14,107	16,573	15,617
Taiwan [Member]
Revenues from External Customers and Long-Lived Assets [Line Items]
Net revenue	13,461	11,605	10,058
Other Countries [Member]
Revenues from External Customers and Long-Lived Assets [Line Items]
Net revenue	$ 16,061	$ 11,587	$ 10,614

Earnings Per Share (Detail)

Earnings Per Share (Detail) - USD ($) $ / shares in Units, shares in Millions, $ in Millions	12 Months Ended
	Dec. 25, 2021	Dec. 26, 2020	Dec. 28, 2019
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Net Income	$ 19,868	$ 20,899	$ 21,048
Weighted average shares of common stock outstanding-basic	4,059	4,199	4,417
Dilutive effect of employee equity incentive plans (shares)	31	33	41
Dilutive effect of convertible debt (shares)	0	0	15
Weighted average shares of common stock outstanding-diluted	4,090	4,232	4,473
Earnings per share—basic	$ 4.89	$ 4.98	$ 4.77
Earnings per share—diluted	$ 4.86	$ 4.94	$ 4.71

Contract Liabilities (Details)

Contract Liabilities (Details) - USD ($) $ in Millions	3 Months Ended	12 Months Ended
	Mar. 27, 2021	Dec. 25, 2021	Dec. 26, 2020
Capitalized Contract Cost [Line Items]
Contract with Customer, Liability		$ 498	$ 1,900
Contract liability balance	$ 1,600
Prepaid Supply Agreements [Member]
Capitalized Contract Cost [Line Items]
Contract with Customer, Liability		42	$ 1,625
Contract with Customer, Liability, Concession Payments		(950)
Contract with Customer, Liability, Revenue Recognized		$ (633)
Contract with Customer, Liability, Current	950
Contract with Customer, Liability, Revenue Recognized and Retained During Period	$ 584

Other Financial Statement Det_3

Other Financial Statement Details Inventories (Details) - USD ($) $ in Millions	Dec. 25, 2021	Dec. 26, 2020
Inventory, Net [Abstract]
Raw materials	$ 1,441	$ 908
Work in process	6,656	5,693
Finished goods	2,679	1,826
Total inventories	$ 10,776	$ 8,427

Other Financial Statement Det_4

Other Financial Statement Details Property, Plant and Equipment (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 25, 2021	Dec. 26, 2020
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Gross	$ 148,539	$ 134,229
Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment	(85,294)	(77,645)
Property, plant and equipment, net	63,245	56,584
UNITED STATES
Property, Plant and Equipment [Line Items]
Property, plant and equipment, net	43,428	38,829
ISRAEL
Property, Plant and Equipment [Line Items]
Property, plant and equipment, net	7,754	7,837
IRELAND
Property, Plant and Equipment [Line Items]
Property, plant and equipment, net	7,503	5,828
Other Countries [Member]
Property, Plant and Equipment [Line Items]
Property, plant and equipment, net	4,560	4,090
Land and Building [Member]
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Gross	40,039	37,536
Machinery and Equipment [Member]
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Gross	86,955	79,384
Construction in Progress [Member]
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Gross	$ 21,545	$ 17,309
Minimum | Machinery and Equipment [Member]
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Useful Life	2 years
Minimum | Building [Member]
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Useful Life	10 years
Maximum | Machinery and Equipment [Member]
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Useful Life	5 years
Maximum | Building [Member]
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Useful Life	25 years

Other Financial Statement Det_5

Other Financial Statement Details Other Accrued Liabilities (Details) - USD ($) $ in Millions	Dec. 25, 2021	Dec. 26, 2020
Statement of Financial Position [Abstract]
Deferred compensation liabilities	$ 2,800	$ 2,500
Collateral received under credit support annex agreements	$ 1,000	$ 2,000

Other Financial Statement Det_6

Other Financial Statement Details Advertising (Details) - USD ($)	12 Months Ended
	Dec. 25, 2021	Dec. 26, 2020	Dec. 28, 2019
Income Statement [Abstract]
Advertising Expense	$ 1,100,000,000	$ 763,000,000	$ 832,000,000

Other Financial Statement Det_7

Other Financial Statement Details Interest and Other, Net (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 25, 2021	Dec. 26, 2020	Dec. 28, 2019
Other Nonoperating Income (Expense) [Abstract]
Interest income	$ 144	$ 272	$ 483
Interest expense	(597)	(629)	(489)
Other, net	(29)	(147)	490
Total Interest and other, net	(482)	(504)	484
Interest Costs, Capitalized During Period	$ 398	$ 338	$ 472

Restructuring and Other Charg_3

Restructuring and Other Charges (Detail) - USD ($) $ in Millions	3 Months Ended	12 Months Ended
	Mar. 27, 2021	Dec. 25, 2021	Dec. 26, 2020	Dec. 28, 2019
Restructuring Cost and Reserve [Line Items]
Litigation Settlement, Expense	$ 2,200
Severance Costs		$ 48	$ 124
Litigation Charges and Other		2,291	67
Asset Impairment Charges		287	7
Restructuring and Related Cost, Incurred Cost		2,626	198
Restructuring and other charges		$ 2,626	$ 198	$ 393

Income Taxes (Detail)

Income Taxes (Detail) - USD ($) $ in Millions	12 Months Ended
	Dec. 25, 2021	Dec. 26, 2020	Dec. 28, 2019
Income Tax Disclosure [Abstract]
Income before taxes: U.S.	$ 9,361	$ 15,452	$ 13,729
Income before taxes: Non-U.S.	12,342	9,626	10,329
Income before taxes	21,703	25,078	24,058
Provision for taxes, Current: Federal	1,304	1,120	1,391
Provision for taxes, Current: State	75	46	37
Provision for taxes, Current: Non-U.S.	1,198	1,244	1,060
Total current provision for taxes	2,577	2,410	2,488
Provision for taxes, Deferred: Federal	(863)	1,369	597
Deferred State and Local Income Tax Expense (Benefit)	(25)	25	1
Deferred Other Tax Expense (Benefit)	146	375	(76)
Total deferred provision for taxes	(742)	1,769	522
Total Provision for taxes	$ 1,835	$ 4,179	$ 3,010
Effective tax rate	8.50%	16.70%	12.50%
Effective Income Tax Rate, Continuing Operations, Tax Rate Reconciliation [Abstract]
Statutory federal income tax rate	21.00%	21.00%	21.00%
Increase (reduction) in rate resulting from: Non-U.S. income taxed at different rates	(5.90%)	(3.70%)	(3.70%)
Increase (reduction) in rate resulting from: Research and Development tax credits	(2.40%)	(2.10%)	(2.30%)
Increase (reduction) in rate resulting from: Domestic manufacturing deduction benefit	(3.40%)	0.00%	0.00%
Income Tax Reconciliation, Transition Tax for Accumulated Foreign Earnings	(2.20%)	(1.90%)	(3.20%)
Effective Income Tax Rate Reconciliation, Change in Permanent Reinvestment Assertion, Percent	0.00%	1.60%	0.00%
Increase (reduction) in rate resulting from: Other	1.40%	1.80%	0.70%
Effective tax rate	8.50%	16.70%	12.50%
Income Tax Disclosure [Line Items]
Statutory federal income tax rate	21.00%	21.00%	21.00%
Increase (reduction) in rate resulting from: Non-U.S. income taxed at different rates	(5.90%)	(3.70%)	(3.70%)
Income Tax Holiday, Termination Date	2056
Income Tax Expense (Benefit)	$ 1,835	$ 4,179	$ 3,010
Undistributed earnings on certain foreign subsidiaries	18,900
Accrued Income Taxes, Current	1,100	756
Long-term income taxes payable	4,305	4,578
Income Taxes Receivable, Current	23	131
Components of Deferred Tax Assets and Liabilities [Abstract]
Deferred tax assets, Accrued compensation and other benefits	1,019	865
Deferred tax assets, Share-based compensation	477	324
Deferred Tax Assets, Tax Deferred Expense, Litigation Expense	467	0
Deferred tax assets, Inventory	914	835
Deferred Tax Assets, Research and Development Capitalized	519	0
Deferred tax assets, State credits and net operating losses	2,010	1,829
Deferred tax assets, Other, net	819	617
Gross deferred tax assets	6,225	4,470
Deferred tax assets, Valuation allowance	(2,259)	(1,963)
Total deferred tax assets	3,966	2,507
Deferred tax liabilities, Property, plant and equipment	(4,213)	(3,109)
Deferred tax liabilities, Licenses and intangibles	(486)	(725)
Deferred Tax Liabilities, Unrealized Gains On Investments And Derivatives	(819)	(735)
Deferred Tax Liabilities, Undistributed Foreign Earnings	0	(403)
Deferred tax liabilities, Other, net	(241)	(146)
Total deferred tax liabilities	(5,759)	(5,118)
Net deferred tax assets (liabilities)	(1,793)	(2,611)
Deferred tax assets	874	1,232
Deferred tax liabilities	(2,667)	(3,843)
Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward]
Beginning gross unrecognized tax benefits	828	548	283
Settlements and effective settlements with tax authorities	(25)	(142)	(4)
Changes in balances related to tax position taken during prior periods	(26)	165	122
Changes in balances related to tax position taken during current period	243	257	147
Ending gross unrecognized tax benefits	1,020	828	$ 548
Unrecognized Tax Benefits that Would Impact Effective Tax Rate	721	550
Operating Loss Carryforwards [Line Items]
Valuation Allowance, Amount	(2,259)	$ (1,963)
Decrease in Unrecognized Tax Benefits is Reasonably Possible	327
Domestic Tax Authority [Member]
Income Tax Disclosure [Line Items]
Operating loss carryforward, subject to expiration	357
Operating Loss Carryforwards [Line Items]
Operating Loss Carryforwards	644
Non-U.S. [Member]
Income Tax Disclosure [Line Items]
Operating loss carryforward, subject to expiration	860
Operating Loss Carryforwards [Line Items]
Operating Loss Carryforwards	$ 1,100
Minimum
Income Tax Disclosure [Line Items]
Effective Income Tax Rate Reconciliation, at Foreign Statutory Income Tax Rate, Percent	12.50%
Maximum
Income Tax Disclosure [Line Items]
Effective Income Tax Rate Reconciliation, at Foreign Statutory Income Tax Rate, Percent	24.00%

Income Taxes - Valuation Allowa

Income Taxes - Valuation Allowance (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 25, 2021	Dec. 26, 2020	Dec. 28, 2019	Dec. 29, 2018
Income Tax Contingency [Line Items]
Unrealized state credit carryforwards	$ 2,000
Undistributed earnings on certain foreign subsidiaries	18,900
Balance at Beginning of Year	1,963
Balance at End of Year	2,259	$ 1,963
SEC Schedule, 12-09, Valuation Allowance, Deferred Tax Asset [Member]
Income Tax Contingency [Line Items]
Net (Deductions) Recoveries	(146)	51	$ (7)
SEC Schedule, 12-09, Valuation Allowances and Reserves, Amount	2,259	1,963	1,534	$ 1,302
SEC Schedule, 12-09, Valuation Allowances and Reserves, Increase (Decrease) Adjustment	$ 442	$ 378	$ 239

Investments, Trading Assets (De

Investments, Trading Assets (Detail) - Debt Securities [Member] - USD ($) $ in Millions	12 Months Ended
	Dec. 25, 2021	Dec. 26, 2020	Dec. 28, 2019
Schedule Of Trading Securities And Other Trading Assets [Line Items]
Trading Securities, Change in Unrealized Holding Gain (Loss)	$ (606)	$ 694	$ 26
Unrealized Gain (Loss) on Derivatives	$ 609	$ (667)	$ 22

Investments, Available For Sale

Investments, Available For Sale Investments (Detail) - USD ($) $ in Millions	12 Months Ended
	Dec. 25, 2021	Dec. 26, 2020	Dec. 28, 2019
Debt Securities, Available-for-sale [Line Items]
Adjusted cost for available-for-sale investments	$ 5,000	$ 7,800
Due in 1 year or less	2,931
Due in 1–2 years	559
Due in 2–5 years	281
Due after 5 years	0
Instruments not due at a single maturity date	1,216
Debt Securities, Available-for-sale	4,987
Debt Securities [Member]
Debt Securities, Available-for-sale [Line Items]
Trading Securities, Change in Unrealized Holding Gain (Loss)	(606)	694	$ 26
Unrealized Gain (Loss) on Derivatives	$ 609	$ (667)	$ 22

Investments Investments, Equity

Investments Investments, Equity Investments (Details) - USD ($) $ in Millions	3 Months Ended	12 Months Ended
	Mar. 27, 2021	Dec. 25, 2021	Dec. 26, 2020	Dec. 28, 2019
Schedule of Investments [Line Items]
Marketable equity securities		$ 2,171	$ 1,830
Non-marketable equity securities		4,111	3,304
Equity method investments		16	18
Total		6,298	5,152
Ongoing mark-to-market adjustments on marketable equity securities		(130)	(133)	$ 277
Observable price adjustments on non-marketable equity securities		(750)	(176)	(293)
Impairment charges		(154)	(303)	(122)
Sale of equity investments and other		2,263	2,164	1,091
Gain (Loss) on Investments		2,729	1,904	1,539
Net gains (losses) recognized during the period on equity securities		1,210	1,679	734
Less: Net (gains) losses recognized during the period on equity securities sold during the period		(259)	(254)	(424)
Net unrealized gains (losses) recognized during the period on equity securities still held at the reporting date		951	1,425	310
Proceeds from Equity Method Investment, Distribution, Return of Capital		$ 581	910	2,688
McAfee [Member]
Schedule of Investments [Line Items]
Equity Method Investment, Ownership Percentage		41.00%
Proceeds from Equity Method Investment, Distribution, Return of Capital		$ 1,300	126	632
Cash proceeds from sale of equity method investment		228
McAfee [Member] | McAfee Enterprise Business
Schedule of Investments [Line Items]
Proceeds from Equity Method Investment, Distribution, Return of Capital		1,100
Bejing Unisoc Technology Ltd.
Schedule of Investments [Line Items]
Net gains (losses) recognized during the period on equity securities	$ 471
Equity Securities, FV-NI, Cost		1,100	658
Cost-method Investments [Member]
Schedule of Investments [Line Items]
Impairment charges		$ (154)	$ (290)	$ (122)

Investments, Equity Method and

Investments, Equity Method and Cost Method Investments (Detail) - USD ($) $ in Millions	12 Months Ended
	Dec. 25, 2021	Dec. 26, 2020	Dec. 28, 2019
Schedule of Equity Method Investments [Line Items]
Equity method investments	$ 16	$ 18
Proceeds from Equity Method Investment, Distribution, Return of Capital	581	910	$ 2,688
Impairments	$ 154	303	122
McAfee [Member]
Schedule of Equity Method Investments [Line Items]
Equity Method Investment, Ownership Percentage	41.00%
Cash proceeds from sale of equity method investment	$ 228
Proceeds from Equity Method Investment, Distribution, Return of Capital	1,300	126	632
Cost-method Investments [Member]
Schedule of Equity Method Investments [Line Items]
Impairments	$ 154	$ 290	$ 122

Investments, Non-Marketable Cos

Investments, Non-Marketable Cost Method Investments (Detail) - USD ($) $ in Millions	12 Months Ended
	Dec. 25, 2021	Dec. 26, 2020	Dec. 28, 2019
Gain (Loss) on Securities [Line Items]
Non-marketable equity securities	$ 16	$ 18
Impairments	154	303	$ 122
Cumulative impairment for equity securities without readily determinable fair value	916
Equity Securities without Readily Determinable Fair Value, Upward Price Adjustment, Cumulative Amount	1,100
Cost-method Investments [Member]
Gain (Loss) on Securities [Line Items]
Impairments	$ 154	$ 290	$ 122

Acquisitions (Details)

Acquisitions (Details) $ in Millions	May 04, 2020USD ($)	Dec. 25, 2021USD ($)Acquisition	Dec. 26, 2020USD ($)Acquisition	Dec. 28, 2019USD ($)
Business Acquisition [Line Items]
Goodwill		$ 26,963	$ 26,971	$ 26,276
Series of Individually Immaterial Business Acquisitions [Member]
Business Acquisition [Line Items]
Number of businesses acquired | Acquisition		4	6
Moovit [Member]
Business Acquisition [Line Items]
Total consideration to acquire business	$ 915
Goodwill	638
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Intangible Assets, Other than Goodwill	$ 331

Divestitures (Details)

Divestitures (Details) - USD ($) $ in Millions	Dec. 29, 2021	Oct. 19, 2020	Jul. 31, 2020	Dec. 02, 2019	Mar. 31, 2025	Dec. 25, 2021	Dec. 26, 2020	Dec. 28, 2019	Apr. 02, 2022
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Total consideration in cash			$ 150
Tax expense						$ 1,835	$ 4,179	$ 3,010
Acquisition of property, plant and equipment included in accounts payable and accrued liabilities						1,619	2,973	1,761
Current Income Tax Expense (Benefit)						2,577	2,410	$ 2,488
Forecast
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Additional Capital Purchases Expected						1,600
NAND Memory Business
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Total consideration in cash	$ 7,000	$ 9,000
NAND Memory Business | Discontinued Operations, Held-for-sale
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Inventories						953	962
Property, plant and equipment, net						5,989	4,363
Disposal Group, Including Discontinued Operation, Assets, Total						$ 6,942	$ 5,325
NAND Memory Business | Forecast
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Total consideration in cash					$ 2,000
Pre-tax gain	1,000
Tax expense	450
Deferred consideration	$ 600
Nontrade Receivables, Noncurrent									$ 1,900
Smartphone Modem Business
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Total consideration in cash				$ 267
Disposal Group, Not Discontinued Operation, Gain (Loss) on Disposal				$ 690

Goodwill (Detail)

Goodwill (Detail) - USD ($) $ in Millions	3 Months Ended	12 Months Ended
	Jun. 26, 2021	Dec. 25, 2021	Dec. 26, 2020
Goodwill [Roll Forward]
Goodwill, Beginning Balance		$ 26,971	$ 26,276
Goodwill, Acquisitions		196	729
Goodwill, Other		(204)	(34)
Goodwill, Ending Balance		26,963	26,971
Goodwill, Impaired, Accumulated Impairment Loss		957
Client Computing Group [Member]
Goodwill [Roll Forward]
Goodwill, Beginning Balance		4,360	4,333
Goodwill, Acquisitions		73	27
Goodwill, Other		0	0
Goodwill, Ending Balance		4,433	4,360
Goodwill, Impaired, Accumulated Impairment Loss		365
Data Center Group [Member]
Goodwill [Roll Forward]
Goodwill, Beginning Balance		7,232	7,182
Goodwill, Acquisitions		123	50
Goodwill, Other		0	0
Goodwill, Ending Balance		7,355	7,232
Goodwill, Impaired, Accumulated Impairment Loss		275
Internet of Things Group [Member]
Goodwill [Roll Forward]
Goodwill, Beginning Balance		1,591	1,579
Goodwill, Acquisitions		0	12
Goodwill, Other		0	0
Goodwill, Ending Balance		1,591	1,591
Goodwill, Impaired, Accumulated Impairment Loss		79
Mobileye [Member]
Goodwill [Roll Forward]
Goodwill, Beginning Balance		10,928	10,290
Goodwill, Acquisitions		0	638
Goodwill, Other		0	0
Goodwill, Ending Balance		10,928	10,928
Programmable Solutions Group [Member]
Goodwill [Roll Forward]
Goodwill, Beginning Balance		2,622	2,654
Goodwill, Acquisitions		0	2
Goodwill, Other		34	(34)
Goodwill, Ending Balance		2,656	2,622
All other [Member]
Goodwill [Roll Forward]
Goodwill, Beginning Balance		238	238
Goodwill, Acquisitions		0	0
Goodwill, Other		(238)	0
Goodwill, Ending Balance		$ 0	$ 238
Goodwill, Impairment Loss	$ 238

Identified Intangible Assets (D

Identified Intangible Assets (Detail) - USD ($) $ in Millions	12 Months Ended
	Dec. 25, 2021	Dec. 26, 2020	Dec. 28, 2019
Finite Lived Intangible Assets [Line Items]
Gross Assets, Finite-lived Intangible Assets	$ 16,105	$ 16,389
Accumulated Amortization	(8,835)	(7,363)
Total, net	7,270
Total identified intangible assets	7,270	9,026
Amortization of intangibles	1,839	1,757	$ 1,622
Finite-Lived Intangible Assets, Net, Amortization Expense, Fiscal Year Maturity [Abstract]
Future Amortization Expense, 2020	1,854
Future Amortization Expense, 2021	1,622
Future Amortization Expense, 2022	1,188
Future Amortization Expense, 2023	779
Future Amortization Expense, 2024	598
Future Amortization Expense, Thereafter	1,229
Total, net	7,270
Acquisition-related Developed Technology [Member]
Finite Lived Intangible Assets [Line Items]
Gross Assets, Finite-lived Intangible Assets	11,102	10,188
Accumulated Amortization	(6,026)	(4,880)
Total, net	$ 5,076	5,308
Acquired Finite-lived Intangible Asset, Weighted Average Useful Life (in years)	9 years
Amortization of intangibles	$ 1,283	1,211	1,124
Finite-Lived Intangible Assets, Net, Amortization Expense, Fiscal Year Maturity [Abstract]
Total, net	5,076	5,308
Acquisition-related Customer Relationships and Brands [Member]
Finite Lived Intangible Assets [Line Items]
Gross Assets, Finite-lived Intangible Assets	2,110	2,110
Accumulated Amortization	(1,063)	(854)
Total, net	$ 1,047	1,256
Acquired Finite-lived Intangible Asset, Weighted Average Useful Life (in years)	11 years
Amortization of intangibles	$ 209	205	200
Finite-Lived Intangible Assets, Net, Amortization Expense, Fiscal Year Maturity [Abstract]
Total, net	1,047	1,256
Licensed Technology and Patents [Member]
Finite Lived Intangible Assets [Line Items]
Gross Assets, Finite-lived Intangible Assets	2,893	2,836
Accumulated Amortization	(1,746)	(1,629)
Total, net	$ 1,147	1,207
Acquired Finite-lived Intangible Asset, Weighted Average Useful Life (in years)	13 years
Amortization of intangibles	$ 347	341	$ 298
Finite-Lived Intangible Assets, Net, Amortization Expense, Fiscal Year Maturity [Abstract]
Total, net	1,147	1,207
In Process Research and Development [Member]
Indefinite-lived Intangible Assets [Line Items]
Gross assets, Indefinite-Lived Intangible Assets	0	954
Other Intangible Assets [Member]
Indefinite-lived Intangible Assets [Line Items]
Gross assets, Indefinite-Lived Intangible Assets	$ 0	$ 301

Borrowings, Short-term Debt (De

Borrowings, Short-term Debt (Detail) - USD ($)	Dec. 25, 2021	Dec. 26, 2020
Short-term Debt [Line Items]
Current portion of long-term debt	$ 4,591,000,000	$ 2,504,000,000
Total short-term debt	4,591,000,000	$ 2,504,000,000
Commercial Paper [Member]
Short-term Debt [Line Items]
Maximum borrowing capacity	$ 10,000,000,000

Borrowings, Long-term Debt (Det

Borrowings, Long-term Debt (Detail) - USD ($)	12 Months Ended
	Dec. 25, 2021	Dec. 26, 2020	Dec. 28, 2019
Debt Instrument [Line Items]
Long-term Debt, Gross	$ 37,695,000,000	$ 35,214,000,000
Long-term debt	(4,591,000,000)	(2,504,000,000)
Total long-term debt	33,510,000,000	33,897,000,000
Derivative, notional amount	55,750,000,000	47,696,000,000	$ 40,036,000,000
Long-term Debt, Fair Value	41,500,000,000	40,900,000,000
Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net	(405,000,000)	(378,000,000)
Long-term Debt	38,101,000,000	36,401,000,000
2022	4,586,000,000
2023	400,000,000
2024	1,850,000,000
2025	3,750,000,000
2026	1,000,000,000
2027 and thereafter	$ 26,109,000,000
2017 Senior notes due May 2022 at .35% [Member]
Debt Instrument [Line Items]
Debt Instrument, Basis Spread on Variable Rate	0.35%
Debt Instrument, Interest Rate, Effective Percentage	0.55%
Long-term Debt, Gross	$ 800,000,000	800,000,000
2016 Senior notes due May 2021 at 1.70% [Member]
Debt Instrument [Line Items]
Effective Interest Rate	1.70%
Repayment of debt	$ 500,000,000
Debt Instrument, Interest Rate, Effective Percentage	0.00%
Long-term Debt, Gross	$ 0	500,000,000
2011 Senior notes due October 2021 at 3.30% [Member]
Debt Instrument [Line Items]
Effective Interest Rate	3.30%
Repayment of debt	$ 2,000,000,000
Debt Instrument, Interest Rate, Effective Percentage	0.00%
Long-term Debt, Gross	$ 0	2,000,000,000
2017 Senior notes due May 2022 at 2.35% [Member]
Debt Instrument [Line Items]
Effective Interest Rate	2.35%
Debt Instrument, Interest Rate, Effective Percentage	1.96%
Long-term Debt, Gross	$ 750,000,000	750,000,000
2015 Senior notes due July 2022 at 3.10% [Member]
Debt Instrument [Line Items]
Effective Interest Rate	3.10%
Debt Instrument, Interest Rate, Effective Percentage	2.70%
Long-term Debt, Gross	$ 1,000,000,000	1,000,000,000
2015 Senior notes due December 2022 at 4.00% [Member]
Debt Instrument [Line Items]
Effective Interest Rate	4.00%
Debt Instrument, Interest Rate, Effective Percentage	2.96%
Long-term Debt, Gross	$ 398,000,000	417,000,000
2012 Senior notes due December 2022 at 2.70% [Member]
Debt Instrument [Line Items]
Effective Interest Rate	2.70%
Debt Instrument, Interest Rate, Effective Percentage	2.28%
Long-term Debt, Gross	$ 1,500,000,000	1,500,000,000
2016 Altera acquired Senior notes due November 2023 at 4.10% [Member]
Debt Instrument [Line Items]
Effective Interest Rate	4.10%
Debt Instrument, Interest Rate, Effective Percentage	3.22%
Long-term Debt, Gross	$ 400,000,000	400,000,000
2017 Senior notes due May 2024 at 2.88% [Member]
Debt Instrument [Line Items]
Effective Interest Rate	2.88%
Debt Instrument, Interest Rate, Effective Percentage	2.31%
Long-term Debt, Gross	$ 1,250,000,000	1,250,000,000
2017 Senior notes due June 2024 at 2.70% [Member]
Debt Instrument [Line Items]
Effective Interest Rate	2.70%
Debt Instrument, Interest Rate, Effective Percentage	2.14%
Long-term Debt, Gross	$ 600,000,000	600,000,000
Fixed-rate Senior Notes, 3.40% due March 2025 [Member]
Debt Instrument [Line Items]
Effective Interest Rate	3.40%
Debt Instrument, Interest Rate, Effective Percentage	3.45%
Long-term Debt, Gross	$ 1,500,000,000	1,500,000,000
2015 Senior notes due July 2025 at 3.70% [Member]
Debt Instrument [Line Items]
Effective Interest Rate	3.70%
Debt Instrument, Interest Rate, Effective Percentage	2.16%
Long-term Debt, Gross	$ 2,250,000,000	2,250,000,000
2016 Senior notes due May 2026 at 2.60% [Member]
Debt Instrument [Line Items]
Effective Interest Rate	2.60%
Debt Instrument, Interest Rate, Effective Percentage	0.63%
Long-term Debt, Gross	$ 1,000,000,000	1,000,000,000
Fixed-rate Senior Notes, 3.75% due March 2027 [Member]
Debt Instrument [Line Items]
Effective Interest Rate	3.75%
Debt Instrument, Interest Rate, Effective Percentage	3.79%
Long-term Debt, Gross	$ 1,000,000,000	1,000,000,000
2017 Senior notes due May 2027 at 3.15% [Member]
Debt Instrument [Line Items]
Effective Interest Rate	3.15%
Debt Instrument, Interest Rate, Effective Percentage	1.21%
Long-term Debt, Gross	$ 1,000,000,000	1,000,000,000
Fixed-rate Senior Notes, 1.60% due August 2028
Debt Instrument [Line Items]
Effective Interest Rate	1.60%
Debt Instrument, Interest Rate, Effective Percentage	1.68%
Long-term Debt, Gross	$ 1,000,000,000	0
2019 Senior Notes due December 2029 at 2.45% [Member]
Debt Instrument [Line Items]
Effective Interest Rate	2.45%
Debt Instrument, Interest Rate, Effective Percentage	2.39%
Long-term Debt, Gross	$ 2,000,000,000	2,000,000,000
Fixed-rate Senior Notes, 3.90%, due March 2030 [Member]
Debt Instrument [Line Items]
Effective Interest Rate	3.90%
Debt Instrument, Interest Rate, Effective Percentage	3.93%
Long-term Debt, Gross	$ 1,500,000,000	1,500,000,000
Fixed-rate Senior Notes, 2.00% due August 2031
Debt Instrument [Line Items]
Effective Interest Rate	2.00%
Debt Instrument, Interest Rate, Effective Percentage	2.04%
Long-term Debt, Gross	$ 1,250,000,000	0
2012 Senior notes due December 2032 at 4.00% [Member]
Debt Instrument [Line Items]
Effective Interest Rate	4.00%
Debt Instrument, Interest Rate, Effective Percentage	1.24%
Long-term Debt, Gross	$ 750,000,000	750,000,000
Fixed-rate Senior Notes, 4.60%, due March 2040 [Member]
Debt Instrument [Line Items]
Effective Interest Rate	4.60%
Debt Instrument, Interest Rate, Effective Percentage	4.61%
Long-term Debt, Gross	$ 750,000,000	750,000,000
Fixed-rate Senior Notes, 2.80%, due August 2041
Debt Instrument [Line Items]
Effective Interest Rate	2.80%
Debt Instrument, Interest Rate, Effective Percentage	2.82%
Long-term Debt, Gross	$ 750,000,000	0
2011 Senior notes due October 2041 at 4.80% [Member]
Debt Instrument [Line Items]
Effective Interest Rate	4.80%
Debt Instrument, Interest Rate, Effective Percentage	2.01%
Long-term Debt, Gross	$ 802,000,000	802,000,000
2012 Senior notes due December 2042 at 4.25% [Member]
Debt Instrument [Line Items]
Effective Interest Rate	4.25%
Debt Instrument, Interest Rate, Effective Percentage	1.42%
Long-term Debt, Gross	$ 567,000,000	567,000,000
2015 Senior notes due July 2045 at 4.90% [Member]
Debt Instrument [Line Items]
Effective Interest Rate	4.90%
Debt Instrument, Interest Rate, Effective Percentage	2.13%
Long-term Debt, Gross	$ 772,000,000	772,000,000
2016 Senior notes due May 2046 at 4.10% [Member]
Debt Instrument [Line Items]
Effective Interest Rate	4.10%
Debt Instrument, Interest Rate, Effective Percentage	1.40%
Long-term Debt, Gross	$ 1,250,000,000	1,250,000,000
2017 Senior notes due May 2047 at 4.10% [Member]
Debt Instrument [Line Items]
Effective Interest Rate	4.10%
Debt Instrument, Interest Rate, Effective Percentage	1.37%
Long-term Debt, Gross	$ 1,000,000,000	1,000,000,000
$640, 4.10%, Senior Notes due August 2047 [Member]
Debt Instrument [Line Items]
Effective Interest Rate	4.10%
Debt Instrument, Interest Rate, Effective Percentage	0.92%
Long-term Debt, Gross	$ 640,000,000	640,000,000
2017 Senior notes due December 2047 at 3.73% [Member]
Debt Instrument [Line Items]
Effective Interest Rate	3.73%
Debt Instrument, Interest Rate, Effective Percentage	1.77%
Long-term Debt, Gross	$ 1,967,000,000	1,967,000,000
2019 Senior Notes due December 2049 at 3.25% [Member]
Debt Instrument [Line Items]
Effective Interest Rate	3.25%
Debt Instrument, Interest Rate, Effective Percentage	3.20%
Long-term Debt, Gross	$ 2,000,000,000	2,000,000,000
Fixed-rate Senior Notes, 4.75%, due March 2050 [Member]
Debt Instrument [Line Items]
Effective Interest Rate	4.75%
Debt Instrument, Interest Rate, Effective Percentage	4.74%
Long-term Debt, Gross	$ 2,250,000,000	2,250,000,000
Fixed-rate Senior Notes, 3.05% due August 2051
Debt Instrument [Line Items]
Effective Interest Rate	3.05%
Debt Instrument, Interest Rate, Effective Percentage	3.07%
Long-term Debt, Gross	$ 1,250,000,000	0
Fixed-rate Senior Notes, 3.10%, due February 2060 [Member]
Debt Instrument [Line Items]
Effective Interest Rate	3.10%
Debt Instrument, Interest Rate, Effective Percentage	3.11%
Long-term Debt, Gross	$ 1,000,000,000	1,000,000,000
Fixed-rate Senior Notes, 4.95%, due March 2060 [Member]
Debt Instrument [Line Items]
Effective Interest Rate	4.95%
Debt Instrument, Interest Rate, Effective Percentage	4.99%
Long-term Debt, Gross	$ 1,000,000,000	1,000,000,000
Fixed-rate Senior Notes, 3.20% due August 2061
Debt Instrument [Line Items]
Effective Interest Rate	3.20%
Debt Instrument, Interest Rate, Effective Percentage	3.22%
Long-term Debt, Gross	$ 750,000,000	0
Oregon and Arizona Bonds [Member]
Debt Instrument [Line Items]
Debt Instrument, Interest Rate, Effective Percentage	2.49%
Long-term Debt, Gross	$ 423,000,000	423,000,000
State of Oregon Business Development Commission [Member]
Debt Instrument [Line Items]
Debt Instrument, Interest Rate, Effective Percentage	2.13%
Long-term Debt, Gross	$ 138,000,000	138,000,000
Industrial Authority of the City of Chandler, Arizona [Member]
Debt Instrument [Line Items]
Debt Instrument, Interest Rate, Effective Percentage	2.15%
Long-term Debt, Gross	$ 438,000,000	$ 438,000,000
State of Oregon Business Development Commission, 2.40% due December 2035 [Member]
Debt Instrument [Line Items]
Effective Interest Rate	2.40%
Industrial Authority of the City of Chandler, Arizona, 2.70% due December 2035 [Member]
Debt Instrument [Line Items]
Effective Interest Rate	2.70%
State of Oregon Business Development Commission, 5.00% due March 2049 [Member]
Debt Instrument [Line Items]
Effective Interest Rate	5.00%
Industrial Authority of the City of Chandler, Arizona, 5.00% due June 2049 [Member]
Debt Instrument [Line Items]
Effective Interest Rate	5.00%
Senior Notes, 1.85%, due May 2020 [Member]
Debt Instrument [Line Items]
Effective Interest Rate		1.85%
Repayment of debt		$ 1,000,000,000
Senior Notes, 2.45% due July 2020 [Member]
Debt Instrument [Line Items]
Effective Interest Rate		2.45%
Repayment of debt		$ 1,800,000,000
Floating-rate Senior Notes due 2020 [Member]
Debt Instrument [Line Items]
Repayment of debt		700,000,000
Junior Subordinate due August 2039 at 3.25% [Member]
Debt Instrument [Line Items]
Repayment of debt		1,100,000,000
Conversion obligation		372,000,000
Gain (Loss) on Extinguishment of Debt		109,000,000
Adjustments to Additional Paid in Capital, Convertible Debt with Conversion Feature		750,000,000
Cross Currency Interest Rate Contract [Member] | 2015 AUD-denominated Senior notes [Member]
Debt Instrument [Line Items]
Derivative, notional amount	$ 396,000,000
Fair Value Hedging [Member] | Interest Rate Swaps [Member]
Debt Instrument [Line Items]
Derivative, Gain (Loss) on Derivative, Net	775,000,000	1,498,000,000
Fair Value Hedging [Member] | Long-term Debt [Member] | Interest Rate Swaps [Member]
Debt Instrument [Line Items]
Derivative, Amount of Hedged Item	12,000,000,000	12,000,000,000
Derivative, Gain (Loss) on Derivative, Net	811,000,000	1,565,000,000
Senior Notes [Member]
Debt Instrument [Line Items]
Debt Instrument, Face Amount	5,000,000,000	$ 10,300,000,000
Line of Credit | Revolving Credit Facility
Debt Instrument [Line Items]
Maximum borrowing capacity	$ 5,000,000,000

Fair Value (Detail)

Fair Value (Detail) - USD ($) $ in Millions	12 Months Ended
	Dec. 25, 2021	Dec. 26, 2020	Dec. 28, 2019
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Trading assets	$ 21,483	$ 15,738
Derivative Assets, Fair Value Disclosure	1,427	2,235
Derivative Financial Instruments, Liabilities, Fair Value Disclosure	392	711
Other than Temporary Impairment Losses, Investments	154	303	$ 122
Fair Value, Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Assets, Fair Value Disclosure	31,880	30,257
Liabilities, Fair Value Disclosure	529	815
Fair Value, Nonrecurring [Member] | Carrying Value [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Grants Receivable	317	139
Corporate debt | Fair Value, Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Trading assets	5,143	3,815
Financial institution instruments | Fair Value, Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Trading assets	3,883	2,978
Government Debt Securities [Member] | Fair Value, Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Trading assets	12,457	8,945
Equity securities | Fair Value, Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Investments, Fair Value Disclosure	2,171	1,830
Cost-method Investments [Member] | Fair Value, Nonrecurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Other than Temporary Impairment Losses, Investments	138	266	$ 113
Cash Equivalents [Member] | Corporate debt | Fair Value, Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Investments, Fair Value Disclosure	65	50
Cash Equivalents [Member] | Financial institution instruments | Fair Value, Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Investments, Fair Value Disclosure	1,979	3,417
Cash Equivalents [Member] | Repurchase Agreements [Member] | Fair Value, Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Investments, Fair Value Disclosure	1,595	1,900
Short-Term Investments [Member] | Corporate debt | Fair Value, Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Investments, Fair Value Disclosure	648	428
Short-Term Investments [Member] | Financial institution instruments | Fair Value, Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Investments, Fair Value Disclosure	1,243	1,179
Short-Term Investments [Member] | Government Debt Securities [Member] | Fair Value, Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Investments, Fair Value Disclosure	212	685
Other Current Assets [Member] | Fair Value, Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Derivative Assets, Fair Value Disclosure	656	692
Loans Receivable, Fair Value Disclosure	152	439
Other Long-Term Investments [Member] | Corporate debt | Fair Value, Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Investments, Fair Value Disclosure	576	1,520
Other Long-Term Investments [Member] | Financial institution instruments | Fair Value, Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Investments, Fair Value Disclosure	190	257
Other Long-Term Investments [Member] | Government Debt Securities [Member] | Fair Value, Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Investments, Fair Value Disclosure	74	415
Other Long-Term Assets [Member] | Fair Value, Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Derivative Assets, Fair Value Disclosure	779	1,550
Loans Receivable, Fair Value Disclosure	57	157
Other Accrued Liabilities [Member] | Fair Value, Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Derivative Financial Instruments, Liabilities, Fair Value Disclosure	520	810
Other Long-Term Liabilities [Member] | Fair Value, Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Derivative Financial Instruments, Liabilities, Fair Value Disclosure	9	5
Level 1 [Member] | Fair Value, Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Assets, Fair Value Disclosure	3,354	3,096
Liabilities, Fair Value Disclosure	4	0
Level 1 [Member] | Corporate debt | Fair Value, Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Trading assets	0	0
Level 1 [Member] | Financial institution instruments | Fair Value, Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Trading assets	154	131
Level 1 [Member] | Government Debt Securities [Member] | Fair Value, Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Trading assets	0	0
Level 1 [Member] | Equity securities | Fair Value, Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Investments, Fair Value Disclosure	1,854	136
Level 1 [Member] | Cash Equivalents [Member] | Corporate debt | Fair Value, Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Investments, Fair Value Disclosure	0	0
Level 1 [Member] | Cash Equivalents [Member] | Financial institution instruments | Fair Value, Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Investments, Fair Value Disclosure	1,216	2,781
Level 1 [Member] | Cash Equivalents [Member] | Repurchase Agreements [Member] | Fair Value, Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Investments, Fair Value Disclosure	0	0
Level 1 [Member] | Short-Term Investments [Member] | Corporate debt | Fair Value, Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Investments, Fair Value Disclosure	0	0
Level 1 [Member] | Short-Term Investments [Member] | Financial institution instruments | Fair Value, Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Investments, Fair Value Disclosure	0	0
Level 1 [Member] | Short-Term Investments [Member] | Government Debt Securities [Member] | Fair Value, Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Investments, Fair Value Disclosure	0	0
Level 1 [Member] | Other Current Assets [Member] | Fair Value, Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Derivative Assets, Fair Value Disclosure	80	48
Loans Receivable, Fair Value Disclosure	0	0
Level 1 [Member] | Other Long-Term Investments [Member] | Corporate debt | Fair Value, Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Investments, Fair Value Disclosure	0	0
Level 1 [Member] | Other Long-Term Investments [Member] | Financial institution instruments | Fair Value, Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Investments, Fair Value Disclosure	0	0
Level 1 [Member] | Other Long-Term Investments [Member] | Government Debt Securities [Member] | Fair Value, Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Investments, Fair Value Disclosure	50	0
Level 1 [Member] | Other Long-Term Assets [Member] | Fair Value, Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Derivative Assets, Fair Value Disclosure	0	0
Loans Receivable, Fair Value Disclosure	0	0
Level 1 [Member] | Other Accrued Liabilities [Member] | Fair Value, Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Derivative Financial Instruments, Liabilities, Fair Value Disclosure	4	0
Level 1 [Member] | Other Long-Term Liabilities [Member] | Fair Value, Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Derivative Financial Instruments, Liabilities, Fair Value Disclosure	0	0
Level 2 [Member] | Fair Value, Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Assets, Fair Value Disclosure	28,519	27,131
Liabilities, Fair Value Disclosure	525	815
Level 2 [Member] | Corporate debt | Fair Value, Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Trading assets	5,143	3,815
Level 2 [Member] | Financial institution instruments | Fair Value, Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Trading assets	3,729	2,847
Level 2 [Member] | Government Debt Securities [Member] | Fair Value, Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Trading assets	12,457	8,945
Level 2 [Member] | Equity securities | Fair Value, Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Investments, Fair Value Disclosure	317	1,694
Level 2 [Member] | Cash Equivalents [Member] | Corporate debt | Fair Value, Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Investments, Fair Value Disclosure	65	50
Level 2 [Member] | Cash Equivalents [Member] | Financial institution instruments | Fair Value, Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Investments, Fair Value Disclosure	763	636
Level 2 [Member] | Cash Equivalents [Member] | Repurchase Agreements [Member] | Fair Value, Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Investments, Fair Value Disclosure	1,595	1,900
Level 2 [Member] | Short-Term Investments [Member] | Corporate debt | Fair Value, Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Investments, Fair Value Disclosure	648	428
Level 2 [Member] | Short-Term Investments [Member] | Financial institution instruments | Fair Value, Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Investments, Fair Value Disclosure	1,243	1,179
Level 2 [Member] | Short-Term Investments [Member] | Government Debt Securities [Member] | Fair Value, Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Investments, Fair Value Disclosure	212	685
Level 2 [Member] | Other Current Assets [Member] | Fair Value, Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Derivative Assets, Fair Value Disclosure	576	644
Loans Receivable, Fair Value Disclosure	152	439
Level 2 [Member] | Other Long-Term Investments [Member] | Corporate debt | Fair Value, Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Investments, Fair Value Disclosure	576	1,520
Level 2 [Member] | Other Long-Term Investments [Member] | Financial institution instruments | Fair Value, Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Investments, Fair Value Disclosure	190	257
Level 2 [Member] | Other Long-Term Investments [Member] | Government Debt Securities [Member] | Fair Value, Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Investments, Fair Value Disclosure	24	415
Level 2 [Member] | Other Long-Term Assets [Member] | Fair Value, Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Derivative Assets, Fair Value Disclosure	772	1,520
Loans Receivable, Fair Value Disclosure	57	157
Level 2 [Member] | Other Accrued Liabilities [Member] | Fair Value, Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Derivative Financial Instruments, Liabilities, Fair Value Disclosure	516	810
Level 2 [Member] | Other Long-Term Liabilities [Member] | Fair Value, Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Derivative Financial Instruments, Liabilities, Fair Value Disclosure	9	5
Level 3 [Member] | Fair Value, Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Assets, Fair Value Disclosure	7	30
Liabilities, Fair Value Disclosure	0	0
Level 3 [Member] | Corporate debt | Fair Value, Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Trading assets	0	0
Level 3 [Member] | Financial institution instruments | Fair Value, Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Trading assets	0	0
Level 3 [Member] | Government Debt Securities [Member] | Fair Value, Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Trading assets	0	0
Level 3 [Member] | Equity securities | Fair Value, Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Investments, Fair Value Disclosure	0	0
Level 3 [Member] | Cash Equivalents [Member] | Corporate debt | Fair Value, Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Investments, Fair Value Disclosure	0	0
Level 3 [Member] | Cash Equivalents [Member] | Financial institution instruments | Fair Value, Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Investments, Fair Value Disclosure	0	0
Level 3 [Member] | Cash Equivalents [Member] | Repurchase Agreements [Member] | Fair Value, Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Investments, Fair Value Disclosure	0	0
Level 3 [Member] | Short-Term Investments [Member] | Corporate debt | Fair Value, Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Investments, Fair Value Disclosure	0	0
Level 3 [Member] | Short-Term Investments [Member] | Financial institution instruments | Fair Value, Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Investments, Fair Value Disclosure	0	0
Level 3 [Member] | Short-Term Investments [Member] | Government Debt Securities [Member] | Fair Value, Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Investments, Fair Value Disclosure	0	0
Level 3 [Member] | Other Current Assets [Member] | Fair Value, Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Derivative Assets, Fair Value Disclosure	0	0
Loans Receivable, Fair Value Disclosure	0	0
Level 3 [Member] | Other Long-Term Investments [Member] | Corporate debt | Fair Value, Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Investments, Fair Value Disclosure	0	0
Level 3 [Member] | Other Long-Term Investments [Member] | Financial institution instruments | Fair Value, Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Investments, Fair Value Disclosure	0	0
Level 3 [Member] | Other Long-Term Investments [Member] | Government Debt Securities [Member] | Fair Value, Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Investments, Fair Value Disclosure	0	0
Level 3 [Member] | Other Long-Term Assets [Member] | Fair Value, Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Derivative Assets, Fair Value Disclosure	7	30
Loans Receivable, Fair Value Disclosure	0	0
Level 3 [Member] | Other Accrued Liabilities [Member] | Fair Value, Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Derivative Financial Instruments, Liabilities, Fair Value Disclosure	0	0
Level 3 [Member] | Other Long-Term Liabilities [Member] | Fair Value, Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Derivative Financial Instruments, Liabilities, Fair Value Disclosure	$ 0	$ 0

Other Comprehensive Income (L_3

Other Comprehensive Income (Loss), Accumulated Other Comprehensive Income (Loss) (Detail) - USD ($) $ in Millions	12 Months Ended
	Dec. 25, 2021	Dec. 26, 2020	Dec. 28, 2019	Dec. 29, 2018
Accumulated Other Comprehensive Income (Loss) [Line Items]
Other Comprehensive Income (Loss), before Reclassifications, before Tax	$ (16)	$ 538	$ (655)
Amounts Reclassified Out Of Accumulated Other Comprehensive Income (Loss), before Tax	(144)	70	256
Tax effects	31	(79)	93
Other comprehensive income (loss)	(129)	529	(306)
Net derivative gains included in accumulated comprehensive income (loss) into earnings within next 12 months	8
Unrealized holding gains (losses) on derivatives [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest	211	731	54	$ (123)
Other Comprehensive Income (Loss), before Reclassifications, before Tax	(434)	806	(11)
Amounts Reclassified Out Of Accumulated Other Comprehensive Income (Loss), before Tax	(226)	(8)	195
Tax effects	140	(121)	(7)
Other comprehensive income (loss)	(520)	677	177
Actuarial gains (losses) [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest	(1,114)	(1,565)	(1,382)	(818)
Other Comprehensive Income (Loss), before Reclassifications, before Tax	476	(323)	(753)
Amounts Reclassified Out Of Accumulated Other Comprehensive Income (Loss), before Tax	101	89	67
Tax effects	(126)	51	122
Other comprehensive income (loss)	451	(183)	(564)
Foreign Currency translation adjustment [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest	23	83	48	(33)
Other Comprehensive Income (Loss), before Reclassifications, before Tax	(58)	55	109
Amounts Reclassified Out Of Accumulated Other Comprehensive Income (Loss), before Tax	(19)	(11)	(6)
Tax effects	17	(9)	(22)
Other comprehensive income (loss)	(60)	35	81
AOCI Including Portion Attributable to Noncontrolling Interest [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest	$ (880)	$ (751)	$ (1,280)	$ (974)

Derivative Financial Instrume_3

Derivative Financial Instruments (Detail) - USD ($) $ in Millions	12 Months Ended
	Dec. 25, 2021	Dec. 26, 2020	Dec. 28, 2019
Derivative [Line Items]
Derivative Asset, Fair Value, Gross Asset	$ 1,427	$ 2,235
Effect of Fair Value Hedges on Results of Operations [Abstract]
Change in Unrealized Gain (Loss) on Hedged Item in Fair Value Hedge	723	(817)	$ (1,071)
Gross Notional Amounts [Abstract]
Derivative, notional amount	55,750	47,696	40,036
Offsetting Derivative Assets [Abstract]
Derivative Assets Subject To Master Netting Arrangements, Gross Amounts Offset In The Balance Sheet	0	0
Derivative Assets, Fair Value Disclosure	1,427	2,235
Derivative Asset, Not Offset, Policy Election Deduction	(332)	(264)
Derivative, Collateral, Obligation to Return Cash	(986)	(1,904)
Derivative Asset, Fair Value, Offset Against Collateral, Net of Not Subject to Master Netting Arrangement, Policy Election	109	67
Reverse Repurchase Agreements, Gross Amounts Recognized	1,595	1,900
Reverse Repurchase Agreements, Gross Amounts Offset In The Balance Sheet	0	0
Securities Purchased under Agreements to Resell	1,595	1,900
Securities Purchased under Agreements to Resell, Not Offset, Policy Election Deduction	0	0
Reverse Repurchase Agreements, Gross Amounts Not Offset In The Balance Sheet - Financial Instruments	(1,595)	(1,900)
Securities Purchased under Agreements to Resell, Offset Against Collateral, Net of Not Subject to Master Netting Arrangement, Policy Election	0	0
Total Assets, Gross Amounts Recognized	3,022	4,135
Total Assets, Gross Amounts Offset In The Balance Sheet	0	0
Derivative Asset, Securities Purchased under Agreements to Resell, Securities Borrowed	3,022	4,135
Derivative Asset, Securities Purchased under Agreements to Resell, Securities Borrowed, Not Offset, Policy Election Deduction	(332)	(264)
Total Assets, Gross Amounts Not Offset In The Balance Sheet - Cash and Non-Cash Collateral Received Or Pledged	(2,581)	(3,804)
Derivative Asset, Securities Purchased under Agreements to Resell, Securities Borrowed, Offset Against Collateral, Net of Not Subject to Master Netting Arrangement, Policy Election	109	67
Offsetting Derivative Liabilities [Abstract]
Total Liabilities, Gross Amounts Recognized	392	711
Derivative Liabilities Subject To Master Netting Arrangements, Gross Amounts Offset In The Balance Sheet	0	0
Derivative Financial Instruments, Liabilities, Fair Value Disclosure	392	711
Derivative Liability, Not Offset, Policy Election Deduction	(332)	(264)
Derivative, Collateral, Right to Reclaim Cash	(60)	(447)
Derivative Liability, Fair Value, Offset Against Collateral, Net of Not Subject to Master Netting Arrangement, Policy Election	0	0
Designated as Hedging Instrument [Member] | Interest and other, net [Member]
Derivative Assets (Liabilities), at Fair Value, Net, by Balance Sheet Classification [Abstract]
Gains (Losses) Recognized in Income on Derivatives	0	0	0
Derivative Instruments Not Designation as Hedging Instruments [Abstract]
Gains (Losses) Recognized in Income on Derivatives	0	0	0
Not Designated as Hedging Instrument [Member]
Derivative Assets (Liabilities), at Fair Value, Net, by Balance Sheet Classification [Abstract]
Gains (Losses) Recognized in Income on Derivatives	1,068	(378)	469
Derivative Instruments Not Designation as Hedging Instruments [Abstract]
Gains (Losses) Recognized in Income on Derivatives	1,068	(378)	469
Fair Value Hedging [Member]
Derivative [Line Items]
Derivative, Net Hedge Ineffectiveness Gain (Loss)	0	0
Assets [Member]
Derivative [Line Items]
Derivative Asset, Fair Value, Gross Asset	1,435	2,242
Assets [Member] | Designated as Hedging Instrument [Member]
Derivative [Line Items]
Derivative Asset, Fair Value, Gross Asset	854	2,049
Assets [Member] | Not Designated as Hedging Instrument [Member]
Derivative [Line Items]
Derivative Asset, Fair Value, Gross Asset	581	193
Liabilities [Member]
Offsetting Derivative Liabilities [Abstract]
Total Liabilities, Gross Amounts Recognized	529	815
Liabilities [Member] | Designated as Hedging Instrument [Member]
Offsetting Derivative Liabilities [Abstract]
Total Liabilities, Gross Amounts Recognized	163	2
Liabilities [Member] | Not Designated as Hedging Instrument [Member]
Offsetting Derivative Liabilities [Abstract]
Total Liabilities, Gross Amounts Recognized	366	813
Foreign currency contracts [Member]
Gross Notional Amounts [Abstract]
Derivative, notional amount	38,024	31,209	23,981
Derivative Instruments Not Designation as Hedging Instruments [Abstract]
Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), after Reclassification, before Tax	(434)	806	(11)
Foreign currency contracts [Member] | Not Designated as Hedging Instrument [Member] | Interest and other, net [Member]
Derivative Assets (Liabilities), at Fair Value, Net, by Balance Sheet Classification [Abstract]
Gains (Losses) Recognized in Income on Derivatives	677	(572)	204
Derivative Instruments Not Designation as Hedging Instruments [Abstract]
Gains (Losses) Recognized in Income on Derivatives	677	(572)	204
Foreign currency contracts [Member] | Assets [Member] | Designated as Hedging Instrument [Member]
Derivative [Line Items]
Derivative Asset, Fair Value, Gross Asset	80	551
Foreign currency contracts [Member] | Assets [Member] | Not Designated as Hedging Instrument [Member]
Derivative [Line Items]
Derivative Asset, Fair Value, Gross Asset	475	142
Foreign currency contracts [Member] | Liabilities [Member] | Designated as Hedging Instrument [Member]
Offsetting Derivative Liabilities [Abstract]
Total Liabilities, Gross Amounts Recognized	163	2
Foreign currency contracts [Member] | Liabilities [Member] | Not Designated as Hedging Instrument [Member]
Offsetting Derivative Liabilities [Abstract]
Total Liabilities, Gross Amounts Recognized	297	685
Interest Rate Contracts [Member]
Effect of Fair Value Hedges on Results of Operations [Abstract]
Change in Unrealized Gain (Loss) on Fair Value Hedging Instruments	(723)	817	1,071
Gross Notional Amounts [Abstract]
Derivative, notional amount	15,209	14,461	14,302
Interest Rate Contracts [Member] | Not Designated as Hedging Instrument [Member] | Interest and other, net [Member]
Derivative Assets (Liabilities), at Fair Value, Net, by Balance Sheet Classification [Abstract]
Gains (Losses) Recognized in Income on Derivatives	31	(90)	(32)
Derivative Instruments Not Designation as Hedging Instruments [Abstract]
Gains (Losses) Recognized in Income on Derivatives	31	(90)	(32)
Interest Rate Contracts [Member] | Assets [Member] | Designated as Hedging Instrument [Member]
Derivative [Line Items]
Derivative Asset, Fair Value, Gross Asset	774	1,498
Interest Rate Contracts [Member] | Assets [Member] | Not Designated as Hedging Instrument [Member]
Derivative [Line Items]
Derivative Asset, Fair Value, Gross Asset	26	3
Interest Rate Contracts [Member] | Liabilities [Member] | Designated as Hedging Instrument [Member]
Offsetting Derivative Liabilities [Abstract]
Total Liabilities, Gross Amounts Recognized	0	0
Interest Rate Contracts [Member] | Liabilities [Member] | Not Designated as Hedging Instrument [Member]
Offsetting Derivative Liabilities [Abstract]
Total Liabilities, Gross Amounts Recognized	65	128
Other contracts [Member]
Gross Notional Amounts [Abstract]
Derivative, notional amount	2,517	2,026	1,753
Other contracts [Member] | Not Designated as Hedging Instrument [Member] | Various [Member]
Derivative Assets (Liabilities), at Fair Value, Net, by Balance Sheet Classification [Abstract]
Gains (Losses) Recognized in Income on Derivatives	360	284	297
Derivative Instruments Not Designation as Hedging Instruments [Abstract]
Gains (Losses) Recognized in Income on Derivatives	360	284	297
Other contracts [Member] | Assets [Member] | Not Designated as Hedging Instrument [Member]
Derivative [Line Items]
Derivative Asset, Fair Value, Gross Asset	80	48
Other contracts [Member] | Liabilities [Member] | Not Designated as Hedging Instrument [Member]
Offsetting Derivative Liabilities [Abstract]
Total Liabilities, Gross Amounts Recognized	4	0
Interest Rate Swaps [Member] | Fair Value Hedging [Member]
Derivative [Line Items]
Derivative, amount discontinued			7,100
Gain to be amortized over remaining life of debt			$ 111
Derivative Assets (Liabilities), at Fair Value, Net, by Balance Sheet Classification [Abstract]
Gains (Losses) Recognized in Income on Derivatives	(775)	(1,498)
Derivative Instruments Not Designation as Hedging Instruments [Abstract]
Gains (Losses) Recognized in Income on Derivatives	(775)	(1,498)
Interest Rate Swaps [Member] | Long-term Debt [Member] | Fair Value Hedging [Member]
Derivative [Line Items]
Derivative, Amount of Hedged Item	12,000	12,000
Derivative Assets (Liabilities), at Fair Value, Net, by Balance Sheet Classification [Abstract]
Derivative, Fair Value, Net	(12,772)	(13,495)
Gains (Losses) Recognized in Income on Derivatives	(811)	(1,565)
Derivative Instruments Not Designation as Hedging Instruments [Abstract]
Gains (Losses) Recognized in Income on Derivatives	$ (811)	$ (1,565)

Retirement Benefit Plans (Detai

Retirement Benefit Plans (Detail) - USD ($) $ in Millions	12 Months Ended
	Dec. 25, 2021	Dec. 26, 2020	Dec. 28, 2019
Defined Benefit Plan Disclosure [Line Items]
Beginning projected benefit obligation	$ 4,456	$ 4,929	$ 4,284
Service cost	54	49
Interest cost	91	97
Actuarial (gain) loss	(284)	373
Currency exchange rate changes	(150)	261
Plan settlements	(126)	(79)
Other changes in projected benefit obligation	(58)	(56)
Fair value of plan assets	2,817	2,878	$ 2,654
Actual return on plan assets	145	203
Currency exchange rate changes	(63)	113
Defined Benefit Plan, Plan Assets, Payment for Settlement	(126)	(79)
Other	(17)	(13)
Net unfunded status	1,639	2,051
Accumulated other comprehensive loss (income), before tax3	$ 1,445	1,911
Defined Benefit Plan, Additional Information [Abstract]
Net Actuarial (Gain) Loss Amortization Percent	10.00%
Accumulated benefit obligations	$ 4,086	$ 4,429
Defined Benefit Plan, Funded Status Percentage [Abstract]
Defined Benefit Plan, Funded Percentage	68.00%
Defined Benefit Plan, Component Of Worldwide Pension And Postretirement Benefit Obligation (percent)	28.00%
Defined Benefit Plan, Weighted Average Assumptions Used in Calculating Benefit Obligation [Abstract]
Discount rate	2.20%	1.90%
Rate of compensation increase	3.20%	3.20%
Defined Benefit Plan, Weighted Average Assumptions Used in Calculating Net Periodic Benefit Cost [Abstract]
Discount rate	1.90%	2.30%	3.40%
Expected long-term rate of return on plan assets	2.70%	3.30%	4.70%
Rate of compensation increase	3.20%	3.20%	3.50%
Defined Benefit Plan, Expected Future Benefit Payment [Abstract]
Estimated Benefit Payments, 2019	$ 147
Estimated Benefit Payments, 2020	144
Estimated Benefit Payments, 2021	141
Estimated Benefit Payments, 2022	142
Estimated Benefit Payments, 2023	146
Estimated Benefit Payments, 2024-2028	765
Other long-term liabilities [Member]
Defined Benefit Plan Disclosure [Line Items]
Net unfunded status	1,639	$ 2,051
Pension Plan [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	$ 484	$ 455
UNITED STATES
Defined Benefit Plan Disclosure [Line Items]
Projected Benefit Obligations Percentage Split	30.00%	35.00%
Fair Value of Plan Assets Percentage Split	50.00%	55.00%
AOCI Percentage Split	30.00%	35.00%
Defined Contribution Plan, Employer Discretionary Contribution Amount	$ 444	$ 398	$ 379
Defined Benefit Plan, Funded Status Percentage [Abstract]
Defined Benefit Plan, Funded Percentage	99.00%
UNITED STATES | Pension Plan [Member]
Defined Benefit Plan, Net Periodic Benefit Cost (Credit) [Abstract]
Defined Benefit Plan, Net Periodic Benefit Cost (Credit)	$ 162	164	$ 135
UNITED STATES | Postretirement Health Coverage [Member]
Defined Benefit Plan Disclosure [Line Items]
Beginning projected benefit obligation	682	741
Fair value of plan assets	$ 669	$ 600
Defined Benefit Plan, Weighted Average Assumptions Used in Calculating Benefit Obligation [Abstract]
Discount rate	2.80%	2.40%
Defined Benefit Plan, Expected Future Benefit Payment [Abstract]
Estimated Benefit Payments, 2019	$ 37
Estimated Benefit Payments, 2020	38
Estimated Benefit Payments, 2021	39
Estimated Benefit Payments, 2022	41
Estimated Benefit Payments, 2023	42
Estimated Benefit Payments, 2024-2028	$ 219
Foreign Plan [Member]
Defined Benefit Plan Disclosure [Line Items]
Projected Benefit Obligations Percentage Split	70.00%	65.00%
Fair Value of Plan Assets Percentage Split	50.00%	45.00%
AOCI Percentage Split	70.00%	65.00%
Equity securities
Defined Benefit Plan Disclosure [Line Items]
Defined Benefit Plan, Target Plan Asset Allocations (percent)	35.00%
Fair value of plan assets	$ 342	$ 320
Equity securities | UNITED STATES
Defined Benefit Plan Disclosure [Line Items]
Defined Benefit Plan, Target Plan Asset Allocations (percent)	10.00%
Equity securities | UNITED STATES | Postretirement Health Coverage [Member]
Defined Benefit Plan Disclosure [Line Items]
Defined Benefit Plan, Target Plan Asset Allocations (percent)	65.00%
Fixed income
Defined Benefit Plan Disclosure [Line Items]
Defined Benefit Plan, Target Plan Asset Allocations (percent)	45.00%
Fair value of plan assets	$ 142	135
Fixed income | UNITED STATES
Defined Benefit Plan Disclosure [Line Items]
Defined Benefit Plan, Target Plan Asset Allocations (percent)	90.00%
Fixed income | UNITED STATES | Postretirement Health Coverage [Member]
Defined Benefit Plan Disclosure [Line Items]
Defined Benefit Plan, Target Plan Asset Allocations (percent)	35.00%
Assets measured at net asset value [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	$ 2,311	2,401
Cash [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	$ 22	$ 22
Hedge Funds [Member] | Foreign Plan [Member]
Defined Benefit Plan Disclosure [Line Items]
Defined Benefit Plan, Target Plan Asset Allocations (percent)	20.00%
Level 1 [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	$ 0
Level 1 [Member] | Equity securities
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	0
Level 1 [Member] | Fixed income
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	0
Level 2 [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	464
Level 2 [Member] | Equity securities
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	342
Level 2 [Member] | Fixed income
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	122
Level 3 [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	20
Level 3 [Member] | Equity securities
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	0
Level 3 [Member] | Fixed income
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	$ 20

Employee Equity Incentive Pla_3

Employee Equity Incentive Plans (Detail) - USD ($) $ / shares in Units, shares in Millions, $ in Millions	12 Months Ended
	Dec. 25, 2021	Dec. 26, 2020	Dec. 28, 2019
Share-based Compensation Arrangement by Share-based Payment Award, Additional General Disclosures [Abstract]
Market-Based Restricted Stock Units Performance Period (In Years)	3 years
Share-based Payment Arrangement, Noncash Expense	$ 2,036	$ 1,854	$ 1,705
Tax Benefit from Compensation Expense	$ 377	380	359
Restricted Stock Units (RSUs) [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Additional General Disclosures [Abstract]
Award Requisite Service Period	4 years
RSUs Vested in Period, Total Fair Value	$ 1,700	1,900	1,900
RSUs Aggregate Intrinsic Value, Vested	1,400	$ 1,300	$ 1,300
Compensation Cost Not yet Recognized	$ 3,800
Compensation Cost Not yet Recognized, Period for Recognition	1 year 6 months
Estimated Values And Weighted Average Assumptions [Abstract]
Estimated values (in dollars per share)	$ 50.82	$ 54.82	$ 48.06
Risk-free interest rate	0.20%	0.40%	2.30%
Dividend yield	2.60%	2.30%	2.50%
Restricted Stock Units Activity [Roll Forward]
Number of RSUs outstanding, beginning balance	82.7
Number of RSUs granted	76.8
Number of RSUs vested	(30.2)
Number of RSUs forfeited	(11.3)
Number of RSUs outstanding, ending balance	118	82.7
Number of RSUs expected to vest	105.9
Weighted average grant date fair value, RSUs outstanding	$ 51.29	$ 50.14
Weighted average grant date fair value, RSUs granted	50.82
Weighted average grant date fair value, RSUs vested	47.64
Weighted average grant date fair value, RSUs forfeited	49.48
Weighted average grant date fair value, RSUs expected to vest	$ 51.47
Share-based Payment Arrangement, Option [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Additional General Disclosures [Abstract]
Expiration Period	10 years
Market-Based Restricted Stock Units (OSUs) [Member]
Estimated Values And Weighted Average Assumptions [Abstract]
Volatility (percent)	37.00%	30.00%	25.00%
Restricted Stock Units Activity [Roll Forward]
Number of RSUs outstanding, ending balance	15
Market-Based Restricted Stock Units (OSUs) [Member] | Minimum
Share-based Compensation Arrangement by Share-based Payment Award, Additional General Disclosures [Abstract]
Vesting range (percent)	0.00%
Market-Based Restricted Stock Units (OSUs) [Member] | Maximum
Share-based Compensation Arrangement by Share-based Payment Award, Additional General Disclosures [Abstract]
Vesting range (percent)	200.00%
Stock Purchase Plan RIghts [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Additional General Disclosures [Abstract]
Compensation Cost Not yet Recognized	$ 48
Compensation Cost Not yet Recognized, Period for Recognition	2 months
Stock Purchase Plan Shares Issued in Period	22	21	17
Employee Purchases, Amount	$ 925	$ 876	$ 688
2006 Equity Incentive Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Additional General Disclosures [Abstract]
Number of Shares Authorized	866
Number of Shares Available for Grant	128
2006 Stock Purchase Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Additional General Disclosures [Abstract]
Number of Shares Authorized	523
Number of Shares Available for Grant	227
Stock Purchase Plan, Purchase Price of Common Stock, Percent	85.00%

Leases (Details)

Leases (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 25, 2021	Dec. 26, 2020	Dec. 28, 2019
Lessee, Lease, Description [Line Items]
Operating Lease, Liability	$ 1,455
Lessor, Operating Lease, Renewal Term	37 years
Operating Lease, Weighted Average Remaining Lease Term	3 years 9 months 18 days
Operating Lease, Weighted Average Discount Rate, Percent	2.50%
Operating Lease, Expense	$ 798	$ 416	$ 185
Variable Lease, Cost	620
Finance Lease, Liability, Payment, Due	$ 980
Minimum
Lessee, Lease, Description [Line Items]
Lessee, Operating Lease, Term of Contract	1 year
Maximum
Lessee, Lease, Description [Line Items]
Lessee, Operating Lease, Term of Contract	14 years
Other Long-Term Assets [Member]
Lessee, Lease, Description [Line Items]
Operating Lease, Right-of-Use Asset	$ 549
Accrued Liabilities [Member]
Lessee, Lease, Description [Line Items]
Operating Lease, Liability	180
Other Long-Term Liabilities [Member]
Lessee, Lease, Description [Line Items]
Operating Lease, Liability	$ 295

Commitments (Details)

Commitments (Details) - USD ($) $ in Billions	Dec. 25, 2021	Dec. 26, 2020
Unrecorded Unconditional Purchase Obligation [Line Items]
Unrecorded Unconditional Purchase Obligation	$ 12.4	$ 2.6
Capital Addition Purchase Commitments [Member]
Unrecorded Unconditional Purchase Obligation [Line Items]
Unrecorded Unconditional Purchase Obligation	$ 27	$ 8.6

Contingencies (Details)

Contingencies (Details) - 1 months ended May 31, 2009 € in Billions, $ in Billions	EUR (€)	USD ($)
EC Fine [Member]
Loss Contingencies [Line Items]
Loss Contingency, Damages Paid, Value	€ 1.1	$ 1.4

Schedule of Payments on Operati

Schedule of Payments on Operating Lease Liabilities (Details) $ in Millions	Dec. 25, 2021USD ($)
Commitments and Contingencies Disclosure [Abstract]
Lessee, Operating Lease, Liability, to be Paid, Year One	$ 183
Lessee, Operating Lease, Liability, to be Paid, Year Two	139
Lessee, Operating Lease, Liability, to be Paid, Year Three	79
Lessee, Operating Lease, Liability, to be Paid, Year Four	55
Lessee, Operating Lease, Liability, to be Paid, Year Five	16
Lessee, Operating Lease, Liability, to be Paid, Thereafter	27
Lessee, Operating Lease, Liability, to be Paid	499
Operating Lease, Liability	1,455
Finance Lease, Liability, to be Paid, Year One	451
Finance Lease, Liability, to be Paid, Year Two	529
Finance Lease, Liability, Payment, Due	$ 980